16. Literaturverzeichnis – Prostate Cancer
1. Robert, Koch-Institut, Gesellschaft epidemiologischer Krebsregister in, Deutschland, Krebs in Deutschland für 2015/2016, 2019., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_node.html
2. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., et.al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 2013. 49(6): p. 1374-1403., http://www.ncbi.nlm.nih.gov/pubmed
3. Haas, G.P., Delongchamps, N., Brawley, O.W., Wang, C.Y., de la, Roza G., The worldwide epidemiology of prostate cancer: perspectives from autopsy studies, Can J Urol, 2008. 15(1): p. 3866-3871., http://www.ncbi.nlm.nih.gov/pubmed/18304396
4. Robert Koch Institut (RKI), Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID), Krebs in Deutschland für 2013/2014RKI, 2017.
5. Bott, S.R., Birtle, A.J., Taylor, C.J., Kirby, R.S., Prostate cancer management: (1) an update on localised disease, Postgrad. Med J, 2003. 79(936): p. 575-580., http://www.ncbi.nlm.nih.gov/pubmed/14612600
6. Eurostat, Todesursachen - standardisierte Sterbeziffer je 100 000 Einwohner, 2018., http://ec.europa.eu/eurostat/web/products-datasets/-/hlth_cd_asdr2
7. Albertsen, P.C., Hanley, J.A., Fine, J., 20-year outcomes following conservative management of clinically localized prostate cancer, JAMA, 2005. 293(17): p. 2095-2101., http://www.ncbi.nlm.nih.gov/pubmed/15870412
8. Zeegers, M.P., Jellema, A., Ostrer, H., Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis, Cancer, 2003. 97(8): p. 1894-1903., https://www.ncbi.nlm.nih.gov/pubmed/12673715
9. Johns, L.E., Houlston, R.S., A systematic review and meta-analysis of familial prostate cancer risk, BJU Int, 2003. 91(9): p. 789-794., http://www.ncbi.nlm.nih.gov/pubmed/12780833
10. Taylor, M.L., Mainous, A.G., III, Wells, B.J., Prostate cancer and sexually transmitted diseases: a meta-analysis, Fam Med, 2005. 37(7): p. 506-512., http://www.ncbi.nlm.nih.gov/pubmed/15988645
11. Ries, L.A.G., Melbert, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J., et.al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Section 23: Prostate Cancer, 2007., http://www.seer.cancer.gov/csr/1975_2004/results_merged/sect_23_prostate.pdf
12. Graham, S., Haughey, B., Marshall, J., Priore, R., Byers, T., Rzepka, T., et.al. Diet in the epidemiology of carcinoma of the prostate gland, J Natl. Cancer Inst, 1983. 70(4): p. 687-692., http://www.ncbi.nlm.nih.gov/pubmed/6572757
13. Hebert, J.R., Hurley, T.G., Olendzki, B.C., Teas, J., Ma, Y., Hampl, J.S., Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study, J Natl. Cancer Inst, 1998. 90(21): p. 1637-1647., http://www.ncbi.nlm.nih.gov/pubmed/9811313
14. Morton, R.A., Jr., Racial differences in adenocarcinoma of the prostate in North American men, Urology, 1994. 44(5): p. 637-645., http://www.ncbi.nlm.nih.gov/pubmed/7526522
15. Ozasa, K., Nakao, M., Watanabe, Y., Hayashi, K., Miki, T., Mikami, K., et.al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men, Cancer Sci, 2004. 95(1): p. 65-71., http://www.ncbi.nlm.nih.gov/pubmed/14720329
16. Etminan, M., Takkouche, B., Caamano-Isorna, F., The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies, Cancer Epidemiol Biomarkers Prev, 2004. 13(3): p. 340-345., http://www.ncbi.nlm.nih.gov/pubmed/15006906
17. Wertz, K., Siler, U., Goralczyk, R., Lycopene: modes of action to promote prostate health, Arch Biochem. Biophys, 2004. 430(1): p. 127-134., http://www.ncbi.nlm.nih.gov/pubmed/15325920
18. Nelson, W.G., Prostate cancer prevention, Curr. Opin. Urol, 2007. 17(3): p. 157-167., http://www.ncbi.nlm.nih.gov/pubmed/17414513
19. Dennis, L.K., Dawson, D.V., Meta-analysis of measures of sexual activity and prostate cancer, Epidemiology, 2002. 13(1): p. 72-79., http://www.ncbi.nlm.nih.gov/pubmed/11805589
20. Dennis, L.K., Lynch, C.F., Torner, J.C., Epidemiologic association between prostatitis and prostate cancer, Urology, 2002. 60(1): p. 78-83., http://www.ncbi.nlm.nih.gov/pubmed/12100928
21. Dennis, L.K., Dawson, D.V., Resnick, M.I., Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy, Prostate Cancer Prostatic. Dis, 2002. 5(3): p. 193-203., http://www.ncbi.nlm.nih.gov/pubmed/12496981
22. Strickler, H.D., Wylie-Rosett, J., Rohan, T., Hoover, D.R., Smoller, S., Burk, R.D., et.al. The relation of type 2 diabetes and cancer, Diabetes Technol. Ther, 2001. 3(2): p. 263-274., http://www.ncbi.nlm.nih.gov/pubmed/11478333
23. Kasper, J.S., Giovannucci, E., A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 2006. 15(11): p. 2056-2062., http://www.ncbi.nlm.nih.gov/pubmed/17119028
24. Bonovas, S., Filioussi, K., Tsantes, A., Diabetes mellitus and risk of prostate cancer: a meta-analysis, Diabetologia, 2004. 47(6): p. 1071-1078., http://www.ncbi.nlm.nih.gov/pubmed/15164171
25. MacInnis, R.J., English, D.R., Body size and composition and prostate cancer risk: systematic review and meta-regression analysis, Cancer Causes Control, 2006. 17(8): p. 989-1003., http://www.ncbi.nlm.nih.gov/pubmed/16933050
26. Giovannucci, E., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Willett, W.C., Height, body weight, and risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 1997. 6(8): p. 557-563., http://www.ncbi.nlm.nih.gov/pubmed/9264267
27. Calof, O.M., Singh, A.B., Lee, M.L., Kenny, A.M., Urban, R.J., Tenover, J.L., et.al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials, J Gerontol. A Biol Sci Med Sci, 2005. 60(11): p. 1451-1457., https://www.ncbi.nlm.nih.gov/pubmed/16339333
28. Gerstenbluth, R.E., Maniam, P.N., Corty, E.W., Seftel, A.D., Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement, J Androl, 2002. 23(6): p. 922-926., http://www.ncbi.nlm.nih.gov/pubmed/12399540
29. Hajjar, R.R., Kaiser, F.E., Morley, J.E., Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis, J Clin Endocrinol. Metab, 1997. 82(11): p. 3793-3796., http://www.ncbi.nlm.nih.gov/pubmed/9360543
30. Marks, L.S., Mazer, N.A., Mostaghel, E., Hess, D.L., Dorey, F.J., Epstein, J.I., et.al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial, JAMA, 2006. 296(19): p. 2351-2361., http://www.ncbi.nlm.nih.gov/pubmed/17105798
31. Rhoden, E.L., Morgentaler, A., Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia, J Urol, 2003. 170(6 Pt 1): p. 2348-2351., http://www.ncbi.nlm.nih.gov/pubmed/14634413
32. Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A.M., Snyder, P.J., et.al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men, J Clin Endocrinol. Metab, 2004. 89(5): p. 2085-2098., http://www.ncbi.nlm.nih.gov/pubmed/15126525
33. Boyle, P., Koechlin, A., Bota, M., d'Onofrio, A., Zaridze, D.G., Perrin, P., et.al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis, BJU Int, 2016., http://www.ncbi.nlm.nih.gov/pubmed/26779889
34. Kang, D.Y., Li, H.J., The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis, Medicine (Baltimore), 2015. 94(3): p. e410., http://www.ncbi.nlm.nih.gov/pubmed/25621688
35. Cui, Y., Zong, H., Yan, H., Zhang, Y., The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis, Prostate Cancer Prostatic. Dis, 2014. 17(2): p. 132-143., http://www.ncbi.nlm.nih.gov/pubmed/24445948
36. Loblaw, D.A., Virgo, K.S., Nam, R., Somerfield, M.R., Ben-Josef, E., Mendelson, D.S., et.al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 2007. 25(12): p. 1596-1605., http://www.ncbi.nlm.nih.gov/pubmed/17404365
37. Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., et.al. The influence of finasteride on the development of prostate cancer, N Engl J Med, 2003. 349(3): p. 215-224., http://www.ncbi.nlm.nih.gov/pubmed/12824459
38. Thompson, I.M., Lucia, M.S., Redman, M.W., Darke, A., La Rosa, F.G., Parnes, H.L., et.al. Finasteride decreases the risk of prostatic intraepithelial neoplasia, J Urol, 2007. 178(1): p. 107-109., http://www.ncbi.nlm.nih.gov/pubmed/17499284
39. Wilt, T.J., MacDonald, R., Hagerty, K., Schellhammer, P., Kramer, B.S., Five-alpha-reductase Inhibitors for prostate cancer prevention, Cochrane Database Syst Rev, 2008. p. CD007091., http://www.ncbi.nlm.nih.gov/pubmed/18425978
40. Kramer, B.S., Hagerty, K.L., Justman, S., Somerfield, M.R., Albertsen, P.C., Blot, W.J., et.al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline, J Clin Oncol, 2009. 27(9): p. 1502-1516., http://www.ncbi.nlm.nih.gov/pubmed/19252137
41. Kushi, L.H., Byers, T., Doyle, C., Bandera, E.V., McCullough, M., McTiernan, A., et.al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity, CA Cancer J Clin, 2006. 56(5): p. 254-281., http://www.ncbi.nlm.nih.gov/pubmed/17005596
42. Lippman, S.M., Klein, E.A., Goodman, P.J., Lucia, M.S., Thompson, I.M., Ford, L.G., et.al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 2009. 301(1): p. 39-51., http://www.ncbi.nlm.nih.gov/pubmed/19066370
43. Lucia, M.S., Epstein, J.I., Goodman, P.J., Darke, A.K., Reuter, V.E., Civantos, F., et.al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 2007. 99(18): p. 1375-1383., http://www.ncbi.nlm.nih.gov/pubmed/17848673
44. Teillac, P., Abrahamsson, P.A., The prostate cancer prevention trial and its implications for clinical practice: a European consensus, Eur Urol Suppl, 2006. 5(9): p. 640-646.
45. Andriole, G.L., Headline Results of the REDUCE Trial: The Effect of Dutasteride on Prostate Cancer Risk Reduction. 107th Annual Meeting, American Urological Association (AUA)AUA, 2009.
46. Harris, R., Lohr, K.N., Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force, Ann Intern Med, 2002. 137(11): p. 917-929., http://www.ncbi.nlm.nih.gov/pubmed/12458993
47. Mistry, K., Cable, G., Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma, J Am Board Fam Pract, 2003. 16(2): p. 95-101., http://www.ncbi.nlm.nih.gov/pubmed/12665174
48. Auvinen, A., Maattanen, L., Finne, P., Stenman, U.H., Aro, J., Juusela, H., et.al. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial, Int J Cancer, 2004. 111(6): p. 940-943., https://www.ncbi.nlm.nih.gov/pubmed/15300807
49. Maattanen, L., Hakama, M., Tammela, T.L., Ruutu, M., la-Opas, M., Juusela, H., et.al. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial, Br J Cancer, 2007. 96(1): p. 56-60., http://www.ncbi.nlm.nih.gov/pubmed/17213825
50. McLernon, D.J., Donnan, P.T., Gray, M., Weller, D., Sullivan, F., Receiver operating characteristics of the prostate specific antigen test in an unselected population, J Med Screen, 2006. 13(2): p. 102-107., http://www.ncbi.nlm.nih.gov/pubmed/16792835
51. Halpern, J.A., Shoag, J.E., Mittal, S., Oromendia, C., Ballman, K.V., Hershman, D.L., et.al. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm, J Urol, 2017. 197(2): p. 363-368., http://www.ncbi.nlm.nih.gov/pubmed/27569432
52. Cui, T., Kovell, R.C., Terlecki, R.P., Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature, Curr Med Res Opin, 2016. p. 1-7., http://www.ncbi.nlm.nih.gov/pubmed/27264113
53. Belbase, N.P., Agrawal, C.S., Pokharel, P.K., Agrawal, S., Lamsal, M., Shakya, V.C., Prostate cancer screening in a healthy population cohort in eastern Nepal: an explanatory trial study, Asian Pac J Cancer Prev, 2013. 14(5): p. 2835-2838., http://www.ncbi.nlm.nih.gov/pubmed/23803040
54. Rabah, D.M., Arafa, M.A., Prostate cancer screening in a Saudi population: an explanatory trial study, Prostate Cancer Prostatic. Dis, 2010. 13(2): p. 191-194., http://www.ncbi.nlm.nih.gov/pubmed/20066007
55. Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R.E., Levesque, J., et.al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer, Prostate, 2000. 45(1): p. 19-35., http://www.ncbi.nlm.nih.gov/pubmed/10960839
56. Lilja, H., Cronin, A.M., Dahlin, A., Manjer, J., Nilsson, P.M., Eastham, J.A., et.al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50, Cancer, 2011. 117(6): p. 1210-1219., http://www.ncbi.nlm.nih.gov/pubmed/20960520
57. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Zappa, M., Nelen, V., et.al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 2014., http://www.ncbi.nlm.nih.gov/pubmed/25108889
58. Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., et.al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial, Lancet Oncol, 2010. 11(8): p. 725-732., http://www.ncbi.nlm.nih.gov/pubmed/20598634
59. Pinsky, P.F., Prorok, P.C., Yu, K., Kramer, B.S., Black, A., Gohagan, J.K., et.al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years, Cancer, 2017. 123(4): p. 592-599., http://www.ncbi.nlm.nih.gov/pubmed/27911486
60. Tsodikov, A., Gulati, R., Heijnsdijk, E.A.M., Pinsky, P.F., Moss, S.M., Qiu, S., et.al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials, Annals of internal medicine, 2017. 167(7): p. 449-455., https://pubmed.ncbi.nlm.nih.gov/28869989/
61. Vickers, A.J., Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms, Annals of internal medicine, 2017. 167(7): p. 509-510., www.ncbi.nlm.nih.gov/pubmed/28869975
62. Ilic, D., Neuberger, M.M., Djulbegovic, M., Dahm, P., Screening for prostate cancer, Cochrane. Database. Syst. Rev, 2013. 1: p. CD004720., http://www.ncbi.nlm.nih.gov/pubmed/23440794
63. Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., et.al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer, European urology, 2019. 76(1): p. 43-51., https://pubmed.ncbi.nlm.nih.gov/30824296/
64. Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Stranne, J., et.al. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Goteborg randomised population-based prostate cancer screening trial, Eur J Cancer, 2011. 47(4): p. 545-553., http://www.ncbi.nlm.nih.gov/pubmed/21087857
65. Heijnsdijk, E. A. M., Wever, E. M., Auvinen, A., Hugosson, J., Ciatto, S., Nelen, V., et.al. Quality-of-life effects of prostate-specific antigen screening, The New England journal of medicine, 2012. 367(7): p. 595-605., https://pubmed.ncbi.nlm.nih.gov/22894572/
66. Vickers, A.J., Ulmert, D., Sjoberg, D.D., Bennette, C.J., Björk, T., Gerdtsson, A., et.al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis, BMJ (Clinical research ed.), 2013. 346: p. f2023., www.ncbi.nlm.nih.gov/pubmed/23596126
67. Randazzo, M., Beatrice, J., Huber, A., Grobholz, R., Manka, L., Chun, F.K., et.al. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml, European urology, 2015. 68(4): p. 591-597., https://pubmed.ncbi.nlm.nih.gov/24794075/
68. Bul, M., van den Bergh, R.C., Rannikko, A., Valdagni, R., Pickles, T., Bangma, C.H., et.al. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program, Eur Urol, 2012. 61(2): p. 370-377., http://www.ncbi.nlm.nih.gov/pubmed/21704447
69. Heidenreich, A., Bolla, M., Joniau, S., Mason, M.D., Matveev, V., Mottet, N., et.al. EAU guidelines on prostate cancer, 2013., https://uroweb.org/wp-content/uploads/09_Prostate_Cancer_LR.pdf
70. Carroll, P., Albertsen, P.C., Greene, K., Babaian, R.J., Ballentine Carter, H., Gann, P.H., et.al. Prostate-Specific Antigen Best Practice Statement: 2009 UpdateAmerican Urological Association (AUA), 2009.
71. Stephan, C., Klaas, M., Muller, C., Schnorr, D., Loening, S.A., Jung, K., Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update, Clin Chem, 2006. 52(1): p. 59-64., http://www.ncbi.nlm.nih.gov/pubmed/16391327
72. Lilja, H., Semjonow, A., Sibley, P., Babaian, R., Dowell, B., Rittenhouse, H., et.al. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Prostate CancerAmerican Association for Clinical Chemistry (AACC), 2006.
73. Semjonow, A., Zechel, C., Brandt, B., Flammang, F., Pepping, B., Hertle, L., Teststreifenuntersuchungen: prostataspezifisches Antigen (PSA), Urologe A, 1995. 34(Suppl 1): p. S91.
74. Lein, M., Jung, K., Schnorr, D., Henke, W., Brux, B., Loening, S.A., Rapid screening of PSA: evaluation of an immunochemical membrane strip test, Clin Chem, 1995. 41(10): p. 1545-1547., http://www.ncbi.nlm.nih.gov/pubmed/7586540
75. Berg, W., Linder, C., Eschholz, G., Link, S., Schubert, J., Possibility of improving the acceptance rateof early detection testing for prostate cancerwith a one-step test for prostate-specific antigen in whole blood, Urol Int, 1999. 63(2): p. 102-106., http://www.ncbi.nlm.nih.gov/pubmed/10592497
76. Oberpenning, F., Hetzel, S., Weining, C., Brandt, B., De, Angelis G., Heinecke, A., et.al. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?, Eur Urol, 2003. 43(5): p. 478-484., http://www.ncbi.nlm.nih.gov/pubmed/12705990
77. Carter, H.B., Albertsen, P.C., Barry, M.J., Etzioni, R., Freedland, S.J., Greene, K.L., et.al. Early Detection of Prostate Cancer: AUA Guideline, J Urol, 2013., http://www.ncbi.nlm.nih.gov/pubmed/23659877
78. Carter, H.B., Epstein, J.I., Chan, D.W., Fozard, J.L., Pearson, J.D., Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer, JAMA, 1997. 277(18): p. 1456-1460., http://www.ncbi.nlm.nih.gov/pubmed/9145718
79. Schröder, F.H., Carter, H.B., Wolters, T., van den Bergh, R.C., Gosselaar, C., Bangma, C.H., et.al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics, Eur Urol, 2008. 53(3): p. 468-477., http://www.ncbi.nlm.nih.gov/pubmed/17997011
80. Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., et.al. Prostate-cancer mortality at 11 years of follow-up, N. Engl. J Med, 2012. 366(11): p. 981-990., https://pubmed.ncbi.nlm.nih.gov/22417251/
81. van der Cruijsen-Koeter, I.W., van der Kwast, T.H., Schroder, F.H., Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam, J Natl Cancer Inst, 2003. 95(19): p. 1462-1466., http://www.ncbi.nlm.nih.gov/pubmed/14519752
82. Roobol, M.J., Roobol, D.W., Schroder, F.H., Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam), Urology, 2005. 65(2): p. 343-346., http://www.ncbi.nlm.nih.gov/pubmed/15708050
83. Vickers, A.J., Cronin, A.M., Bjork, T., Manjer, J., Nilsson, P.M., Dahlin, A., et.al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study, BMJ, 2010. 341: p. c4521., http://www.ncbi.nlm.nih.gov/pubmed/20843935
84. Catalona, W.J., Richie, J.P., Ahmann, F.R., Hudson, M.A., Scardino, P.T., Flanigan, R.C., et.al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men, J Urol, 1994. 151(5): p. 1283-1290., http://www.ncbi.nlm.nih.gov/pubmed/7512659
85. Brooks, D.D., Wolf, A., Smith, R.A., Dash, C., Guessous, I., Prostate cancer screening 2010: updated recommendations from the American Cancer Society, J Natl Med Assoc, 2010. 102(5): p. 423-429., http://www.ncbi.nlm.nih.gov/pubmed/20533778
86. Babaian, R.J., Fritsche, H.A., Evans, R.B., Prostate-specific antigen and prostate gland volume: correlation and clinical application, J Clin. Lab Anal, 1990. 4(2): p. 135-137., http://www.ncbi.nlm.nih.gov/pubmed/1690280
87. Benson, M.C., Whang, I.S., Olsson, C.A., McMahon, D.J., Cooner, W.H., The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen, J Urol, 1992. 147(3 Pt 2): p. 817-821., http://www.ncbi.nlm.nih.gov/pubmed/1371555
88. Semjonow, A., Hamm, M., Rathert, P., Hertle, L., Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer, Br. J Urol, 1994. 73(5): p. 538-543., http://www.ncbi.nlm.nih.gov/pubmed/7516808
89. Partin, A.W., Catalona, W.J., Southwick, P.C., Subong, E.N., Gasior, G.H., Chan, D.W., Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age, Urology, 1996. 48(6A Suppl): p. 55-61., http://www.ncbi.nlm.nih.gov/pubmed/8973701
90. Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., et.al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, JAMA, 1998. 279(19): p. 1542-1547., http://www.ncbi.nlm.nih.gov/pubmed/9605898
91. Woodrum, D.L., Brawer, M.K., Partin, A.W., Catalona, W.J., Southwick, P.C., Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer, J Urol, 1998. 159(1): p. 5-12., http://www.ncbi.nlm.nih.gov/pubmed/9400426
92. Berger, A.P., Deibl, M., Strasak, A., Bektic, J., Pelzer, A.E., Klocker, H., et.al. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer, Urology, 2007. 69(1): p. 134-138., http://www.ncbi.nlm.nih.gov/pubmed/17270635
93. Loeb, S., Roehl, K.A., Catalona, W.J., Nadler, R.B., Prostate specific antigen velocity threshold for predicting prostate cancer in young men, J. Urol, 2007. 177(3): p. 899-902., http://www.ncbi.nlm.nih.gov/pubmed/17296371
94. Kawachi, M.H., Bahnson, R.R., Barry, M., Busby, J.E., Carroll, P.R., Carter, H.B., et.al. NCCN clinical practice guidelines in oncology: prostate cancer early detection, J Natl Compr. Canc. Netw, 2010. 8(2): p. 240-262., http://www.ncbi.nlm.nih.gov/pubmed/20141680
95. Soletormos, G., Semjonow, A., Sibley, P.E., Lamerz, R., Petersen, P.H., Albrecht, W., et.al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice, Clin Chem, 2005. 51(8): p. 1342-1351., http://www.ncbi.nlm.nih.gov/pubmed/15961552
96. Heidenreich, A., Aus, G., Abbou, C.C., Bolla, M., Joniau, S., Matveev, V., et.al. EAU guidelines on prostate cancerEAU, 2007.
97. National Comprehensive Cancer Network (NCCN), Prostate Cancer Early Detection. Clinical Practice Guidelines in Oncology. V.2.2007NCCN, 2007.
98. Turkeri, L., Tarcan, T., Biren, T., Kullu, S., Akdas, A., Transrectal ultrasonography versus digitally guided prostate biopsies in patients with palpable lesions on digital rectal examination, Br J Urol, 1995. 76(2): p. 184-186., http://www.ncbi.nlm.nih.gov/pubmed/7545063
99. Renfer, L.G., Schow, D., Thompson, I.M., Optenberg, S., Is ultrasound guidance necessary for transrectal prostate biopsy?, J Urol, 1995. 154(4): p. 1390-1391., http://www.ncbi.nlm.nih.gov/pubmed/7658544
100. Hodge, K.K., McNeal, J.E., Terris, M.K., Stamey, T.A., Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate, J Urol, 1989. 142(1): p. 71-74., http://www.ncbi.nlm.nih.gov/pubmed/2659827
101. National Collaborating Centre for Cancer, National Institute for Health and Clinical Excellence (NICE), Prostate Cancer: diagnosis and treatment, 2008., http://www.nice.org.uk/Guidance/CG58
102. Eichler, K., Hempel, S., Wilby, J., Myers, L., Bachmann, L.M., Kleijnen, J., Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review, J Urol, 2006. 175(5): p. 1605-1612., http://www.ncbi.nlm.nih.gov/pubmed/16600713
103. NHS Cancer Screening Programmes, Undertaking a transrectal ultrasound guided biopsy of the prostate. PCRMP Guide No 1NHS Cancer Screening Programmes, 2006.
104. Bootsma, A.M., Laguna Pes, M.P., Geerlings, S.E., Goossens, A., Antibiotic prophylaxis in urologic procedures: a systematic review, Eur Urol, 2008. 54(6): p. 1270-1286., http://www.ncbi.nlm.nih.gov/pubmed/18423974
105. Hergan, L., Kashefi, C., Parsons, J.K., Local anesthetic reduces pain associated with transrectal ultrasound-guided prostate biopsy: a meta-analysis, Urology, 2007. 69(3): p. 520-525., https://www.ncbi.nlm.nih.gov/pubmed/17382157
106. Richman, J.M., Carter, H.B., Hanna, M.N., Murphy, J.D., Rowlingson, A.J., Andrews, R.A., et.al. Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis, Urology, 2006. 67(6): p. 1224-1228., http://www.ncbi.nlm.nih.gov/pubmed/16765183
107. Tiong, H.Y., Liew, L.C., Samuel, M., Consigliere, D., Esuvaranathan, K., A meta-analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate, Prostate Cancer Prostatic Dis, 2007. 10(2): p. 127-136., http://www.ncbi.nlm.nih.gov/pubmed/17211441
108. Borboroglu, P.G., Sur, R.L., Roberts, J.L., Amling, C.L., Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy, J Urol, 2001. 166(3): p. 866-870., http://www.ncbi.nlm.nih.gov/pubmed/11490235
109. Iczkowski, K.A., Bassler, T.J., Schwob, V.S., Bassler, I.C., Kunnel, B.S., Orozco, R.E., et.al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer, Urology, 1998. 51(5): p. 749-757., http://www.ncbi.nlm.nih.gov/pubmed/9610588
110. Davidson, D., Bostwick, D.G., Qian, J., Wollan, P.C., Oesterling, J.E., Rudders, R.A., et.al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies, J Urol, 1995. 154(4): p. 1295-1299., http://www.ncbi.nlm.nih.gov/pubmed/7544835
111. Epstein, J.I., Herawi, M., Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care, J Urol, 2006. 175(3 Pt 1): p. 820-834., http://www.ncbi.nlm.nih.gov/pubmed/16469560
112. Netto, G.J., Epstein, J.I., Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma, Am J Surg Pathol, 2006. 30(9): p. 1184-1188., http://www.ncbi.nlm.nih.gov/pubmed/16931964
113. Hoogendam, A., Buntinx, F., de Vet, H.C., The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis, Fam Pract, 1999. 16(6): p. 621-626., http://www.ncbi.nlm.nih.gov/pubmed/10625141
114. Philip, J., Dutta, Roy S., Ballal, M., Foster, C.S., Javle, P., Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?, BJU Int, 2005. 95(7): p. 969-971., http://www.ncbi.nlm.nih.gov/pubmed/15839915
115. Lavoipierre, A.M., Snow, R.M., Frydenberg, M., Gunter, D., Reisner, G., Royce, P.L., et.al. Prostatic cancer: role of color Doppler imaging in transrectal sonography, AJR Am J Roentgenol, 1998. 171(1): p. 205-210., http://www.ncbi.nlm.nih.gov/pubmed/9648790
116. Halpern, E.J., Strup, S.E., Using gray-scale and color and power Doppler sonography to detect prostatic cancer, AJR Am J Roentgenol, 2000. 174(3): p. 623-627., http://www.ncbi.nlm.nih.gov/pubmed/10701599
117. Lee, H.Y., Lee, H.J., Byun, S.S., Lee, S.E., Hong, S.K., Kim, S.H., Classification of focal prostatic lesions on transrectal ultrasound (TRUS) and the accuracy of TRUS to diagnose prostate cancer, Korean J Radiol, 2009. 10(3): p. 244-251., http://www.ncbi.nlm.nih.gov/pubmed/19412512
118. Tamsel, S., Killi, R., Hekimgil, M., Altay, B., Soydan, S., Demirpolat, G., Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels, J Med Imaging Radiat Oncol, 2008. 52(1): p. 24-28., http://www.ncbi.nlm.nih.gov/pubmed/18373822
119. Aigner, F., Pallwein, L., Mitterberger, M., Pinggera, G.M., Mikuz, G., Horninger, W., et.al. Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate, BJU Int, 2009. 103(4): p. 458-463., http://www.ncbi.nlm.nih.gov/pubmed/19021610
120. Colleselli, D., Bektic, J., Schaefer, G., Frauscher, F., Mitterberger, M., Brunner, A., et.al. The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy, BJU Int, 2007. 100(6): p. 1264-1267., http://www.ncbi.nlm.nih.gov/pubmed/17850369
121. Mitterberger, M., Horninger, W., Pelzer, A., Strasser, H., Bartsch, G., Moser, P., et.al. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection, Prostate, 2007. 67(14): p. 1537-1542., http://www.ncbi.nlm.nih.gov/pubmed/17705242
122. Tang, J., Yang, J.C., Li, Y., Li, J., Shi, H., Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography, J Ultrasound Med, 2007. 26(12): p. 1671-1679., http://www.ncbi.nlm.nih.gov/pubmed/18029918
123. Taymoorian, K., Thomas, A., Slowinski, T., Khiabanchian, M., Stephan, C., Lein, M., et.al. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies, Anticancer Res, 2007. 27(6C): p. 4315-4320., http://www.ncbi.nlm.nih.gov/pubmed/18214038
124. Wink, M., Frauscher, F., Cosgrove, D., Chapelon, J.Y., Palwein, L., Mitterberger, M., et.al. Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project, Eur Urol, 2008. 54(5): p. 982-992., http://www.ncbi.nlm.nih.gov/pubmed/18584944
125. Yang, J.C., Tang, J., Li, J., Luo, Y., Li, Y., Shi, H., Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels, Acad Radiol, 2008. 15(10): p. 1291-1297., http://www.ncbi.nlm.nih.gov/pubmed/18790401
126. Cochlin, D.L., Ganatra, R.H., Griffiths, D.F., Elastography in the detection of prostatic cancer, Clin Radiol, 2002. 57(11): p. 1014-1020., https://www.ncbi.nlm.nih.gov/pubmed/12409113
127. Eggert, T., Khaled, W., Wenske, S., Ermert, H., Noldus, J., Stellenwert der Elastographie in der klinischen Diagnostik des lokalisierten Prostatakarzinoms. Vergleich von Detektionsraten der B-Modus-Sonographie und der elastographieunterstutzten systematischen 10fach-Biopsie, Urologe A, 2008. 47(9): p. 1212-1217., http://www.ncbi.nlm.nih.gov/pubmed/18704361
128. Kamoi, K., Okihara, K., Ochiai, A., Ukimura, O., Mizutani, Y., Kawauchi, A., et.al. The utility of transrectal real-time elastography in the diagnosis of prostate cancer, Ultrasound Med Biol, 2008. 34(7): p. 1025-1032., http://www.ncbi.nlm.nih.gov/pubmed/18255215
129. Konig, K., Scheipers, U., Pesavento, A., Lorenz, A., Ermert, H., Senge, T., Initial experiences with real-time elastography guided biopsies of the prostate, J Urol, 2005. 174(1): p. 115-117., http://www.ncbi.nlm.nih.gov/pubmed/15947593
130. Miyagawa, T., Tsutsumi, M., Matsumura, T., Kawazoe, N., Ishikawa, S., Shimokama, T., et.al. Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images, Jpn J Clin Oncol, 2009. 39(6): p. 394-398., http://www.ncbi.nlm.nih.gov/pubmed/19359330
131. Nelson, E.D., Slotoroff, C.B., Gomella, L.G., Halpern, E.J., Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score, Urology, 2007. 70(6): p. 1136-1140., http://www.ncbi.nlm.nih.gov/pubmed/18158034
132. Salomon, G., Köllerman, J., Thederan, I., Chun, F.K., Budäus, L., Schlomm, T., et.al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy, Eur Urol, 2008. 54(6): p. 1354-1362., http://www.ncbi.nlm.nih.gov/pubmed/18374470
133. Tsutsumi, M., Miyagawa, T., Matsumura, T., Kawazoe, N., Ishikawa, S., Shimokama, T., et.al. The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis, Int J Clin Oncol, 2007. 12(4): p. 250-255., http://www.ncbi.nlm.nih.gov/pubmed/17701002
134. Braeckman, J., Autier, P., Garbar, C., Marichal, M.P., Soviany, C., Nir, R., et.al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer, BJU. Int, 2008. 101(3): p. 293-298., http://www.ncbi.nlm.nih.gov/pubmed/17922870
135. Braeckman, J., Autier, P., Soviany, C., Nir, R., Nir, D., Michielsen, D., et.al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers, BJU. Int, 2008. 102(11): p. 1560-1565., http://www.ncbi.nlm.nih.gov/pubmed/18710457
136. Schoots, I.G., Barentsz, J.O., Bittencourt, L.K., Haider, M.A., Macura, K.J., Margolis, D.J.A., et.al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer, AJR. American journal of roentgenology, 2021. 216(1): p. 3-19., https://pubmed.ncbi.nlm.nih.gov/32812795/
137. Turkbey, B., Rosenkrantz, A.B., Haider, M.A., Padhani, A.R., Villeirs, G., Macura, K.J., et.al. Prostate Imaging Reporting and Data System Version 2.1, European urology, 2019. 76(3): p. 340-351., https://pubmed.ncbi.nlm.nih.gov/30898406/
138. Drost, F. J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., et.al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer, Cochrane Database Syst Rev, 2019. 4(4): p. CD012663., https://pubmed.ncbi.nlm.nih.gov/31022301/
139. Wegelin, O., van Melick, H.H., Hooft, L., Bosch, J.L., Reitsma, H.B., Barentsz, J.O., et.al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?, Eur Urol, 2017. 71(4): p. 517-531., http://www.ncbi.nlm.nih.gov/pubmed/27568655
140. Gayet, M., van der Aa, A., Beerlage, H.P., Schrier, B.P., Mulders, P.F., Wijkstra, H., The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review, BJU Int, 2016. 117(3): p. 392-400., http://www.ncbi.nlm.nih.gov/pubmed/26237632
141. Wu, J., Ji, A., Xie, B., Wang, X., Zhu, Y., Wang, J., et.al. Is magnetic resonance/ultrasound fusion prostate biopsy better than systematic prostate biopsy? An updated meta- and trial sequential analysis, Oncotarget, 2015. 6(41): p. 43571-43580., http://www.ncbi.nlm.nih.gov/pubmed/26498362
142. Valerio, M., Donaldson, I., Emberton, M., Ehdaie, B., Hadaschik, B.A., Marks, L.S., et.al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review, Eur Urol, 2015. 68(1): p. 8-19., http://www.ncbi.nlm.nih.gov/pubmed/25454618
143. Schoots, I.G., Roobol, M.J., Nieboer, D., Bangma, C.H., Steyerberg, E.W., Hunink, M.G., Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis, Eur Urol, 2015. 68(3): p. 438-450., http://www.ncbi.nlm.nih.gov/pubmed/25480312
144. Filson, C.P., Natarajan, S., Margolis, D.J., Huang, J., Lieu, P., Dorey, F.J., et.al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies, Cancer, 2016. 122(6): p. 884-892., http://www.ncbi.nlm.nih.gov/pubmed/26749141
145. Klein, J., de Gorski, A., Benamran, D., Vallee, J.P., De, Perrot T., Wirth, G.J., et.al. Transrectal Ultrasound-Guided Prostate Biopsy for Cancer Detection: Performance of 2D-, 3D- and 3D-MRI Fusion Targeted Techniques, Urol Int, 2017. 98(1): p. 7-14., http://www.ncbi.nlm.nih.gov/pubmed/27784024
146. Mendhiratta, N., Rosenkrantz, A.B., Meng, X., Wysock, J.S., Fenstermaker, M., Huang, R., et.al. Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification, J Urol, 2015. 194(6): p. 1601-1606., http://www.ncbi.nlm.nih.gov/pubmed/26100327
147. Porpiglia, F., De Luca, S., Passera, R., Manfredi, M., Mele, F., Bollito, E., et.al. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score, Anticancer Res, 2016. 36(9): p. 4833-4839., http://www.ncbi.nlm.nih.gov/pubmed/27630337
148. Siddiqui, M.M., Rais, Bahrami S., Turkbey, B., George, A.K., Rothwax, J., Shakir, N., et.al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer, JAMA, 2015. 313(4): p. 390-397., http://www.ncbi.nlm.nih.gov/pubmed/25626035
149. Rastinehad, A.R., Waingankar, N., Turkbey, B., Yaskiv, O., Sonstegard, A.M., Fakhoury, M., et.al. Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies, PLoS One, 2015. 10(11): p. e0143404., http://www.ncbi.nlm.nih.gov/pubmed/26605548
150. Porpiglia, F., Russo, F., Manfredi, M., Mele, F., Fiori, C., Regge, D., Preoperative prostate biopsy and multiparametric magnetic resonance imaging: reliability in detecting prostate cancer, Int Braz J Urol, 2015. 41(1): p. 124-133., http://www.ncbi.nlm.nih.gov/pubmed/25928518
151. de Gorski, A., Roupret, M., Peyronnet, B., Le, Cossec C., Granger, B., Comperat, E., et.al. Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates, J Urol, 2015. 194(3): p. 669-673., http://www.ncbi.nlm.nih.gov/pubmed/25784374
152. Drost, F. J. H., Osses, D., Nieboer, D., Bangma, C. H., Steyerberg, E. W., Roobol, M. J., et.al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer, Eur Urol, 2020. 77(1): p. 78-94., https://pubmed.ncbi.nlm.nih.gov/31326219/
153. Naji, L., Randhawa, H., Sohani, Z., Dennis, B., Lautenbach, D., Kavanagh, O., et.al. Digital Rectal Examination for Prostate Cancer Screening in Primary Care, Annals of family medicine, 2018. 16(2): p. 149-154., https://pubmed.ncbi.nlm.nih.gov/29531107/
154. Sen, J., Choudhary, L., Marwah, S., Godara, R., Marwah, N., Sen, R., Role of colour Doppler imaging in detecting prostate cancer, Asian J Surg, 2008. 31(1): p. 16-19., http://www.ncbi.nlm.nih.gov/pubmed/18334464
155. Franiel, T., Asbach, P. , Beyersdorff, D. , Blondin, D., Kaufmann, S. , Mueller-Lisse, U.G. , et.al. mpMRI of the Prostate (MR-Prostatography): Updated Recommendations of the DRG and BDR on Patient Preparation and Scanning ProtocolRofo, 2021. Online ahead of print:, https://pubmed.ncbi.nlm.nih.gov/33735931/
156. Franiel, T., Quentin, M., Mueller-Lisse, U.G., Schimmoeller, L., Asbach, P., Rodel, S., et.al. MRT der Prostata: Empfehlungen zur Vorbereitung und Durchführung, Rofo, 2017. 189(1): p. 21-28., http://www.ncbi.nlm.nih.gov/pubmed/28002857
157. Cheikh, A.B., Girouin, N., Colombel, M., Marechal, J.M., Gelet, A., Bissery, A., et.al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy, Eur Radiol, 2009. 19(3): p. 770-778., http://www.ncbi.nlm.nih.gov/pubmed/18925403
158. Labanaris, A.P., Engelhard, K., Zugor, V., Nutzel, R., Kuhn, R., Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate, Prostate Cancer Prostatic Dis, 2010. 13(1): p. 65-70., http://www.ncbi.nlm.nih.gov/pubmed/19752886
159. Sciarra, A., Panebianco, V., Ciccariello, M., Salciccia, S., Cattarino, S., Lisi, D., et.al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy, Clin Cancer Res, 2010. 16(6): p. 1875-1883., https://www.ncbi.nlm.nih.gov/pubmed/20197480
160. Seitz, M., Shukla-Dave, A., Bjartell, A., Touijer, K., Sciarra, A., Bastian, P.J., et.al. Functional magnetic resonance imaging in prostate cancer, Eur Urol, 2009. 55(4): p. 801-814., http://www.ncbi.nlm.nih.gov/pubmed/19185981
161. Haider, M.A., Yao, X., Loblaw, A., Finelli, A., Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review, Clin Oncol (R Coll Radiol), 2016. 28(9): p. 550-567., https://www.ncbi.nlm.nih.gov/pubmed/27256655
162. Delongchamps, N.B., Portalez, D., Bruguiere, E., Rouviere, O., Malavaud, B., Mozer, P., et.al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?, J Urol, 2016. 196(4): p. 1069-1075., http://www.ncbi.nlm.nih.gov/pubmed/27079582
163. Peltier, A., Aoun, F., Lemort, M., Kwizera, F., Paesmans, M., van, Velthoven R., MRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naive men, Biomed Res Int, 2015. 2015: p. 571708., http://www.ncbi.nlm.nih.gov/pubmed/25692142
164. Mariotti, G.C., Costa, D.N., Pedrosa, I., Falsarella, P.M., Martins, T., Roehrborn, C.G., et.al. Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients, Urol Oncol, 2016. 34(9): p. 416-416., http://www.ncbi.nlm.nih.gov/pubmed/27197921
165. Baco, E., Rud, E., Eri, L.M., Moen, G., Vlatkovic, L., Svindland, A., et.al. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy, Eur Urol, 2016. 69(1): p. 149-156., http://www.ncbi.nlm.nih.gov/pubmed/25862143
166. Panebianco, V., Barchetti, F., Sciarra, A., Ciardi, A., Indino, E.L., Papalia, R., et.al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study, Urol Oncol, 2015. 33(1): p. 17-17., http://www.ncbi.nlm.nih.gov/pubmed/25443268
167. Tonttila, P.P., Lantto, J., Paakko, E., Piippo, U., Kauppila, S., Lammentausta, E., et.al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial, Eur Urol, 2016. 69(3): p. 419-425., http://www.ncbi.nlm.nih.gov/pubmed/26033153
168. Ahmed, H.U., El-Shater, Bosaily A., Brown, L.C., Gabe, R., Kaplan, R., Parmar, M.K., et.al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, 2017. 389(10071): p. 815-822., http://www.ncbi.nlm.nih.gov/pubmed/28110982
169. Kasivisvanathan, V., Stabile, A., Neves, J. B., Giganti, F., Valerio, M., Shanmugabavan, Y., et.al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer, Eur Urol, 2019. 76(3): p. 284-303., https://pubmed.ncbi.nlm.nih.gov/31130434/
170. Ahdoot, M., Wilbur, A.R., Reese, S.E., Lebastchi, A.H., Mehralivand, S., Gomella, P.T., et.al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis, The New England journal of medicine, 2020. 382(10): p. 917-928., https://pubmed.ncbi.nlm.nih.gov/32130814/
171. Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., et.al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST), The Lancet. Oncology, 2019. 20(1): p. 100-109., https://pubmed.ncbi.nlm.nih.gov/30470502/
172. Tschirdewahn, S., Wiesenfarth, M., Bonekamp, D., Püllen, L., Reis, H., Panic, A., et.al. Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy, European urology focus, 2020. p. [Epub ahead of print]., https://pubmed.ncbi.nlm.nih.gov/32660838/
173. Dimitroulis, P., Rabenalt, R., Nini, A., Hiester, A., Esposito, I., Schimmöller, L., et.al. Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy-Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?, The Journal of urology, 2018. 200(5): p. 1030-1034., https://pubmed.ncbi.nlm.nih.gov/29733837/
174. Osses, D. F., Arsov, C., Schimmöller, L., Schoots, I. G., van Leenders, G. J. L. H., Esposito, I., et.al. Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging, Journal of personalized medicine, 2020. 10(4):, https://pubmed.ncbi.nlm.nih.gov/33321791/
175. National Institute for Health and Care Excellence (NICE), Prostate cancer: diagnosis and managementNICE, NICE Guideline; 175, 2014., http://www.nice.org.uk/guidance/cg175/resources/prostate-cancer-diagnosis-and-management-pdf-35109753913285
176. Krause, B.J., Souvatzoglou, M., Treiber, U., Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates, Urol Oncol, 2011., http://www.ncbi.nlm.nih.gov/pubmed/21388835
177. Püllen, L., Radtke, J.P., Wiesenfarth, M., Roobol, M.J., Verbeek, J.F.M., Wetter, A., et.al. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction, BJU international, 2020. 125(3): p. 407-416., https://pubmed.ncbi.nlm.nih.gov/31758738/
178. Alberts, A.R., Roobol, M.J., Verbeek, J.F.M., Schoots, I.G., Chiu, P.K., Osses, D.F., et.al. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging, European urology, 2019. 75(2): p. 310-318., https://pubmed.ncbi.nlm.nih.gov/30082150/
179. Perrin, A., Venderink, W., Patak, M. A., Möckel, Cl., Fehr, J.L., Jichlinski, P., et.al. The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy, Urologic oncology, 2020., https://pubmed.ncbi.nlm.nih.gov/33341358/
180. Schoots, I.G., Petrides, N., Giganti, F., Bokhorst, L.P., Rannikko, A., Klotz, L., et.al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review, Eur Urol, 2015. 67(4): p. 627-636., http://www.ncbi.nlm.nih.gov/pubmed/25511988
181. Guo, R., Cai, L., Fan, Y., Jin, J., Zhou, L., Zhang, K., Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis, Prostate Cancer Prostatic. Dis, 2015. 18(3): p. 221-228., http://www.ncbi.nlm.nih.gov/pubmed/25986915
182. Scarpato, K.R., Barocas, D.A., Use of mpMRI in active surveillance for localized prostate cancer, Urol Oncol, 2016. 34(7): p. 320-325., http://www.ncbi.nlm.nih.gov/pubmed/27036218
183. Radtke, J.P., Kuru, T.H., Bonekamp, D., Freitag, M.T., Wolf, M.B., Alt, C.D., et.al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance, Prostate Cancer Prostatic. Dis, 2016. 19(3): p. 283-291., http://www.ncbi.nlm.nih.gov/pubmed/27184812
184. Klotz, L., Pond, G., Loblaw, A., Sugar, L., Moussa, M., Berman, D., et.al. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST), European urology, 2020. 77(3): p. 311-317., https://pubmed.ncbi.nlm.nih.gov/31708295/
185. Dieffenbacher, S., Nyarangi-Dix, J., Giganti, F., Bonekamp, D., Kesch, C., Müller-Wolf, M. B., et.al. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance, European urology focus, 2019. p. [Epub ahead of print]., https://pubmed.ncbi.nlm.nih.gov/30878348/
186. Amin, A., Scheltema, M.J., Shnier, R., Blazevski, A., Moses, D., Cusick, T., et.al. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial, The Journal of urology, 2020. 203(5): p. 910-917., https://pubmed.ncbi.nlm.nih.gov/31825297/
187. Giganti, F., Stabile, A., Stavrinides, V., Osinibi, E., Retter, A., Orczyk, C., et.al. Natural history of prostate cancer on active surveillance, European radiology, 2021. 31(3): p. 1644-1655., https://pubmed.ncbi.nlm.nih.gov/33000302/
188. Moore, C. M., Giganti, F., Albertsen, P., Allen, C., Bangma, C., Briganti, A., et.al. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer, European urology, 2017. 71(4): p. 648-655., https://pubmed.ncbi.nlm.nih.gov/27349615/
189. Wittekind, C., Klimpfinger, M., Sobin, L.H., TNM : Klassifikation maligner TumorenWiley-VCH, 2017.
190. Dutch Urological Association, Prostate Cancer. Nation-wide guideline. Version 1.0Dutch Urological Association, 2007.
191. Thompson, I., Thrasher, J.B., Aus, G., Burnett, A.L., Canby-Hagino, E.D., Cookson, M.S., et.al. Guideline for the management of clinically localized prostate cancer: 2007 update (confirmed 2009), J Urol, 2007. 177(6): p. 2106-2131., http://www.ncbi.nlm.nih.gov/pubmed/17509297
192. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Blank, K., Broderick, G.A., et.al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 1998. 280(11): p. 969-974., http://www.ncbi.nlm.nih.gov/pubmed/9749478
193. Manikandan, R., Qazi, H.A., Philip, J., Mistry, R., Lamb, G.H., Woolfenden, K.A., et.al. Routine use of magnetic resonance imaging in the management of T(1c) carcinoma of the prostate: is it necessary?, J Endourol, 2007. 21(10): p. 1171-1174., http://www.ncbi.nlm.nih.gov/pubmed/17949319
194. Nogueira, L., Wang, L., Fine, S.W., Pinochet, R., Kurta, J.M., Katz, D., et.al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI, Urology, 2010. 75(2): p. 472-477., http://www.ncbi.nlm.nih.gov/pubmed/19643467
195. Turkbey, B., Pinto, P.A., Mani, H., Bernardo, M., Pang, Y., McKinney, Y.L., et.al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation, Radiology, 2010. 255(1): p. 89-99., http://www.ncbi.nlm.nih.gov/pubmed/20308447
196. Weinreb, J.C., Blume, J.D., Coakley, F.V., Wheeler, T.M., Cormack, J.B., Sotto, C.K., et.al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study, Radiology, 2009. 251(1): p. 122-133., http://www.ncbi.nlm.nih.gov/pubmed/19332850
197. Abuzallouf, S., Dayes, I., Lukka, H., Baseline staging of newly diagnosed prostate cancer: a summary of the literature, J Urol, 2004. 171(6 Pt 1): p. 2122-2127., http://www.ncbi.nlm.nih.gov/pubmed/15126770
198. Ayyathurai, R., Mahapatra, R., Rajasundaram, R., Srinivasan, V., Archard, N.P., Toussi, H., A study on staging bone scans in newly diagnosed prostate cancer, Urol Int, 2006. 76(3): p. 209-212., http://www.ncbi.nlm.nih.gov/pubmed/16601380
199. Ishizuka, O., Tanabe, T., Nakayama, T., Kawakami, M., Kinebuchi, Y., Nishizawa, O., Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan, Int J Urol, 2005. 12(8): p. 728-732., http://www.ncbi.nlm.nih.gov/pubmed/16174046
200. Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., et.al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA), Lancet, 2020. 395(10231): p. 1208-1216., https://pubmed.ncbi.nlm.nih.gov/32209449/
201. Briganti, A., Chun, F.K., Salonia, A., Gallina, A., Farina, E., Da Pozzo, L.F., et.al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer, BJU Int, 2006. 98(4): p. 788-793., http://www.ncbi.nlm.nih.gov/pubmed/16796698
202. Steuber, T., Graefen, M., Haese, A., Erbersdobler, A., Chun, F.K., Schlom, T., et.al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy, J Urol, 2006. 175(3 Pt 1): p. 939-944., http://www.ncbi.nlm.nih.gov/pubmed/16469587
203. Chun, F.K., Briganti, A., Graefen, M., Montorsi, F., Porter, C., Scattoni, V., et.al. Development and external validation of an extended 10-core biopsy nomogram, Eur Urol, 2007. 52(2): p. 436-444., http://www.ncbi.nlm.nih.gov/pubmed/17010505
204. Engelbrecht, M.R., Jager, G.J., Laheij, R.J., Verbeek, A.L., van Lier, H.J., Barentsz, J.O., Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis, Eur Radiol, 2002. 12(9): p. 2294-2302., http://www.ncbi.nlm.nih.gov/pubmed/12195484
205. Soulie, M., Aziza, R., Escourrou, G., Seguin, P., Tollon, C., Molinier, L., et.al. Assessment of the risk of positive surgical margins with pelvic phased-array magnetic resonance imaging in patients with clinically localized prostate cancer: a prospective study, Urology, 2001. 58(2): p. 228-232., http://www.ncbi.nlm.nih.gov/pubmed/11489708
206. Nakashima, J., Tanimoto, A., Imai, Y., Mukai, M., Horiguchi, Y., Nakagawa, K., et.al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer, Urology, 2004. 64(1): p. 101-105., http://www.ncbi.nlm.nih.gov/pubmed/15245944
207. Wang, L., Hricak, H., Kattan, M.W., Schwartz, L.H., Eberhardt, S.C., Chen, H.N., et.al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer, AJR Am J Roentgenol, 2006. 186(3): p. 743-748., http://www.ncbi.nlm.nih.gov/pubmed/16498101
208. Park, B.K., Kim, B., Kim, C.K., Lee, H.M., Kwon, G.Y., Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer, J Comput Assist Tomogr, 2007. 31(4): p. 534-538., http://www.ncbi.nlm.nih.gov/pubmed/17882027
209. Pfister, D., Porres, D., Heidenreich, A., Heidegger, I., Knuechel, R., Steib, F., et.al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT, Eur J Nucl Med Mol Imaging, 2016., http://www.ncbi.nlm.nih.gov/pubmed/26993315
210. Sterzing, F., Kratochwil, C., Fiedler, H., Katayama, S., Habl, G., Kopka, K., et.al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 2016. 43(1): p. 34-41., http://www.ncbi.nlm.nih.gov/pubmed/26404016
211. Morigi, J.J., Stricker, P.D., van Leeuwen, P.J., Tang, R., Ho, B., Nguyen, Q., et.al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy, J Nucl Med, 2015. 56(8): p. 1185-1190., http://www.ncbi.nlm.nih.gov/pubmed/26112024
212. Afshar-Oromieh, A., Zechmann, C.M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H.G., et.al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 2014. 41(1): p. 11-20., http://www.ncbi.nlm.nih.gov/pubmed/24072344
213. van Leeuwen, P.J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., et.al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment, BJU Int, 2016. 117(5): p. 732-739., http://www.ncbi.nlm.nih.gov/pubmed/26683282
214. Shakespeare, T.P., Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists, Radiat Oncol, 2015. 10: p. 233., http://www.ncbi.nlm.nih.gov/pubmed/26582424
215. Boni, R.A., Hutter, B.E., Trinkler, F., Jochum, W., Pestalozzi, D., Krestin, G.P., Präoperatives T-Staging des Prostatakarzinoms: Endorektale Magnetresonanztomographie im Vergleich zu anderen bildgebenden und klinischen Methoden, Rofo, 1996. 165(2): p. 152-158., http://www.ncbi.nlm.nih.gov/pubmed/8924668
216. Smith, J.A., Jr., Scardino, P.T., Resnick, M.I., Hernandez, A.D., Rose, S.C., Egger, M.J., Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial, J Urol, 1997. 157(3): p. 902-906., http://www.ncbi.nlm.nih.gov/pubmed/9072596
217. Hsu, C.Y., Joniau, S., Oyen, R., Roskams, T., Van Poppel, H., Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography?, BJU Int, 2006. 98(5): p. 982-985., http://www.ncbi.nlm.nih.gov/pubmed/16945120
218. Hsu, C.Y., Joniau, S., Oyen, R., Roskams, T., Van, Poppel H., Transrectal ultrasound in the staging of clinical T3a prostate cancer, Eur J Surg Oncol, 2007. 33(1): p. 79-82., http://www.ncbi.nlm.nih.gov/pubmed/17067773
219. Mullerad, M., Hricak, H., Wang, L., Chen, H.N., Kattan, M.W., Scardino, P.T., Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging, Radiology, 2004. 232(1): p. 140-146., http://www.ncbi.nlm.nih.gov/pubmed/15166319
220. Sonnad, S.S., Langlotz, C.P., Schwartz, J.S., Accuracy of MR imaging for staging prostate cancer: a meta-analysis to examine the effect of technologic change, Acad Radiol, 2001. 8(2): p. 149-157., http://www.ncbi.nlm.nih.gov/pubmed/11227643
221. Wang, L., Hricak, H., Kattan, M.W., Chen, H.N., Scardino, P.T., Kuroiwa, K., Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms, Radiology, 2006. 238(2): p. 597-603., http://www.ncbi.nlm.nih.gov/pubmed/16344335
222. Wang, L., Hricak, H., Kattan, M.W., Chen, H.N., Kuroiwa, K., Eisenberg, H.F., et.al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram, Radiology, 2007. 242(1): p. 182-188., http://www.ncbi.nlm.nih.gov/pubmed/17090712
223. Brown, J.A., Rodin, D.M., Harisinghani, M., Dahl, D.M., Impact of preoperative endorectal MRI stage classification on neurovascular bundle sparing aggressiveness and the radical prostatectomy positive margin rate, Urol Oncol, 2009. 27(2): p. 174-179., http://www.ncbi.nlm.nih.gov/pubmed/18640062
224. Brajtbord, J.S., Lavery, H.J., Nabizada-Pace, F., Senaratne, P., Samadi, D.B., Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer, BJU Int, 2010., http://www.ncbi.nlm.nih.gov/pubmed/20804475
225. Torricelli, P., Barberini, A., Cinquantini, F., Sighinolfi, M., Cesinaro, A.M., 3-T MRI with phased-array coil in local staging of prostatic cancer, Acad Radiol, 2008. 15(9): p. 1118-1125., http://www.ncbi.nlm.nih.gov/pubmed/18692752
226. Ren, J., Huan, Y., Li, F., Wang, H., Ge, Y., Chang, Y., et.al. Combined T2-weighted and diffusion-weighted MRI for diagnosis of urinary bladder invasion in patients with prostate carcinoma, J Magn Reson. Imaging, 2009. 30(2): p. 351-356., http://www.ncbi.nlm.nih.gov/pubmed/19591203
227. Even-Sapir, E., Metser, U., Mishani, E., Lievshitz, G., Lerman, H., Leibovitch, I., The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT, J Nucl Med, 2006. 47(2): p. 287-297., http://www.ncbi.nlm.nih.gov/pubmed/16455635
228. Tu, X., Zhang, C., Liu, Z., Shen, G., Wu, X., Nie, L., et.al. The Role of (68)Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer, Front Oncol, 2020. 10(1365): p. 1-11., https://pubmed.ncbi.nlm.nih.gov/33014777/
229. Evangelista, L., Zattoni, F., Cassarino, G., Artioli, P., Cecchin, D., Dal Moro, F., et.al. PET/MRI in prostate cancer, Eur J Nucl Med Mol Imaging, 2021. 3: p. 859 - 873., https://pubmed.ncbi.nlm.nih.gov/32901351/
230. Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., et.al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer, JAMA Oncol, 2020. 6(5): p. 650-659., https://pubmed.ncbi.nlm.nih.gov/32215577/
231. Feria Cardet, R. E., Hofman, M. S., Segard, T., Yim, J., Williams, S., Francis, R. J., et.al. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer, European urology, 2021. 79(3): p. 413-418., https://pubmed.ncbi.nlm.nih.gov/33341285/
232. Kattan, M.W., Eastham, J.A., Stapleton, A.M., Wheeler, T.M., Scardino, P.T., A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer, J Natl Cancer Inst, 1998. 90(10): p. 766-771., http://www.ncbi.nlm.nih.gov/pubmed/9605647
233. Kattan, M.W., Zelefsky, M.J., Kupelian, P.A., Scardino, P.T., Fuks, Z., Leibel, S.A., Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer, J Clin Oncol, 2000. 18(19): p. 3352-3359., http://www.ncbi.nlm.nih.gov/pubmed/11013275
234. Kattan, M.W., Potters, L., Blasko, J.C., Beyer, D.C., Fearn, P., Cavanagh, W., et.al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer, Urology, 2001. 58(3): p. 393-399., http://www.ncbi.nlm.nih.gov/pubmed/11549487
235. Herlemann, A., Wenter, V., Kretschmer, A., Thierfelder, K.M., Bartenstein, P., Faber, C., et.al. Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer, Eur Urol, 2016., http://www.ncbi.nlm.nih.gov/pubmed/26810345
236. Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M.S., Murphy, D.G., et.al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis, Eur Urol, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27363387
237. Bostwick, D.G., Grignon, D.J., Hammond, M.E., Amin, M.B., Cohen, M., Crawford, D., et.al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med, 2000. 124(7): p. 995-1000., http://www.ncbi.nlm.nih.gov/pubmed/10888774
238. Bostwick, D.G., Foster, C.S., Algaba, F., Hutter, R.V., Montironi, R., Mostofi, F.K., Prostate tissue factors, in Prostate cancer. Second international consultation on prostate cancer, Murphy, G.Denis, L.Khoury, S.Partin, A. and Denis, L.2000, Plymbridge: Plymouth. p. 162-201.
239. Bennett, V., Varma, M., Bailey, D., Guidelines for the Macroscopic Processing of Radical Prostatectomy and Pelvic Lymphadenectomy Specimens, J Clin Pathol, 2008. 61: p. 713-721.
240. Samaratunga, H., Montironi, R., True, L., Epstein, J.I., Griffiths, D.F., Humphrey, P.A., et.al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling, Mod. Pathol, 2011. 24(1): p. 6-15., http://www.ncbi.nlm.nih.gov/pubmed/20834234
241. Berney, D.M., Wheeler, T.M., Grignon, D.J., Epstein, J.I., Griffiths, D.F., Humphrey, P.A., et.al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes, Mod. Pathol, 2011. 24(1): p. 39-47., http://www.ncbi.nlm.nih.gov/pubmed/20818343
242. van der Kwast, T.H., Amin, M.B., Billis, A., Epstein, J.I., Griffiths, D., Humphrey, P.A., et.al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume, Mod. Pathol, 2011. 24(1): p. 16-25., http://www.ncbi.nlm.nih.gov/pubmed/20818340
243. Magi-Galluzzi, C., Evans, A.J., Delahunt, B., Epstein, J.I., Griffiths, D.F., van der Kwast, T.H., et.al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease, Mod. Pathol, 2011. 24(1): p. 26-38., http://www.ncbi.nlm.nih.gov/pubmed/20802467
244. Egevad, L., Srigley, J.R., Delahunt, B., International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: rationale and organization, Mod. Pathol, 2011. 24(1): p. 1-5., http://www.ncbi.nlm.nih.gov/pubmed/20802466
245. Tan, P.H., Cheng, L., Srigley, J.R., Griffiths, D., Humphrey, P.A., van der Kwast, T.H., et.al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins, Mod. Pathol, 2011. 24(1): p. 48-57., http://www.ncbi.nlm.nih.gov/pubmed/20729812
246. Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R., Humphrey, P.A., The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, Am J Surg Pathol, 2016. 40(2): p. 244-252., http://www.ncbi.nlm.nih.gov/pubmed/26492179
247. Bundesverband Deutscher Pathologen (BDP), Deutsche Gesellschaft für Pathologie (DGP), Anleitung zur pathologisch-anatomischen Diagnostik von Prostatatumoren. Version 2.0 des Bundesverbandes Deutscher Pathologen und der Deutschen Gesellschaft fuer Pathologie, 2011., http://www.dgp-berlin.de/downloads/public/guidelines/anleitungen/Anleitung_Prostatakarzinom.pdf
248. Roehl, K.A., Han, M., Ramos, C.G., Antenor, J.A., Catalona, W.J., Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results, J Urol, 2004. 172(3): p. 910-914., http://www.ncbi.nlm.nih.gov/pubmed/15310996
249. Lopez-Beltran, A., Mikuz, G., Luque, R.J., Mazzucchelli, R., Montironi, R., Current practice of Gleason grading of prostate carcinoma, Virchows Arch, 2006. 448(2): p. 111-118., http://www.ncbi.nlm.nih.gov/pubmed/16328356
250. Epstein, J.I., Partin, A.W., Sauvageot, J., Walsh, P.C., Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up, Am J Surg Pathol, 1996. 20(3): p. 286-292., http://www.ncbi.nlm.nih.gov/pubmed/8772781
251. Partin, A.W., Mangold, L.A., Lamm, D.M., Walsh, P.C., Epstein, J.I., Pearson, J.D., Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium, Urology, 2001. 58(6): p. 843-848., http://www.ncbi.nlm.nih.gov/pubmed/11744442
252. Svanholm, H., Mygind, H., Prostatic carcinoma reproducibility of histologic grading, Acta Pathol Microbiol. Immunol. Scand A, 1985. 93(2): p. 67-71., http://www.ncbi.nlm.nih.gov/pubmed/3984736
253. Makarov, D.V., Trock, B.J., Humphreys, E.B., Mangold, L.A., Walsh, P.C., Epstein, J.I., et.al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005, Urology, 2007. 69(6): p. 1095-1101., http://www.ncbi.nlm.nih.gov/pubmed/17572194
254. Kattan, M.W., Eastham, J., Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer, Clin Prostate Cancer, 2003. 1(4): p. 221-226., http://www.ncbi.nlm.nih.gov/pubmed/15040880
255. Kristiansen, G., Diagnostic and prognostic molecular biomarkers for prostate cancer, Histopathology, 2012. 60(1): p. 125-141., http://www.ncbi.nlm.nih.gov/pubmed/22212082
256. Epstein, J.I., Egevad, L., Humphrey, P.A., Montironi, R., Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference, Am J Surg Pathol, 2014. 38(8): p. e6-e19., http://www.ncbi.nlm.nih.gov/pubmed/25029122
257. Schlesinger, C., Bostwick, D.G., Iczkowski, K.A., High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice, Am J Surg Pathol, 2005. 29(9): p. 1201-1207., http://www.ncbi.nlm.nih.gov/pubmed/16096410
258. Moore, C.K., Karikehalli, S., Nazeer, T., Fisher, H.A., Kaufman, R.P., Jr., Mian, B.M., Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era, J Urol, 2005. 173(1): p. 70-72., http://www.ncbi.nlm.nih.gov/pubmed/15592031
259. Brawer, M.K., Peehl, D.M., Stamey, T.A., Bostwick, D.G., Keratin immunoreactivity in the benign and neoplastic human prostate, Cancer Res, 1985. 45(8): p. 3663-3667., http://www.ncbi.nlm.nih.gov/pubmed/2410099
260. Moll, R., Franke, W.W., Schiller, D.L., Geiger, B., Krepler, R., The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells, Cell, 1982. 31(1): p. 11-24., http://www.ncbi.nlm.nih.gov/pubmed/6186379
261. Shah, R.B., Zhou, M., LeBlanc, M., Snyder, M., Rubin, M.A., Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer, Am J Surg Pathol, 2002. 26(9): p. 1161-1168., https://www.ncbi.nlm.nih.gov/pubmed/12218572
262. Wernert, N., Seitz, G., Achtstatter, T., Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma, Pathol Res Pract, 1987. 182(5): p. 617-626., http://www.ncbi.nlm.nih.gov/pubmed/2446293
263. Moch, H., Humphrey, P.A., Ulbright, T.M., Reuter, V.E., WHO Classification of Tumours of the Urinary System and Male Genital Organs, World Health Organization classification of tumours; 8, 2016., http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4008
264. Qian, J., Wollan, P., Bostwick, D.G., The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma, Hum Pathol, 1997. 28(2): p. 143-148., http://www.ncbi.nlm.nih.gov/pubmed/9023393
265. Keetch, D.W., Humphrey, P., Stahl, D., Smith, D.S., Catalona, W.J., Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate, J Urol, 1995. 154(2 Pt 1): p. 347-351., http://www.ncbi.nlm.nih.gov/pubmed/7541850
266. Jiang, Z., Wu, C.L., Woda, B.A., Iczkowski, K.A., Chu, P.G., Tretiakova, M.S., et.al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker, Histopathology, 2004. 45(3): p. 218-225., http://www.ncbi.nlm.nih.gov/pubmed/15330799
267. Epstein, J.I., PSA and PAP as immunohistochemical markers in prostate cancer, Urol Clin North Am, 1993. 20(4): p. 757-770., http://www.ncbi.nlm.nih.gov/pubmed/7505984
268. Magi-Galluzzi, C., Xu, X., Hlatky, L., Hahnfeldt, P., Kaplan, I., Hsiao, P., et.al. Heterogeneity of androgen receptor content in advanced prostate cancer, Mod Pathol, 1997. 10(8): p. 839-845., http://www.ncbi.nlm.nih.gov/pubmed/9267828
269. Murphy, G.P., Elgamal, A.A., Su, S.L., Bostwick, D.G., Holmes, E.H., Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen, Cancer, 1998. 83(11): p. 2259-2269., http://www.ncbi.nlm.nih.gov/pubmed/9840525
270. Kristiansen, I., Stephan, C., Jung, K., Dietel, M., Rieger, A., Tolkach, Y., et.al. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA, Int J Mol Sci, 2017. 18(6):, http://www.ncbi.nlm.nih.gov/pubmed/28555048
271. Bostwick, D.G., Amin, M.B., Dundore, P., Marsh, W., Schultz, D.S., Architectural patterns of high-grade prostatic intraepithelial neoplasia, Hum Pathol, 1993. 24(3): p. 298-310., http://www.ncbi.nlm.nih.gov/pubmed/8454275
272. Bostwick, D.G., Qian, J., High-grade prostatic intraepithelial neoplasia, Mod Pathol, 2004. 17(3): p. 360-379., http://www.ncbi.nlm.nih.gov/pubmed/14739906
273. Wolters, T., Roobol, M.J., van Leeuwen, P.J., van den Bergh, R.C., Hoedemaeker, R.F., van Leenders, G.J., et.al. Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer, Eur Urol, 2010. 57(5): p. 821-829., http://www.ncbi.nlm.nih.gov/pubmed/19664875
274. Marks, R.A., Lin, H., Koch, M.O., Cheng, L., Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence, Am J Surg Pathol, 2007. 31(6): p. 877-881., http://www.ncbi.nlm.nih.gov/pubmed/17527074
275. Epstein, J.I., Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens, J Urol, 2011. 186(3): p. 790-797., http://www.ncbi.nlm.nih.gov/pubmed/21788055
276. Renshaw, A.A., Adequate tissue sampling of prostate core needle biopsies, Am. J. Clin. Pathol, 1997. 107(1): p. 26-29., https://www.ncbi.nlm.nih.gov/pubmed/8980363
277. Brat, D.J., Wills, M.L., Lecksell, K.L., Epstein, J.I., How often are diagnostic features missed with less extensive histologic sampling of prostate needle biopsy specimens?, Am J Surg Pathol, 1999. 23(3): p. 257-262., http://www.ncbi.nlm.nih.gov/pubmed/10078914
278. Amin, M., Boccon-Gibod, L., Egevad, L., Epstein, J.I., Humphrey, P.A., Mikuz, G., et.al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens, Scand J Urol Nephrol Suppl, 2005. p. 20-33., http://www.ncbi.nlm.nih.gov/pubmed/16019757
279. Freedland, S.J., Csathy, G.S., Dorey, F., Aronson, W.J., Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score, J Urol, 2002. 167(2 Pt 1): p. 516-520., http://www.ncbi.nlm.nih.gov/pubmed/11792909
280. Kattan, M.W., Eastham, J.A., Wheeler, T.M., Maru, N., Scardino, P.T., Erbersdobler, A., et.al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors, J Urol, 2003. 170(5): p. 1792-1797., https://www.ncbi.nlm.nih.gov/pubmed/14532778
281. Mosse, C.A., Magi-Galluzzi, C., Tsuzuki, T., Epstein, J.I., The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens, Am. J. Surg. Pathol, 2004. 28(3): p. 394-398., http://www.ncbi.nlm.nih.gov/pubmed/15104304
282. Pan, C.C., Potter, S.R., Partin, A.W., Epstein, J.I., The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system, Am. J. Surg. Pathol, 2000. 24(4): p. 563-569., https://www.ncbi.nlm.nih.gov/pubmed/10757404
283. Dhom, G., Degro, S., Therapy of prostatic cancer and histopathologic follow-up, Prostate, 1982. 3(6): p. 531-542., http://www.ncbi.nlm.nih.gov/pubmed/7155986
284. Bostwick, D.G., Egbert, B.M., Fajardo, L.F., Radiation injury of the normal and neoplastic prostate, Am J Surg Pathol, 1982. 6(6): p. 541-551., http://www.ncbi.nlm.nih.gov/pubmed/7149094
285. Helpap, B., Kollermann, J., Therapieinduzierte Tumorregression des Prostatakarzinoms, Pathologe, 2004. 25(6): p. 461-468., http://www.ncbi.nlm.nih.gov/pubmed/15221282
286. Vailancourt, L., Ttu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., et.al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study, Am. J Surg. Pathol, 1996. 20(1): p. 86-93., http://www.ncbi.nlm.nih.gov/pubmed/8540613
287. McNeal, J.E., Normal histology of the prostate, Am. J. Surg. Pathol, 1988. 12(8): p. 619-633., http://www.ncbi.nlm.nih.gov/pubmed/2456702
288. McNeal, J.E., The zonal anatomy of the prostate, Prostate, 1981. 2(1): p. 35-49., http://www.ncbi.nlm.nih.gov/pubmed/7279811
289. Wise, A.M., Stamey, T.A., McNeal, J.E., Clayton, J.L., Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens, Urology, 2002. 60(2): p. 264-269., http://www.ncbi.nlm.nih.gov/pubmed/12137824
290. Arora, R., Koch, M.O., Eble, J.N., Ulbright, T.M., Li, L., Cheng, L., Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate, Cancer, 2004. 100(11): p. 2362-2366., http://www.ncbi.nlm.nih.gov/pubmed/15160339
291. Mehra, R., Han, B., Tomlins, S.A., Wang, L., Menon, A., Wasco, M.J., et.al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases, Cancer Res, 2007. 67(17): p. 7991-7995., http://www.ncbi.nlm.nih.gov/pubmed/17804708
292. Desai, A., Wu, H., Sun, L., Sesterhenn, I.A., Mostofi, F.K., McLeod, D., et.al. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients, Prostate Cancer Prostatic Dis, 2002. 5(3): p. 212-218., http://www.ncbi.nlm.nih.gov/pubmed/12496984
293. Epstein, J.I., Carmichael, M., Partin, A.W., Walsh, P.C., Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup, J Urol, 1993. 149(6): p. 1478-1481., http://www.ncbi.nlm.nih.gov/pubmed/8501792
294. Fromont, G., Cathelineau, X., Rozet, F., Prapotnich, D., Validire, P., Vallancien, G., Impact of margin size on the incidence of local residual tumor after laparoscopic radical prostatectomy, J Urol, 2004. 172(5 Pt 1): p. 1845-1847., http://www.ncbi.nlm.nih.gov/pubmed/15540735
295. Fromont, G., Baumert, H., Cathelineau, X., Rozet, F., Validire, P., Vallancien, G., Intraoperative frozen section analysis during nerve sparing laparoscopic radical prostatectomy: feasibility study, J Urol, 2003. 170(5): p. 1843-1846., http://www.ncbi.nlm.nih.gov/pubmed/14532789
296. Newman, A.J., Jr., Graham, M.A., Carlton, C.E., Jr., Lieman, S., Incidental carcinoma of the prostate at the time of transurethral resection: importance of evaluating every chip, J. Urol, 1982. 128(5): p. 948-950., http://www.ncbi.nlm.nih.gov/pubmed/6184491
297. Murphy, W.M., Dean, P.J., Brasfield, J.A., Tatum, L., Incidental carcinoma of the prostate. How much sampling is adequate?, Am. J. Surg. Pathol, 1986. 10(3): p. 170-174., http://www.ncbi.nlm.nih.gov/pubmed/3513636
298. Martino, P., Palazzo, S., Battaglia, M., Lucarelli, G., Selvaggi, F.P., Incidental prostatic cancer: repeat TURP or biopsy?, Urol. Int, 2004. 73(3): p. 193-197., http://www.ncbi.nlm.nih.gov/pubmed/15539835
299. van Andel, G., Vleeming, R., Kurth, K., de Reijke, T.M., Incidental carcinoma of the prostate, Semin. Surg. Oncol, 1995. 11(1): p. 36-45., http://www.ncbi.nlm.nih.gov/pubmed/7538693
300. Epstein, J.I., Amin, M., Boccon-Gibod, L., Egevad, L., Humphrey, P.A., Mikuz, G., et.al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens, Scand J Urol Nephrol Suppl, 2005. p. 34-63., http://www.ncbi.nlm.nih.gov/pubmed/16019758
301. Boormans, J.L., Wildhagen, M.F., Bangma, C.H., Verhagen, P.C., van Leenders, G.J., Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer, BJU. Int, 2008. 102(11): p. 1589-1593., http://www.ncbi.nlm.nih.gov/pubmed/18710447
302. Cheng, L., Bergstralh, E.J., Cheville, J.C., Slezak, J., Corica, F.A., Zincke, H., et.al. Cancer volume of lymph node metastasis predicts progression in prostate cancer, Am J Surg Pathol, 1998. 22(12): p. 1491-1500., http://www.ncbi.nlm.nih.gov/pubmed/9850175
303. Höfler, H., Empfehlungen zur Organ-/Gewebeentnahme und Gewebeasservierung für Forschung und Lehre, Pathologe, 2004. 25(4): p. 259-261., http://www.ncbi.nlm.nih.gov/pubmed/15164221
304. Nationaler Ethikrat, Biobanken für die Forschung. StellungnahmeNationaler Ethikrat, 2004.
305. Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J.R., Busch, C., et.al. Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 2011. 364(18): p. 1708-1717., http://www.ncbi.nlm.nih.gov/pubmed/21542742
306. Wilt, T.J., Brawer, M.K., Jones, K.M., Barry, M.J., Aronson, W.J., Fox, S., et.al. Radical prostatectomy versus observation for localized prostate cancer, N. Engl. J Med, 2012. 367(3): p. 203-213., http://www.ncbi.nlm.nih.gov/pubmed/22808955
307. Ip, S., Dahabreh, I.J., Chung, M., Yu, W.W., Balk, E.M., Iovin, R.C., et.al. An evidence review of active surveillance in men with localized prostate cancer, Evid Rep. Technol. Assess. (Full. Rep. ), 2011. p. 1-341., http://www.ncbi.nlm.nih.gov/pubmed/23126653
308. Dale, W., Bilir, P., Han, M., Meltzer, D., The role of anxiety in prostate carcinoma: a structured review of the literature, Cancer, 2005. 104(3): p. 467-478., http://www.ncbi.nlm.nih.gov/pubmed/15959911
309. Klotz, L., Active Surveillance, Quality of Life, and Cancer-related Anxiety, Eur Urol, 2013. 64(1): p. 37-39., http://www.ncbi.nlm.nih.gov/pubmed/23433806
310. Kronenwetter, C., Weidner, G., Pettengill, E., Marlin, R., Crutchfield, L., McCormac, P., et.al. A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial, Cancer Nurs, 2005. 28(2): p. 99-107., http://www.ncbi.nlm.nih.gov/pubmed/15815179
311. Oliffe, J.L., Davison, B.J., Pickles, T., Mroz, L., The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer, Qual Health Res, 2009. 19(4): p. 432-443., http://www.ncbi.nlm.nih.gov/pubmed/19229061
312. Boon, H., Brown, J.B., Gavin, A., Westlake, K., Men with prostate cancer: making decisions about complementary/alternative medicine, Med Decis. Making, 2003. 23(6): p. 471-479., http://www.ncbi.nlm.nih.gov/pubmed/14672107
313. van den Bergh, R.C., Korfage, I.J., Bangma, C.H., Psychological aspects of active surveillance, Curr. Opin. Urol, 2012. 22(3): p. 237-242., http://www.ncbi.nlm.nih.gov/pubmed/22357407
314. van den Bergh, R.C., Korfage, I.J., Borsboom, G.J., Steyerberg, E.W., Essink-Bot, M.L., Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer, Qual Life Res, 2009. 18(8): p. 1061-1066., http://www.ncbi.nlm.nih.gov/pubmed/19669670
315. Pickles, T., Ruether, J.D., Weir, L., Carlson, L., Jakulj, F., Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance, BJU Int, 2007. 100(3): p. 544-551., http://www.ncbi.nlm.nih.gov/pubmed/17532857
316. van den Bergh, R.C., Essink-Bot, M.L., Roobol, M.J., Wolters, T., Schroder, F.H., Bangma, C.H., et.al. Anxiety and distress during active surveillance for early prostate cancer, Cancer, 2009. 115(17): p. 3868-3878., http://www.ncbi.nlm.nih.gov/pubmed/19637245
317. van den Bergh, R.C., Essink-Bot, M.L., Roobol, M.J., Schroder, F.H., Bangma, C.H., Steyerberg, E.W., Do anxiety and distress increase during active surveillance for low risk prostate cancer?, J Urol, 2010. 183(5): p. 1786-1791., http://www.ncbi.nlm.nih.gov/pubmed/20299064
318. Gorin, M.A., Soloway, C.T., Eldefrawy, A., Soloway, M.S., Factors That Influence Patient Enrollment in Active Surveillance for Low-risk Prostate Cancer, Urology, 2011., http://www.ncbi.nlm.nih.gov/pubmed/21215429
319. Pickles, T., Keyes, M., Morris, W.J., Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis, Int J Radiat Oncol Biol Phys, 2010. 76(1): p. 43-49., http://www.ncbi.nlm.nih.gov/pubmed/19570619
320. Burnet, K.L., Parker, C., Dearnaley, D., Brewin, C.R., Watson, M., Does active surveillance for men with localized prostate cancer carry psychological morbidity?, BJU Int, 2007. 100(3): p. 540-543., http://www.ncbi.nlm.nih.gov/pubmed/17550414
321. Thong, M.S., Mols, F., Kil, P.J., Korfage, I.J., LV, van de Poll-Franse, Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden, BJU Int, 2010. 105(5): p. 652-658., http://www.ncbi.nlm.nih.gov/pubmed/19747357
322. Parker, C., Active surveillance: towards a new paradigm in the management of early prostate cancer, Lancet Oncol, 2004. 5(2): p. 101-106., http://www.ncbi.nlm.nih.gov/pubmed/14761814
323. Barry, M.J., Andriole, G.L., Culkin, D.J., Fox, S.H., Jones, K.M., Carlyle, M.H., et.al. Ascertaining cause of death among men in the Prostate Cancer Intervention Versus Observation Trial, Clin Trials, 2013. 10(6): p. 907-914., http://www.ncbi.nlm.nih.gov/pubmed/23988464
324. Bul, M., Zhu, X., Rannikko, A., Staerman, F., Valdagni, R., Pickles, T., et.al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study, Eur Urol, 2012. 62(2): p. 195-200., http://www.ncbi.nlm.nih.gov/pubmed/22342775
325. Wilt, T.J., MacDonald, R., Rutks, I., Shamliyan, T.A., Taylor, B.C., Kane, R.L., Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer, Ann. Intern. Med, 2008. 148(6): p. 435-448., http://www.ncbi.nlm.nih.gov/pubmed/18252677
326. U.S.Preventive Services Task Force, Screening for prostate cancer: recommendation and rationale, Annals of Internal Medicine, 2002. 137(11): p. 915-916.
327. Mambourg, F., van den Bruel, A., Devries, S., Leys, M., Vinck, I., Lona, M., et.al. HTA of prostate cancer screeningBelgian Health Care Knowledge Centre (KCE), 2006.
328. van den Bergh, R.C., Korfage, I.J., Roobol, M.J., Bangma, C.H., de Koning, H.J., Steyerberg, E.W., et.al. Sexual function with localized prostate cancer: active surveillance vs radical therapy, BJU. Int, 2012. 110(7): p. 1032-1039., http://www.ncbi.nlm.nih.gov/pubmed/22260273
329. Talcott, J.A., Manola, J., Clark, J.A., Kaplan, I., Beard, C.J., Mitchell, S.P., et.al. Time course and predictors of symptoms after primary prostate cancer therapy, J. Clin. Oncol, 2003. 21(21): p. 3979-3986., http://www.ncbi.nlm.nih.gov/pubmed/14581420
330. Hoffman, R.M., Hunt, W.C., Gilliland, F.D., Stephenson, R.A., Potosky, A.L., Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study, Cancer, 2003. 97(7): p. 1653-1662., http://www.ncbi.nlm.nih.gov/pubmed/12655522
331. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Nutzenbewertung der interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. Abschlussbericht N04-02IQWiG, 2007., http://www.iqwig.de/download/N04-02_Abschlussbericht_Brachytherapie.pdf
332. Vargas, C., Ghilezan, M., Hollander, M., Gustafson, G., Korman, H., Gonzalez, J., et.al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy, J Urol, 2005. 174(3): p. 882-887., http://www.ncbi.nlm.nih.gov/pubmed/16093980
333. Grills, I.S., Martinez, A.A., Hollander, M., Huang, R., Goldman, K., Chen, P.Y., et.al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds, J Urol, 2004. 171(3): p. 1098-1104., http://www.ncbi.nlm.nih.gov/pubmed/14767279
334. Baxter, N.N., Tepper, J.E., Durham, S.B., Rothenberger, D.A., Virnig, B.A., Increased risk of rectal cancer after prostate radiation: a population-based study, Gastroenterology, 2005. 128(4): p. 819-824., http://www.ncbi.nlm.nih.gov/pubmed/15825064
335. Brenner, D.J., Curtis, R.E., Hall, E.J., Ron, E., Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery, Cancer, 2000. 88(2): p. 398-406., http://www.ncbi.nlm.nih.gov/pubmed/10640974
336. Ojha, R.P., Fischbach, L.A., Zhou, Y., Felini, M.J., Singh, K.P., Thertulien, R., Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma, Cancer Epidemiol, 2010. 34(3): p. 274-278., http://www.ncbi.nlm.nih.gov/pubmed/20427255
337. Liauw, S.L., Sylvester, J.E., Morris, C.G., Blasko, J.C., Grimm, P.D., Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up, Int J Radiat Oncol Biol Phys, 2006. 66(3): p. 669-673., http://www.ncbi.nlm.nih.gov/pubmed/16887293
338. Abdel-Wahab, M., Reis, I.M., Hamilton, K., Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy, Int J Radiat Oncol Biol Phys, 2008. 72(1): p. 58-68., http://www.ncbi.nlm.nih.gov/pubmed/18374503
339. Bill-Axelson, A., Holmberg, L., Filen, F., Ruutu, M., Garmo, H., Busch, C., et.al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial, J Natl Cancer Inst, 2008. 100(16): p. 1144-1154., https://www.ncbi.nlm.nih.gov/pubmed/18695132
340. Bellardita, L., Rancati, T., Alvisi, M.F., Villani, D., Magnani, T., Marenghi, C., et.al. Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance, Eur Urol, 2013., http://www.ncbi.nlm.nih.gov/pubmed/23357351
341. Walz, J., Gallina, A., Saad, F., Montorsi, F., Perrotte, P., Shariat, S.F., et.al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer, J Clin Oncol, 2007. 25(24): p. 3576-3581., http://www.ncbi.nlm.nih.gov/pubmed/17704404
342. Kunz, I., Musch, M., Roggenbuck, U., Klevecka, V., Kroepfl, D., Tumour characteristics, oncological and functional outcomes in patients aged >/= 70 years undergoing radical prostatectomy, BJU. Int, 2013. 111(3 Pt B): p. E24-E29., http://www.ncbi.nlm.nih.gov/pubmed/22947135
343. Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic. Dis, 1987. 40(5): p. 373-383., http://www.ncbi.nlm.nih.gov/pubmed/3558716
344. American Society of Anesthesiologists (ASA), ASA Physical Status Classification System, 2014., https://www.asahq.org/-/media/sites/asahq/files/public/resources/standards-guidelines/asa-physical-status-classification-system.pdf
345. Froehner, M., Koch, R., Litz, R.J., Hakenberg, O.W., Wirth, M.P., Which patients are at the highest risk of dying from competing causes , BJU. Int, 2012. 110(2): p. 206-210., http://www.ncbi.nlm.nih.gov/pubmed/22044591
346. Statistisches Bundesamt, Periodensterbetafeln für Deutschland. Allgemeine Sterbetafeln, abgekürzte Sterbetafeln und Sterbetafeln, 2012., https://www-genesis.destatis.de/genesis/online/link/tabellen/12621*
347. Draisma, G., Boer, R., Otto, S.J., van der Cruijsen, I.W., Damhuis, R.A., Schroder, F.H., et.al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, J Natl Cancer Inst, 2003. 95(12): p. 868-878., http://www.ncbi.nlm.nih.gov/pubmed/12813170
348. Doblhammer, G., Kreft, D., Dethloff, A., Gewonnene Lebensjahre. Langfristige Trends der Sterblichkeit nach Todesursachen in Deutschland und im internationalen Vergleich, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2012. 55(4): p. 448-458., http://www.ncbi.nlm.nih.gov/pubmed/22441514
349. Christensen, K., Doblhammer, G., Rau, R., Vaupel, J.W., Ageing populations: the challenges ahead, Lancet, 2009. 374(9696): p. 1196-1208., http://www.ncbi.nlm.nih.gov/pubmed/19801098
350. Hamdy, F.C., Donovan, J.L., Lane, J.A., Mason, M., Metcalfe, C., Holding, P., et.al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer, N Engl J Med, 2016. 375(15): p. 1415-1424., http://www.ncbi.nlm.nih.gov/pubmed/27626136
351. Klotz, L., Active surveillance for prostate cancer: for whom?, J Clin Oncol, 2005. 23(32): p. 8165-8169., http://www.ncbi.nlm.nih.gov/pubmed/16278468
352. Bastian, P.J., Carter, B.H., Bjartell, A., Seitz, M., Stanislaus, P., Montorsi, F., et.al. Insignificant prostate cancer and active surveillance: from definition to clinical implications, Eur Urol, 2009. 55(6): p. 1321-1330., http://www.ncbi.nlm.nih.gov/pubmed/19286302
353. Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., Loblaw, A., Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer, J Clin Oncol, 2010. 28(1): p. 126-131., http://www.ncbi.nlm.nih.gov/pubmed/19917860
354. Parker, C., The Scandinavian Prostate Cancer Group Study: the case for conservative management, BJU. Int, 2005. 96(7): p. 952-953., http://www.ncbi.nlm.nih.gov/pubmed/16225505
355. Aus, G., Robinson, D., Rosell, J., Sandblom, G., Varenhorst, E., Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden, Cancer, 2005. 103(5): p. 943-951., http://www.ncbi.nlm.nih.gov/pubmed/15651057
356. Lu-Yao, G.L., Yao, S.L., Population-based study of long-term survival in patients with clinically localised prostate cancer, Lancet, 1997. 349(9056): p. 906-910., http://www.ncbi.nlm.nih.gov/pubmed/9093251
357. McLaren, D.B., McKenzie, M., Duncan, G., Pickles, T., Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma, Cancer, 1998. 82(2): p. 342-348., http://www.ncbi.nlm.nih.gov/pubmed/9445192
358. Sakr, W.A., Haas, G.P., Cassin, B.F., Pontes, J.E., Crissman, J.D., The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, J. Urol, 1993. 150(2 Pt 1): p. 379-385., http://www.ncbi.nlm.nih.gov/pubmed/8326560
359. Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., et.al. Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 2009. 360(13): p. 1320-1328., http://www.ncbi.nlm.nih.gov/pubmed/19297566
360. Graefen, M., Ahyai, S., Heuer, R., Salomon, G., Schlomm, T., Isbarn, H., et.al. Aktive Uberwachung des Prostatakarzinoms, Urologe A, 2008. 47(3): p. 261-269., http://www.ncbi.nlm.nih.gov/pubmed/18273597
361. Hirano, D., Werahera, P.N., Crawford, E.D., Lucia, M.S., DeAntoni, E.P., Miller, G.J., Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy, J Urol, 1998. 159(4): p. 1265-1269., http://www.ncbi.nlm.nih.gov/pubmed/9507849
362. Chan, T.Y., Chan, D.Y., Stutzman, K.L., Epstein, J.I., Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?, J Urol, 2001. 166(6): p. 2181-2184., http://www.ncbi.nlm.nih.gov/pubmed/11696731
363. Dong, F., Kattan, M.W., Steyerberg, E.W., Jones, J.S., Stephenson, A.J., Schroder, F.H., et.al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice, J Urol, 2008. 180(1): p. 150-154., http://www.ncbi.nlm.nih.gov/pubmed/18485398
364. Elgamal, A.A., Van Poppel, H.P., Van de Voorde, W.M., Van Dorpe, J.A., Oyen, R.H., Baert, L.V., Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view, J Urol, 1997. 157(1): p. 244-250., http://www.ncbi.nlm.nih.gov/pubmed/8976263
365. Epstein, J.I., Walsh, P.C., Carmichael, M., Brendler, C.B., Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA, 1994. 271(5): p. 368-374., http://www.ncbi.nlm.nih.gov/pubmed/7506797
366. Epstein, J.I., Walsh, P.C., Akingba, G., Carter, H.B., The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer, J Urol, 1999. 162(5): p. 1649-1652., http://www.ncbi.nlm.nih.gov/pubmed/10524890
367. Goto, Y., Ohori, M., Arakawa, A., Kattan, M.W., Wheeler, T.M., Scardino, P.T., Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies, J Urol, 1996. 156(3): p. 1059-1063., http://www.ncbi.nlm.nih.gov/pubmed/8709307
368. Irwin, M.B., Trapasso, J.G., Identification of insignificant prostate cancers: analysis of preoperative parameters, Urology, 1994. 44(6): p. 862-867., http://www.ncbi.nlm.nih.gov/pubmed/7527167
369. Loeb, S., Roehl, K.A., Thaxton, C.S., Catalona, W.J., Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer, Urology, 2008. 72(1): p. 143-147., http://www.ncbi.nlm.nih.gov/pubmed/18436287
370. Roehl, K.A., Antenor, J.A., Catalona, W.J., Serial biopsy results in prostate cancer screening study, J. Urol, 2002. 167(6): p. 2435-2439., http://www.ncbi.nlm.nih.gov/pubmed/11992052
371. Steyerberg, E.W., Roobol, M.J., Kattan, M.W., van der Kwast, T.H., de Koning, H.J., Schroder, F.H., Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram, J. Urol, 2007. 177(1): p. 107-112., http://www.ncbi.nlm.nih.gov/pubmed/17162015
372. Augustin, H., Hammerer, P.G., Graefen, M., Erbersdobler, A., Blonski, J., Palisaar, J., et.al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction, Eur Urol, 2003. 43(5): p. 455-460., http://www.ncbi.nlm.nih.gov/pubmed/12705986
373. Ghavamian, R., Blute, M.L., Bergstralh, E.J., Slezak, J., Zincke, H., Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy, Urology, 1999. 54(1): p. 105-110., http://www.ncbi.nlm.nih.gov/pubmed/10414735
374. Horninger, W., Rogatsch, H., Reissigl, A., Volgger, H., Klocker, H., Hobisch, A., et.al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening, Prostate, 1999. 40(1): p. 56-61., http://www.ncbi.nlm.nih.gov/pubmed/10344724
375. Ochiai, A., Troncoso, P., Chen, M.E., Lloreta, J., Babaian, R.J., The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management, J. Urol, 2005. 174(6): p. 2164-8, discussion., http://www.ncbi.nlm.nih.gov/pubmed/16280756
376. Recker, F., Kwiatkowski, M.K., Huber, A., Stamm, B., Lehmann, K., Tscholl, R., Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience, J. Urol, 2001. 166(3): p. 851-855., http://www.ncbi.nlm.nih.gov/pubmed/11490232
377. Sokoloff, M.H., Yang, X.J., Fumo, M., Mhoon, D., Brendler, C.B., Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL, BJU. Int, 2004. 93(4): p. 499-502., http://www.ncbi.nlm.nih.gov/pubmed/15008717
378. Cupp, M.R., Bostwick, D.G., Myers, R.P., Oesterling, J.E., The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis, J Urol, 1995. 153(5): p. 1543-1548., http://www.ncbi.nlm.nih.gov/pubmed/7714976
379. Jack, G.S., Cookson, M.S., Coffey, C.S., Vader, V., Roberts, R.L., Chang, S.S., et.al. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors, J Urol, 2002. 168(2): p. 519-524., http://www.ncbi.nlm.nih.gov/pubmed/12131301
380. Lee, A.K., Doytchinova, T., Chen, M.H., Renshaw, A.A., Weinstein, M., Richie, J.P., et.al. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core?, Urol Oncol, 2003. 21(2): p. 123-127., http://www.ncbi.nlm.nih.gov/pubmed/12856640
381. Miyake, H., Sakai, I., Harada, K., Hara, I., Eto, H., Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease, Int. J. Urol, 2005. 12(3): p. 270-274., http://www.ncbi.nlm.nih.gov/pubmed/15828954
382. Noguchi, M., Stamey, T.A., McNeal, J.E., Yemoto, C.M., Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer, J. Urol, 2001. 166(1): p. 104-109., http://www.ncbi.nlm.nih.gov/pubmed/11435833
383. Spitz, M.R., Strom, S.S., Yamamura, Y., Troncoso, P., Babaian, R.J., Scardino, P.T., et.al. Epidemiologic determinants of clinically relevant prostate cancer, Int. J. Cancer, 2000. 89(3): p. 259-264., http://www.ncbi.nlm.nih.gov/pubmed/10861502
384. Stamey, T.A., Freiha, F.S., McNeal, J.E., Redwine, E.A., Whittemore, A.S., Schmid, H.P., Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer, Cancer, 1993. 71(3 Suppl): p. 933-938., http://www.ncbi.nlm.nih.gov/pubmed/7679045
385. Terris, M.K., McNeal, J.E., Stamey, T.A., Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies, J. Urol, 1992. 148(3): p. 829-832., http://www.ncbi.nlm.nih.gov/pubmed/1380991
386. Terris, M.K., Haney, D.J., Johnstone, I.M., McNeal, J.E., Stamey, T.A., Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies, Urology, 1995. 45(1): p. 75-80., http://www.ncbi.nlm.nih.gov/pubmed/7529450
387. Harnden, P., Naylor, B., Shelley, M.D., Clements, H., Coles, B., Mason, M.D., The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis, Cancer, 2008. 112(5): p. 971-981., http://www.ncbi.nlm.nih.gov/pubmed/18186496
388. M., Al Otaibi, Ross, P., Fahmy, N., Jeyaganth, S., Trottier, H., Sircar, K., et.al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance, Cancer, 2008. 113(2): p. 286-292., http://www.ncbi.nlm.nih.gov/pubmed/18484590
389. Khatami, A., Aus, G., Damber, J.E., Lilja, H., Lodding, P., Hugosson, J., PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section, Int J Cancer, 2007. 120(1): p. 170-174., http://www.ncbi.nlm.nih.gov/pubmed/17013897
390. Shappley, W.V., III, Kenfield, S.A., Kasperzyk, J.L., Qiu, W., Stampfer, M.J., Sanda, M.G., et.al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort, J Clin Oncol, 2009. 27(30): p. 4980-4985., http://www.ncbi.nlm.nih.gov/pubmed/19720918
391. Sugimoto, M., Shiraishi, T., Tsunemori, H., Demura, T., Saito, Y., Kamoto, T., et.al. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort, Jpn J Clin Oncol, 2010. 40(10): p. 973-979., http://www.ncbi.nlm.nih.gov/pubmed/20534686
392. Stephenson, A.J., Kattan, M.W., Eastham, J.A., Bianco, F.J., Jr., Yossepowitch, O., Vickers, A.J., et.al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J Clin Oncol, 2009. 27(26): p. 4300-4305., http://www.ncbi.nlm.nih.gov/pubmed/19636023
393. Guzzo, T.J., Dluzniewski, P., Orosco, R., Platz, E.A., Partin, A.W., Han, M., Prediction of mortality after radical prostatectomy by Charlson comorbidity index, Urology, 2010. 76(3): p. 553-557., http://www.ncbi.nlm.nih.gov/pubmed/20627284
394. Louie-Johnsun, M., Neill, M., Treurnicht, K., Jarmulowicz, M., Eden, C., Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically, BJU Int, 2009. 104(10): p. 1501-1504., http://www.ncbi.nlm.nih.gov/pubmed/19426187
395. Choo, R., Danjoux, C., Morton, G., Szumacher, E., Sugar, L., Gardner, S., et.al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?, Prostate, 2007. 67(15): p. 1614-1620., http://www.ncbi.nlm.nih.gov/pubmed/17823923
396. Griffin, C.R., Yu, X., Loeb, S., Desireddi, V.N., Han, M., Graif, T., et.al. Pathological features after radical prostatectomy in potential candidates for active monitoring, J Urol, 2007. 178(3 Pt 1): p. 860-863., http://www.ncbi.nlm.nih.gov/pubmed/17631347
397. Suardi, N., Capitanio, U., Chun, F.K., Graefen, M., Perrotte, P., Schlomm, T., et.al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features, Cancer, 2008. 113(8): p. 2068-2072., http://www.ncbi.nlm.nih.gov/pubmed/18792067
398. Conti, S.L., Dall'era, M., Fradet, V., Cowan, J.E., Simko, J., Carroll, P.R., Pathological outcomes of candidates for active surveillance of prostate cancer, J Urol, 2009. 181(4): p. 1628-1633., http://www.ncbi.nlm.nih.gov/pubmed/19233388
399. Thaxton, C.S., Loeb, S., Roehl, K.A., Kan, D., Catalona, W.J., Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols, Urology, 2010. 75(2): p. 414-418., http://www.ncbi.nlm.nih.gov/pubmed/19963249
400. Ganz, P.A., Barry, J.M., Burke, W., Col, N.F., Corso, P.S., Dodson, E., et.al. NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer, NIH Consens. State Sci. Statements, 2011. 28(1): p. 1-27., http://www.ncbi.nlm.nih.gov/pubmed/23392076
401. Dall'Era, M.A., Albertsen, P.C., Bangma, C., Carroll, P.R., Carter, H.B., Cooperberg, M.R., et.al. Active surveillance for prostate cancer: a systematic review of the literature, Eur Urol, 2012. 62(6): p. 976-983., http://www.ncbi.nlm.nih.gov/pubmed/22698574
402. Carter, H.B., Partin, A.W., Walsh, P.C., Trock, B.J., Veltri, R.W., Nelson, W.G., et.al. Gleason score 6 adenocarcinoma: should it be labeled as cancer?, J Clin Oncol, 2012. 30(35): p. 4294-4296., http://www.ncbi.nlm.nih.gov/pubmed/23032616
403. Ross, H.M., Kryvenko, O.N., Cowan, J.E., Simko, J.P., Wheeler, T.M., Epstein, J.I., Do adenocarcinomas of the prostate with Gleason score (GS) , Am J Surg Pathol, 2012. 36(9): p. 1346-1352., http://www.ncbi.nlm.nih.gov/pubmed/22531173
404. Stöckle, M., Wiegel, T., Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk (PREFERE), 2013., http://clinicaltrials.gov/ct2/show/record/NCT01717677
405. Reese, A.C., Landis, P., Han, M., Epstein, J.I., Carter, H.B., Expanded Criteria to Identify Men Eligible for Active Surveillance of Low-Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis, J Urol, 2013., http://www.ncbi.nlm.nih.gov/pubmed/23680308
406. Kundu, S.D., Roehl, K.A., Yu, X., Antenor, J.A., Suarez, B.K., Catalona, W.J., Prostate specific antigen density correlates with features of prostate cancer aggressiveness, J Urol, 2007. 177(2): p. 505-509., http://www.ncbi.nlm.nih.gov/pubmed/17222621
407. Loeb, S., Sutherland, D.E., D'Amico, A.V., Roehl, K.A., Catalona, W.J., PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness, Urology, 2008. 72(5): p. 1116-1120., http://www.ncbi.nlm.nih.gov/pubmed/18571700
408. Isharwal, S., Makarov, D.V., Sokoll, L.J., Landis, P., Marlow, C., Epstein, J.I., et.al. ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program, Urology, 2011., http://www.ncbi.nlm.nih.gov/pubmed/21216447
409. Martin, R.M., Gunnell, D., Hamdy, F., Neal, D., Lane, A., Donovan, J., Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era, J. Urol, 2006. 176(2): p. 439-449., http://www.ncbi.nlm.nih.gov/pubmed/16813862
410. Epstein, J.I., Allsbrook, W.C., Jr., Amin, M.B., Egevad, L.L., The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am J Surg Pathol, 2005. 29(9): p. 1228-1242., http://www.ncbi.nlm.nih.gov/pubmed/16096414
411. Stattin, P., Holmberg, E., Johansson, J.E., Holmberg, L., Adolfsson, J., Hugosson, J., Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study, J Natl. Cancer Inst, 2010. 102(13): p. 950-958., http://www.ncbi.nlm.nih.gov/pubmed/20562373
412. Dall'Era, M.A., Konety, B.R., Cowan, J.E., Shinohara, K., Stauf, F., Cooperberg, M.R., et.al. Active surveillance for the management of prostate cancer in a contemporary cohort, Cancer, 2008. 112(12): p. 2664-2670., http://www.ncbi.nlm.nih.gov/pubmed/18433013
413. van den Bergh, R.C., Vasarainen, H., van der Poel, H.G., Vis-Maters, J.J., Rietbergen, J.B., Pickles, T., et.al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study, BJU Int, 2010. 105(7): p. 956-962., http://www.ncbi.nlm.nih.gov/pubmed/19817747
414. Eggener, S.E., Mueller, A., Berglund, R.K., Ayyathurai, R., Soloway, C., Soloway, M.S., et.al. A multi-institutional evaluation of active surveillance for low risk prostate cancer, J Urol, 2009. 181(4): p. 1635-1641., http://www.ncbi.nlm.nih.gov/pubmed/19233410
415. Ross, A.E., Loeb, S., Landis, P., Partin, A.W., Epstein, J.I., Kettermann, A., et.al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program, J Clin Oncol, 2010. 28(17): p. 2810-2816., http://www.ncbi.nlm.nih.gov/pubmed/20439642
416. Stephenson, A.J., Aprikian, A.G., Souhami, L., Behlouli, H., Jacobson, A.I., Begin, L.R., et.al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer, Urology, 2002. 59(5): p. 652-656., http://www.ncbi.nlm.nih.gov/pubmed/11992834
417. San Francisco, I.F., Werner, L., Regan, M.M., Garnick, M.B., Bubley, G., Dewolf, W.C., Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance, J Urol, 2011. 185(2): p. 471-476., http://www.ncbi.nlm.nih.gov/pubmed/21167525
418. Droz, J.P., Balducci, L., Bolla, M., Emberton, M., Fitzpatrick, J.M., Joniau, S., et.al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology, BJU. Int, 2010. 106(4): p. 462-469., http://www.ncbi.nlm.nih.gov/pubmed/20346033
419. Heidenreich, A., Bolla, M., Joniau, S., Mason, M.D., Matveev, V., Mottet, N., et.al. EAU guidelines on prostate cancerEAU, 2011.
420. Bill-Axelson, A., Holmberg, L., Ruutu, M., Haggman, M., Andersson, S.O., Bratell, S., et.al. Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 2005. 352(19): p. 1977-1984., http://www.ncbi.nlm.nih.gov/pubmed/15888698
421. Swindle, P., Eastham, J.A., Ohori, M., Kattan, M.W., Wheeler, T., Maru, N., et.al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens, J. Urol, 2005. 174(3): p. 903-907., http://www.ncbi.nlm.nih.gov/pubmed?term=16093984
422. Nuttall, M., van der, Meulen J., Phillips, N., Sharpin, C., Gillatt, D., McIntosh, G., et.al. A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures, J. Urol, 2004. 172(6 Pt 1): p. 2145-2152., http://www.ncbi.nlm.nih.gov/pubmed/15538220
423. Hollenbeck, B.K., Dunn, R.L., Miller, D.C., Daignault, S., Taub, D.A., Wei, J.T., Volume-based referral for cancer surgery: informing the debate, J Clin Oncol, 2007. 25(1): p. 91-96., http://www.ncbi.nlm.nih.gov/pubmed/17194909
424. Tooher, R., Swindle, P., Woo, H., Miller, J., Maddern, G., Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studies, J Urol, 2006. 175(6): p. 2011-2017., http://www.ncbi.nlm.nih.gov/pubmed/16697787
425. Australian Cancer Network (ACN), Clinical Practice Guidelines: Evidence-based information and recommendations for the management of localised prostate cancerNHMRC, 2002.
426. Steineck, G., Helgesen, F., Adolfsson, J., Dickman, P.W., Johansson, J.E., Norlen, B.J., et.al. Quality of life after radical prostatectomy or watchful waiting, N. Engl. J. Med, 2002. 347(11): p. 790-796., http://www.ncbi.nlm.nih.gov/pubmed/12226149
427. Schmeller, N., Lubos, W., Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer, Br. J. Urol, 1997. 79(2): p. 226-234., http://www.ncbi.nlm.nih.gov/pubmed/9052475
428. Asimakopoulos, A.D., Pereira Fraga, C.T., Annino, F., Pasqualetti, P., Calado, A.A., Mugnier, C., Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy, J. Sex Med, 2011. 8(5): p. 1503-1512., http://www.ncbi.nlm.nih.gov/pubmed/21324093
429. Michl, U., Graefen, M., Noldus, J., Eggert, T., Huland, H., Funktionelle Ergebnisse unterschiedlicher Operationstechniken der radikalen Prostatektomie, Urologe A, 2003. 42(9): p. 1196-1202., http://www.ncbi.nlm.nih.gov/pubmed/14504752
430. Loeb, S., Roehl, K.A., Helfand, B.T., Catalona, W.J., Complications of open radical retropubic prostatectomy in potential candidates for active monitoring, Urology, 2008. 72(4): p. 887-891., http://www.ncbi.nlm.nih.gov/pubmed/18329080
431. Barocas, D.A., Mitchell, R., Chang, S.S., Cookson, M.S., Impact of surgeon and hospital volume on outcomes of radical prostatectomy, Urol. Oncol, 2010. 28(3): p. 243-250., http://www.ncbi.nlm.nih.gov/pubmed/19395287
432. Wilt, T.J., Shamliyan, T.A., Taylor, B.C., MacDonald, R., Kane, R.L., Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review, J Urol, 2008. 180(3): p. 820-828., http://www.ncbi.nlm.nih.gov/pubmed/18635233
433. Kupelian, P.A., Potters, L., Khuntia, D., Ciezki, J.P., Reddy, C.A., Reuther, A.M., et.al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer, Int J Radiat Oncol Biol Phys, 2004. 58(1): p. 25-33., http://www.ncbi.nlm.nih.gov/pubmed/14697417
434. Yu, T., Zhang, Q., Zheng, T., Shi, H., Liu, Y., Feng, S., et.al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures, PLoS One, 2016. 11(5): p. e0154499., https://www.ncbi.nlm.nih.gov/pubmed/27171271
435. Bauman, G., Rumble, R.B., Chen, J., Loblaw, A., Warde, P., Intensity-modulated radiotherapy in the treatment of prostate cancer, Clin Oncol (R Coll Radiol), 2012. 24(7): p. 461-473., http://www.ncbi.nlm.nih.gov/pubmed/22673744
436. Zelefsky, M.J., Kollmeier, M., Cox, B., Fidaleo, A., Sperling, D., Pei, X., et.al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 2012. 84(1): p. 125-129., http://www.ncbi.nlm.nih.gov/pubmed/22330997
437. Wortel, R.C., Incrocci, L., Pos, F.J., van der Heide, U.A., Lebesque, J.V., Aluwini, S., et.al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts, Int J Radiat Oncol Biol Phys, 2016. 95(2): p. 680-689., http://www.ncbi.nlm.nih.gov/pubmed/27055398
438. Zapatero, A., Roch, M., Buchser, D., Castro, P., Fernandez-Banda, L., Pozo, G., et.al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer, Clin Transl. Oncol, 2017. 19((9)): p. 1161-1167., https://www.ncbi.nlm.nih.gov/pubmed/28374321
439. Sveistrup, J., af Rosenschold, P.M., Deasy, J.O., Oh, J.H., Pommer, T., Petersen, P.M., et.al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance, Radiat Oncol, 2014. 9: p. 44., http://www.ncbi.nlm.nih.gov/pubmed/24495815
440. Peeters, S.T., Lebesque, J.V., Heemsbergen, W.D., van Putten, W.L., Slot, A., Dielwart, M.F., et.al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 2006. 64(4): p. 1151-1161., http://www.ncbi.nlm.nih.gov/pubmed/16414208
441. Zietman, A.L., DeSilvio, M.L., Slater, J.D., Rossi, C.J., Jr., Miller, D.W., Adams, J.A., et.al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial, JAMA, 2005. 294(10): p. 1233-1239., https://www.ncbi.nlm.nih.gov/pubmed/16160131
442. Dearnaley, D.P., Sydes, M.R., Graham, J.D., Aird, E.G., Bottomley, D., Cowan, R.A., et.al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial, Lancet Oncol, 2007. 8(6): p. 475-487., http://www.ncbi.nlm.nih.gov/pubmed/17482880
443. Kuban, D.A., Tucker, S.L., Dong, L., Starkschall, G., Huang, E.H., Cheung, M.R., et.al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 2008. 70(1): p. 67-74., http://www.ncbi.nlm.nih.gov/pubmed/17765406
444. Zapatero, A., Valcarcel, F., Calvo, F.A., Algas, R., Bejar, A., Maldonado, J., et.al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study, J Clin. Oncol, 2005. 23(27): p. 6561-6568., http://www.ncbi.nlm.nih.gov/pubmed/16170164
445. Viani, G.A., Stefano, E.J., Afonso, S.L., Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials, Int J Radiat Oncol Biol Phys, 2009. 74(5): p. 1405-1418., http://www.ncbi.nlm.nih.gov/pubmed/19616743
446. Al-Mamgani, A., Heemsbergen, W.D., Levendag, P.C., Lebesque, J.V., Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial, Radiother Oncol, 2010. 96(1): p. 13-18., http://www.ncbi.nlm.nih.gov/pubmed/20227123
447. Zietman, A.L., Bae, K., Slater, J.D., Shipley, W.U., Efstathiou, J.A., Coen, J.J., et.al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09, J Clin Oncol, 2010. 28(7): p. 1106-1111., http://www.ncbi.nlm.nih.gov/pubmed/20124169
448. Al-Mamgani, A., van Putten, W.L., van der Wielen, G.J., Levendag, P.C., Incrocci, L., Dose Escalation and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial), Int J Radiat Oncol Biol Phys, 2011. 79(4): p. 1004-1012., https://www.ncbi.nlm.nih.gov/pubmed/20421153
449. Beckendorf, V., Guerif, S., Le, Prise E., Cosset, J.M., Lefloch, O., Chauvet, B., et.al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity, Int J Radiat Oncol Biol Phys, 2004. 60(4): p. 1056-1065., http://www.ncbi.nlm.nih.gov/pubmed/15519775
450. Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., et.al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 2016. 17(8): p. 1047-1060., http://www.ncbi.nlm.nih.gov/pubmed/27339115
451. Wilkins, A., Mossop, H., Syndikus, I., Khoo, V., Bloomfield, D., Parker, C., et.al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 2015. 16(16): p. 1605-1616., http://www.ncbi.nlm.nih.gov/pubmed/26522334
452. Lee, W.R., Dignam, J.J., Amin, M.B., Bruner, D.W., Low, D., Swanson, G.P., et.al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer, J Clin Oncol, 2016. 34(20): p. 2325-2332., http://www.ncbi.nlm.nih.gov/pubmed/27044935
453. Aluwini, S., Pos, F., Schimmel, E., Krol, S., van der Toorn, P.P., de, Jager H., et.al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial, Lancet Oncol, 2016. 17(4): p. 464-474., https://www.ncbi.nlm.nih.gov/pubmed/26968359
454. Aluwini, S., Pos, F., Schimmel, E., van, Lin E., Krol, S., van der Toorn, P.P., et.al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial, Lancet Oncol, 2015. 16(3): p. 274-283., http://www.researchgate.net/publication/272079148_Hypofractionated_versus_conventionally_fractionated_radiotherapy_for_patients_with_prostate_cancer_HYPRO_Late_toxicity_results_from_a_randomised_non-inferiority_phase_3_trial
455. Incrocci, L., Wortel, R.C., Alemayehu, W.G., Aluwini, S., Schimmel, E., Krol, S., et.al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 2016. 17(8): p. 1061-1069., http://www.ncbi.nlm.nih.gov/pubmed/27339116
456. Cozzarini, C., Fiorino, C., Deantoni, C., Briganti, A., Fodor, A., La, Macchia M., et.al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients, Eur Urol, 2014. 66(6): p. 1024-1030., http://www.ncbi.nlm.nih.gov/pubmed/24985964
457. Lewis, S.L., Patel, P., Song, H., Freedland, S.J., Bynum, S., Oh, D., et.al. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer, Int J Radiat Oncol Biol Phys, 2016. 94(3): p. 605-611., http://www.ncbi.nlm.nih.gov/pubmed/26867889
458. Koontz, B.F., Bossi, A., Cozzarini, C., Wiegel, T., D'Amico, A., A systematic review of hypofractionation for primary management of prostate cancer, Eur Urol, 2015. 68(4): p. 683-691., http://www.ncbi.nlm.nih.gov/pubmed/25171903
459. Pommier, P., Chabaud, S., Lagrange, J.L., Richaud, P., Lesaunier, F., Le, Prise E., et.al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01, J. Clin. Oncol, 2007. 25(34): p. 5366-5373., http://www.ncbi.nlm.nih.gov/pubmed/18048817
460. Lawton, C.A., DeSilvio, M., Roach, M., III, Uhl, V., Kirsch, R., Seider, M., et.al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions, Int J Radiat Oncol Biol Phys, 2007. 69(3): p. 646-655., http://www.ncbi.nlm.nih.gov/pubmed/17531401
461. Morikawa, L.K., Roach, M., III, Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions, Int. J. Radiat. Oncol. Biol. Phys, 2011. 80(1): p. 6-16., https://www.ncbi.nlm.nih.gov/pubmed/21481721
462. Gemeinsamer Bundesausschuss (G-BA), Protonentherapie Indikation: Prostatakarzinom. Abschlussbericht des Unterausschusses „Methodenbewertung" des Gemeinsamen Bundesausschusses (3. Update-Recherche), 2008., http://www.g-ba.de/downloads/40-268-739/2008-06-19_Abschluss_Protonen-Prostatakarzinom.pdf
463. Ollendorf, D.A., Hayes, J., McMahon, P., Pearson, S.D., Kuba, M., Tramontano, A., Brachytherapy & Proton Beam Therapy for treatment of clinically-localized, low-risk prostate cancer. Institute for Clinical and Economic Review. Final Appraisal Document, 2008.
464. Nihei, K., Ogino, T., Onozawa, M., Murayama, S., Fuji, H., Murakami, M., et.al. Multi-Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer Focusing on the Incidence of Late Rectal Toxicities, Int J Radiat Oncol Biol Phys, 2010., http://www.ncbi.nlm.nih.gov/pubmed/20832180
465. Terasawa, T., Dvorak, T., Ip, S., Raman, G., Lau, J., Trikalinos, T.A., Systematic review: charged-particle radiation therapy for cancer, Ann Intern Med, 2009. 151(8): p. 556-565., http://www.ncbi.nlm.nih.gov/pubmed/19755348
466. Mendenhall, N.P., Li, Z., Hoppe, B.S., Marcus, R.B., Jr., Mendenhall, W.M., Nichols, R.C., et.al. Early Outcomes from Three Prospective Trials of Image-guided Proton Therapy for Prostate Cancer, Int J Radiat Oncol Biol Phys, 2012. 82(1): p. 213-221., http://www.ncbi.nlm.nih.gov/pubmed/21093164
467. Brada, M., Pijls-Johannesma, M., De, Ruysscher D., Current clinical evidence for proton therapy, Cancer J, 2009. 15(4): p. 319-324., http://www.ncbi.nlm.nih.gov/pubmed/19672149
468. Fang, P., Mick, R., Deville, C., Both, S., Bekelman, J.E., Christodouleas, J.P., et.al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer, Cancer, 2015. 121(7): p. 1118-1127., https://www.ncbi.nlm.nih.gov/pubmed/25423899
469. Yu, J.B., Soulos, P.R., Herrin, J., Cramer, L.D., Potosky, A.L., Roberts, K.B., et.al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity, J Natl Cancer Inst, 2013. 105(1): p. 25-32., http://www.ncbi.nlm.nih.gov/pubmed/23243199
470. Sheets, N.C., Goldin, G.H., Meyer, A.M., Wu, Y., Chang, Y., Sturmer, T., et.al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer, JAMA, 2012. 307(15): p. 1611-1620., http://www.ncbi.nlm.nih.gov/pubmed/22511689
471. Hodapp, N., Vergleich der Kombination aus IMRT und IGRT mit konventioneller 3D-CRT bei der Bestrahlung des Prostatakarzinoms: Die Untersuchung des Vorteils hängt stark von den Bedingungen ab, Strahlenther. Onkol, 2017. 193(5): p. 431-432., http://www.ncbi.nlm.nih.gov/pubmed/28321456
472. Kuban, D.A., Levy, L.B., Cheung, M.R., Lee, A.K., Choi, S., Frank, S., et.al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?, Int J Radiat Oncol Biol Phys, 2011. 79(5): p. 1310-1317., http://www.ncbi.nlm.nih.gov/pubmed/20493642
473. Goldner, G., Bombosch, V., Geinitz, H., Becker, G., Wachter, S., Glocker, S., et.al. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial, Strahlenther Onkol, 2009. 185(2): p. 94-100., http://www.ncbi.nlm.nih.gov/pubmed/19240995
474. Pilepich, M.V., Krall, J.M., Johnson, R.J., Sause, W.T., Perez, C.A., Zinninger, M., et.al. Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06, Int. J. Radiat. Oncol. Biol. Phys, 1986. 12(3): p. 345-351., http://www.ncbi.nlm.nih.gov/pubmed/3514555
475. Asbell, S.O., Martz, K.L., Shin, K.H., Sause, W.T., Doggett, R.L., Perez, C.A., et.al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma, Int J Radiat Oncol Biol Phys, 1998. 40(4): p. 769-782., http://www.ncbi.nlm.nih.gov/pubmed/9531360
476. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J.B., Mirimanoff, R.O., et.al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 2002. 360(9327): p. 103-106., http://www.ncbi.nlm.nih.gov/pubmed/12126818
477. Zelefsky, M.J., Yamada, Y., Kollmeier, M.A., Shippy, A.M., Nedelka, M.A., Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer, Eur Urol, 2008. 53(6): p. 1172-1179., http://www.ncbi.nlm.nih.gov/pubmed/18222596
478. Kim, S., Shen, S., Moore, D.F., Shih, W., Lin, Y., Li, H., et.al. Late gastrointestinal toxicities following radiation therapy for prostate cancer, Eur Urol, 2011. 60(5): p. 908-916., http://www.ncbi.nlm.nih.gov/pubmed/21684064
479. Hoppe, B.S., Michalski, J.M., Mendenhall, N.P., Morris, C.G., Henderson, R.H., Nichols, R.C., et.al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer, Cancer, 2014. 120(7): p. 1076-1082., http://www.ncbi.nlm.nih.gov/pubmed/24382757
480. Gray, P.J., Paly, J.J., Yeap, B.Y., Sanda, M.G., Sandler, H.M., Michalski, J.M., et.al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer, Cancer, 2013. 119(9): p. 1729-1735., http://www.ncbi.nlm.nih.gov/pubmed/23436283
481. Giberti, C., Chiono, L., Gallo, F., Schenone, M., Gastaldi, E., Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer, World J Urol, 2009. 27(5): p. 607-612., https://pubmed.ncbi.nlm.nih.gov/19455340/
482. Giberti, C., Gallo, F., Schenone, M., Gastaldi, E., Cortese, P., Ninotta, G., et.al. Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer, The Canadian journal of urology, 2017. 24(2): p. 8728-8733., https://pubmed.ncbi.nlm.nih.gov/28436359/
483. Beyer, D.C., Brachman, D.G., Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy, Radiother Oncol, 2000. 57(3): p. 263-267., http://www.ncbi.nlm.nih.gov/pubmed/11104883
484. Sharkey, J., Cantor, A., Solc, Z., Huff, W., Chovnick, S.D., Behar, R.J., et.al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice, Brachytherapy, 2005. 4(1): p. 34-44., http://www.ncbi.nlm.nih.gov/pubmed/15737905
485. Zaorsky, N.G., Doyle, L.A., Hurwitz, M.D., Dicker, A.P., Den, R.B., Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?, Expert review of anticancer therapy, 2014. 14(1): p. 39-50., www.ncbi.nlm.nih.gov/pubmed/24124755
486. Hinnen, K.A., Battermann, J.J., van Roermund, J.G., Moerland, M.A., Jurgenliemk-Schulz, I.M., Frank, S.J., et.al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 2010. 76(5): p. 1433-1438., http://www.ncbi.nlm.nih.gov/pubmed/19540075
487. Koukourakis, G., Kelekis, N., Armonis, V., Kouloulias, V., Brachytherapy for prostate cancer: a systematic review, Adv Urol, 2009. p. 327945., http://www.ncbi.nlm.nih.gov/pubmed/19730753
488. Jackson, W. C., Hartman, H. E., Dess, R. T., Birer, S. R., Soni, P. D., Hearn, J. W. D., et.al. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer, J Clin Oncol, 2020. 38(26): p. 3024-3031., https://pubmed.ncbi.nlm.nih.gov/32396488/
489. Morris, W. J., Tyldesley, S., Rodda, S., Halperin, R., Pai, H., McKenzie, M., et.al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial), Int J Radiat Oncol Biol Phys, 2017. 98(2): p. 275-285., https://pubmed.ncbi.nlm.nih.gov/28262473/
490. Rodda, S., Tyldesley, S., Morris, W. J., Keyes, M., Halperin, R., Pai, H., et.al. ASCENDE-RT, Int J Radiat Oncol Biol Phys, 2017. 98(2): p. 286-295., https://pubmed.ncbi.nlm.nih.gov/28433432/
491. Nag, S., Bice, W., DeWyngaert, K., Prestidge, B., Stock, R., Yu, Y., The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis, International journal of radiation oncology, biology, physics, 2000. 46(1): p. 221-230., https://pubmed.ncbi.nlm.nih.gov/10656396/
492. Ash, D., Flynn, A., Battermann, J., de, Reijke T., Lavagnini, P., Blank, L., ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer, Radiother Oncol, 2000. 57(3): p. 315-321., https://www.ncbi.nlm.nih.gov/pubmed/11104892
493. Nag, S., Beyer, D., Friedland, J., Grimm, P., Nath, R., American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 1999. 44(4): p. 789-799., http://www.ncbi.nlm.nih.gov/pubmed/10386635
494. Salembier, C., Lavagnini, P., Nickers, P., Mangili, P., Rijnders, A., Polo, A., et.al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy, Radiother. Oncol, 2007. 83(1): p. 3-10., http://www.ncbi.nlm.nih.gov/pubmed/17321620
495. Davis, B. J., Horwitz, E. M., Lee, W. R., Crook, J. M., Stock, R. G., Merrick, G. S., et.al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy, Brachytherapy, 2012. 11(1): p. 6-19., https://pubmed.ncbi.nlm.nih.gov/22265434/
496. Nag, S., Ellis, R. J., Merrick, G. S., Bahnson, R., Wallner, K., Stock, R., American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy, International journal of radiation oncology, biology, physics, 2002. 54(2): p. 462-470., https://www.sciencedirect.com/science/article/pii/S0360301602029371?via%3Dihub
497. Gemeinsamer, Bundesausschuss, Qualitätssicherungs-Richtlinie zur interstitiellen LDR-Brachytherapie beim lokal begrenzten Prostatakarzinom mit niedrigem Risikoprofil, 2020., https://www.g-ba.de/beschluesse/4476/
498. Crook, J. M., Gomez-Iturriaga, A., Wallace, K., Ma, C., Fung, S., Alibhai, S., et.al. Comparison of health-related quality of life 5 years after SPIRIT, Journal of clinical oncology, 2011. 29(4): p. 362-368., https://pubmed.ncbi.nlm.nih.gov/21149658/
499. Eccles, B. K., Cross, W., Rosario, D. J., Doble, A., Parker, C., Logue, J., et.al. SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation), BJU international, 2013. 112(3): p. 330-337., https://pubmed.ncbi.nlm.nih.gov/23826842/
500. Wiegel, T., Albers, P., Bartkowiak, D., Bussar-Maatz, R., Härter, M., Kristiansen, G., et.al. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial), J Cancer Res Clin Oncol, 2021. 147(1): p. 235-242., www.ncbi.nlm.nih.gov/pubmed/32886212
501. Gemeinsamer, Bundesausschuss, Qualitätssicherungs-Richtlinie zur interstitiellen LDR-Brachytherapie beim lokal begrenzten Prostatakarzinom mit niedrigem Risikoprofil, 2020., https://www.g-ba.de/richtlinien/121/
502. Jani, A.B., Feinstein, J.M., Pasciak, R., Krengel, S., Weichselbaum, R.R., Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer, Urology, 2006. 67(5): p. 1007-1011., http://www.ncbi.nlm.nih.gov/pubmed/16635512
503. Stock, R.G., Yalamanchi, S., Hall, S.J., Stone, N.N., Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation, J Urol, 2010. 183(2): p. 546-550., http://www.ncbi.nlm.nih.gov/pubmed/20006854
504. Koontz, B.F., Chino, J., Lee, W.R., Hahn, C.A., Buckley, N., Huang, S., et.al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer, Brachytherapy, 2009. 8(2): p. 191-196., http://www.ncbi.nlm.nih.gov/pubmed/19433320
505. Awad, M.A., Gaither, T.W., Osterberg, E.C., Murphy, G.P., Baradaran, N., Breyer, B.N., Prostate cancer radiation and urethral strictures, Prostate cancer and prostatic diseases, 2018. 21(2): p. 168-174., www.ncbi.nlm.nih.gov/pubmed/29296018
506. van Tol-Geerdink, J.J., Leer, J.W.H., van Oort, I.M., van Lin, E.J.N.T., Weijerman, P.C., Vergunst, H., et.al. Quality of life after prostate cancer treatments in patients comparable at baseline, British journal of cancer, 2013. 108(9): p. 1784-1789., https://pubmed.ncbi.nlm.nih.gov/23612450/
507. Lardas, M., Liew, M., van den Bergh, R. C., Santis, M., Bellmunt, J., van den Broeck, T., et.al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer, Eur Urol, 2017. 72(6): p. 869-885., https://pubmed.ncbi.nlm.nih.gov/28757301/
508. Ramsay, C.R., Adewuyi, T.E., Gray, J., Hislop, J., Shirley, M.D., Jayakody, S., et.al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation, Health Technol Assess, 2015. 19(49): p. 1-490., http://www.ncbi.nlm.nih.gov/pubmed/26140518
509. Eade, T.N., Horwitz, E.M., Ruth, K., Buyyounouski, M.K., D'Ambrosio, D.J., Feigenberg, S.J., et.al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant, Int J Radiat. Oncol Biol Phys, 2008. 71(2): p. 338-345., http://www.ncbi.nlm.nih.gov/pubmed/18207665
510. Potters, L., Morgenstern, C., Calugaru, E., Fearn, P., Jassal, A., Presser, J., et.al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J Urol, 2005. 173(5): p. 1562-1566., http://www.ncbi.nlm.nih.gov/pubmed/15821486
511. Niehaus, A., Merrick, G.S., Butler, W.M., Wallner, K.E., Allen, Z.A., Galbreath, R.W., et.al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys, 2006. 64(1): p. 136-143., http://www.ncbi.nlm.nih.gov/pubmed/16198062
512. Quan, A.L., Ciezki, J.P., Reddy, C.A., Angermeier, K., Ulchaker, J., Mahadevan, A., et.al. Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate, Urology, 2006. 68(6): p. 1237-1241., http://www.ncbi.nlm.nih.gov/pubmed/17169646
513. Potters, L., Torre, T., Ashley, R., Leibel, S., Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy, J. Clin. Oncol, 2000. 18(6): p. 1187-1192., http://www.ncbi.nlm.nih.gov/pubmed/10715287
514. Lee, H.K., Adams, M.T., Shi, Q., Basillote, J., Lamonica, J., Miranda, L., et.al. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy, Int J Radiat. Oncol Biol Phys, 2010. 76(5): p. 1445-1449., http://www.ncbi.nlm.nih.gov/pubmed/19553032
515. Roeloffzen, E.M., Monninkhof, E.M., Battermann, J.J., van Roermund, J.G., Moerland, M.A., Van, Vulpen M., Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate, Int J Radiat. Oncol Biol Phys, 2011. 80(1): p. 76-84., http://www.ncbi.nlm.nih.gov/pubmed/20605364
516. Pal, R.P., Bhatt, J.R., Khan, M.A., Duggleby, S., Camilleri, P., Bell, C.R., et.al. Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy, Brachytherapy, 2011. 10(2): p. 107-116., http://www.ncbi.nlm.nih.gov/pubmed/20724223
517. Kollmeier, M.A., Stock, R.G., Cesaretti, J., Stone, N.N., Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy, J Urol, 2005. 173(3): p. 808-812., http://www.ncbi.nlm.nih.gov/pubmed/15711274
518. Sylvester, J.E., Blasko, J.C., Grimm, P.D., Meier, R., Malmgren, J.A., Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience, Int. J. Radiat. Oncol. Biol. Phys, 2003. 57(4): p. 944-952., http://www.ncbi.nlm.nih.gov/pubmed/14575824
519. Henry, A.M., Al-Qaisieh, B., Gould, K., Bownes, P., Smith, J., Carey, B., et.al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience, Int J Radiat. Oncol Biol Phys, 2010. 76(1): p. 50-56., http://www.ncbi.nlm.nih.gov/pubmed/20005453
520. Sylvester, J.E., Grimm, P.D., Blasko, J.C., Millar, J., Orio, P.F., III, Skoglund, S., et.al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience, Int J Radiat. Oncol Biol Phys, 2007. 67(1): p. 57-64., http://www.ncbi.nlm.nih.gov/pubmed/17084544
521. Prestidge, B. R., Winter, K., Sanda, M. G., Amin, M., Bice, W. S., Michalski, J., et.al. Initial Report of NRG Oncology/RTOG 0232, International journal of radiation oncology, biology, physics, 2016. 96(2): p. S4., https://www.sciencedirect.com/science/article/abs/pii/S0360301616303522?via%3Dihub
522. Merrick, G.S., Butler, W.M., Wallner, K.E., Galbreath, R.W., Allen, Z., Lief, J.H., et.al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy, Urology, 2005. 65(1): p. 95-100., http://www.ncbi.nlm.nih.gov/pubmed/15667872
523. Zelefsky, M.J., Kuban, D.A., Levy, L.B., Potters, L., Beyer, D.C., Blasko, J.C., et.al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int. J Radiat. Oncol. Biol. Phys, 2007. 67(2): p. 327-333., http://www.ncbi.nlm.nih.gov/pubmed/17084558
524. Prada, P.J., Juan, G., Gonzalez-Suarez, H., Fernandez, J., Jimenez, I., Amon, J., et.al. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants, BJU Int, 2010. 106(1): p. 32-36., http://www.ncbi.nlm.nih.gov/pubmed/20067460
525. Taira, A.V., Merrick, G.S., Galbreath, R.W., Wallner, K.E., Butler, W.M., Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy, Int J Radiat Oncol Biol Phys, 2010. 76(2): p. 349-354., http://www.ncbi.nlm.nih.gov/pubmed/19467793
526. Wong, W.W., Vora, S.A., Schild, S.E., Ezzell, G.A., Andrews, P.E., Ferrigni, R.G., et.al. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy, Cancer, 2009. 115(23): p. 5596-5606., http://www.ncbi.nlm.nih.gov/pubmed/19670452
527. Kao, J., Stone, N.N., Lavaf, A., Dumane, V., Cesaretti, J.A., Stock, R.G., (125)I monotherapy using D90 implant doses of 180 Gy or greater, Int J Radiat Oncol Biol Phys, 2008. 70(1): p. 96-101., http://www.ncbi.nlm.nih.gov/pubmed/17980505
528. Stone, N.N., Stone, M.M., Rosenstein, B.S., Unger, P., Stock, R.G., Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy, J Urol, 2011. 185(2): p. 495-500., http://www.ncbi.nlm.nih.gov/pubmed/21167528
529. Ho, A.Y., Burri, R.J., Cesaretti, J.A., Stone, N.N., Stock, R.G., Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys, 2009. 75(1): p. 16-22., http://www.ncbi.nlm.nih.gov/pubmed/19289266
530. Munro, N.P., Al-Qaisieh, B., Bownes, P., Smith, J., Carey, B., Bottomley, D., et.al. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years, Radiother. Oncol, 2010. 96(1): p. 34-37., http://www.ncbi.nlm.nih.gov/pubmed/20362348
531. Vassil, A.D., Murphy, E.S., Reddy, C.A., Angermeier, K.W., Altman, A., Chehade, N., et.al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation, Urology, 2010. 76(5): p. 1251-1257., http://www.ncbi.nlm.nih.gov/pubmed/20378156
532. Merrick, G.S., Butler, W.M., Galbreath, R.W., Lief, J.H., Adamovich, E., Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?, BJU. Int, 2003. 91(1): p. 23-29., http://www.ncbi.nlm.nih.gov/pubmed/12614244
533. Blasko, J.C., Grimm, P.D., Sylsvester, J.E., Cavanagh, W., The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma, Radiother Oncol, 2000. 57(3): p. 273-278., http://www.ncbi.nlm.nih.gov/pubmed/11104885
534. Singh, A.M., Gagnon, G., Collins, B., Niroomand-Rad, A., McRae, D., Zhang, Y., et.al. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis, Prostate, 2005. 62(1): p. 54-60., http://www.ncbi.nlm.nih.gov/pubmed/15389809
535. Nilsson, S., Norlen, B.J., Widmark, A., A systematic overview of radiation therapy effects in prostate cancer, Acta Oncol, 2004. 43(4): p. 316-381., http://www.ncbi.nlm.nih.gov/pubmed/15303499
536. Valakh, V., Kirichenko, A., Miller, R., Sunder, T., Miller, L., Fuhrer, R., Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function, Brachytherapy, 2010., http://www.ncbi.nlm.nih.gov/pubmed/21030319
537. Routman, D.M., Funk, R.K., Stish, B.J., Mynderse, L.A., Wilson, T.M., McLaren, R., et.al. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer, Brachytherapy, 2019. 18(1): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/30293836/
538. Tom, M.C., Reddy, C.A., Smile, T.D., Zhang, R.X., Ciezki, J.P., Stephans, K.L., et.al. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy, Brachytherapy, 2020. 19(1): p. 43-50., https://pubmed.ncbi.nlm.nih.gov/31813740/
539. Fellin, G., Mirri, M. A., Santoro, L., Jereczek-Fossa, B. A., Divan, C., Mussari, S., et.al. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy, Br J Radiol, 2016. 89(1065): p. 20150981., https://pubmed.ncbi.nlm.nih.gov/27384381/
540. Lo, A. C., Morris, W. J., Pickles, T., Keyes, M., McKenzie, M., Tyldesley, S., Patterns of recurrence after low-dose-rate prostate brachytherapy, International journal of radiation oncology, biology, physics, 2015. 91(4): p. 745-751., https://pubmed.ncbi.nlm.nih.gov/25752387/
541. Goy, B. W., Burchette, R., Soper, M. S., Chang, T., Cosmatos, H. A., Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer, Urology, 2020. 136: p. 180-189., https://pubmed.ncbi.nlm.nih.gov/31704459/
542. Pompe, R. S., Davis-Bondarenko, H., Zaffuto, E., Tian, Z., Shariat, S. F., Leyh-Bannurah, S.R., et.al. Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment, The Prostate, 2017. 77(6): p. 686-693., https://pubmed.ncbi.nlm.nih.gov/28156003/
543. Krishnan, V., Delouya, G., Bahary, J. P., Larrivée, S., Taussky, D., The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy, BJU international, 2014. 114(6): p. 865-871., https://pubmed.ncbi.nlm.nih.gov/24274784/
544. Smith, G.D., Pickles, T., Crook, J., Martin, A.G., Vigneault, E., Cury, F.L., et.al. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy, International journal of radiation oncology, biology, physics, 2015. 91(3): p. 505-516., https://pubmed.ncbi.nlm.nih.gov/25596107/
545. Martinez, A.A., Demanes, D.J., Galalae, R., Vargas, C., Bertermann, H., Rodriguez, R., et.al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime, Int. J. Radiat. Oncol. Biol. Phys, 2005. 62(5): p. 1322-1331., http://www.ncbi.nlm.nih.gov/pubmed/16029788
546. Galalae, R.M., Martinez, A., Mate, T., Mitchell, C., Edmundson, G., Nuernberg, N., et.al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer, Int J Radiat Oncol Biol Phys, 2004. 58(4): p. 1048-1055., http://www.ncbi.nlm.nih.gov/pubmed/15001244
547. Deger, S., Boehmer, D., Roigas, J., Schink, T., Wernecke, K.D., Wiegel, T., et.al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer, Eur Urol, 2005. 47(4): p. 441-448., http://www.ncbi.nlm.nih.gov/pubmed/15774239
548. Demanes, D.J., Rodriguez, R.R., Schour, L., Brandt, D., Altieri, G., High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results, Int J Radiat Oncol Biol Phys, 2005. 61(5): p. 1306-1316., http://www.ncbi.nlm.nih.gov/pubmed/15817332
549. Galalae, R.M., Kovacs, G., Schultze, J., Loch, T., Rzehak, P., Wilhelm, R., et.al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer, Int J Radiat Oncol Biol Phys, 2002. 52(1): p. 81-90., http://www.ncbi.nlm.nih.gov/pubmed/11777625
550. Galalae, R.M., Martinez, A., Nuernberg, N., Edmundson, G., Gustafson, G., Gonzalez, J., et.al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?, Strahlenther Onkol, 2006. 182(3): p. 135-141., http://www.ncbi.nlm.nih.gov/pubmed/16520907
551. Hoskin, P.J., Motohashi, K., Bownes, P., Bryant, L., Ostler, P., High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial, Radiother Oncol, 2007. 84(2): p. 114-120., http://www.ncbi.nlm.nih.gov/pubmed/17531335
552. Sathya, J.R., Davis, I.R., Julian, J.A., Guo, Q., Daya, D., Dayes, I.S., et.al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate, J. Clin. Oncol, 2005. 23(6): p. 1192-1199., http://www.ncbi.nlm.nih.gov/pubmed/15718316
553. Vargas, C.E., Martinez, A.A., Boike, T.P., Spencer, W., Goldstein, N., Gustafson, G.S., et.al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study, Int. J Radiat. Oncol. Biol. Phys, 2006. 66(2): p. 416-423., http://www.ncbi.nlm.nih.gov/pubmed/16879929
554. Yoshioka, Y., Nose, T., Yoshida, K., Inoue, T., Yamazaki, H., Tanaka, E., et.al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial, Int. J Radiat. Oncol. Biol. Phys, 2000. 48(3): p. 675-681., http://www.ncbi.nlm.nih.gov/pubmed/11020563
555. Pollack, A., Zagars, G.K., Starkschall, G., Antolak, J.A., Lee, J.J., Huang, E., et.al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial, Int. J. Radiat. Oncol. Biol. Phys, 2002. 53(5): p. 1097-1105., http://www.ncbi.nlm.nih.gov/pubmed/12128107
556. Martinez, A.A., Gustafson, G., Gonzalez, J., Armour, E., Mitchell, C., Edmundson, G., et.al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 2002. 53(2): p. 316-327., http://www.ncbi.nlm.nih.gov/pubmed/12023135
557. Brenner, D.J., Martinez, A.A., Edmundson, G.K., Mitchell, C., Thames, H.D., Armour, E.P., Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue, Int J Radiat Oncol Biol Phys, 2002. 52(1): p. 6-13., http://www.ncbi.nlm.nih.gov/pubmed/11777617
558. Wirth, M.P., Hermann, T., Alken, P., Kovacs, G., Muller, R.P., Hakenberg, O.W., et.al. Empfehlungen zur Durchführung der alleinigen, permanenten, interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom, Strahlenther. Onkol, 2002. 178(2): p. 115-119., http://www.ncbi.nlm.nih.gov/pubmed/11942038
559. Kovacs, G., Potter, R., Loch, T., Hammer, J., Kolkman-Deurloo, I.K., de la Rosette, J.J., et.al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer, Radiother Oncol, 2005. 74(2): p. 137-148., http://www.ncbi.nlm.nih.gov/pubmed/15734201
560. Corner, C., Rojas, A.M., Bryant, L., Ostler, P., Hoskin, P., A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer, Int J Radiat Oncol Biol Phys, 2008. 72(2): p. 441-446., http://www.ncbi.nlm.nih.gov/pubmed/18249501
561. Martin, T., Baltas, D., Kurek, R., Roddiger, S., Kontova, M., Anagnostopoulos, G., et.al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study, Strahlenther. Onkol, 2004. 180(4): p. 225-232., http://www.ncbi.nlm.nih.gov/pubmed/15057433
562. Martinez, A.A., Pataki, I., Edmundson, G., Sebastian, E., Brabbins, D., Gustafson, G., Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report, Int. J. Radiat. Oncol. Biol. Phys, 2001. 49(1): p. 61-69., http://www.ncbi.nlm.nih.gov/pubmed/11163498
563. Bader, P., Burkhard, F.C., Markwalder, R., Studer, U.E., Is a limited lymph node dissection an adequate staging procedure for prostate cancer?, J Urol, 2002. 168(2): p. 514-518., http://www.ncbi.nlm.nih.gov/pubmed/12131300
564. Briganti, A., Chun, F.K., Salonia, A., Zanni, G., Scattoni, V., Valiquette, L., et.al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy, Eur Urol, 2006. 49(6): p. 1019-1026., http://www.ncbi.nlm.nih.gov/pubmed/16530933
565. Joslyn, S.A., Konety, B.R., Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer, Urology, 2006. 68(1): p. 121-125., http://www.ncbi.nlm.nih.gov/pubmed/16806432
566. Touijer, K., Rabbani, F., Otero, J.R., Secin, F.P., Eastham, J.A., Scardino, P.T., et.al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%, J Urol, 2007. 178(1): p. 120-124., http://www.ncbi.nlm.nih.gov/pubmed/17499306
567. Weckermann, D., Goppelt, M., Dorn, R., Wawroschek, F., Harzmann, R., Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy, BJU. Int, 2006. 97(6): p. 1173-1178., http://www.ncbi.nlm.nih.gov/pubmed/16686707
568. Weckermann, D., Dorn, R., Trefz, M., Wagner, T., Wawroschek, F., Harzmann, R., Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients, J Urol, 2007. 177(3): p. 916-920., http://www.ncbi.nlm.nih.gov/pubmed/17296375
569. DiMarco, D.S., Zincke, H., Sebo, T.J., Slezak, J., Bergstralh, E.J., Blute, M.L., The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era, J Urol, 2005. 173(4): p. 1121-1125., http://www.ncbi.nlm.nih.gov/pubmed/15758719
570. Allaf, M.E., Palapattu, G.S., Trock, B.J., Carter, H.B., Walsh, P.C., Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer, J Urol, 2004. 172(5 Pt 1): p. 1840-1844., https://www.ncbi.nlm.nih.gov/pubmed/15540734
571. Bhatta-Dhar, N., Reuther, A.M., Zippe, C., Klein, E.A., No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer, Urology, 2004. 63(3): p. 528-531., http://www.ncbi.nlm.nih.gov/pubmed/15028451
572. Azzouzi, A.R., Vincendeau, S., Barret, E., Cicco, A., Kleinclauss, F., van der Poel, H.G., et.al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial, Lancet Oncol, 2017. 18(2): p. 181-191., http://www.ncbi.nlm.nih.gov/pubmed/28007457
573. Gill, I. S., Azzouzi, A. R., Emberton, M., Coleman, J. A., Coeytaux, E., Scherz, A., et.al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer, The Journal of urology, 2018. 200(4): p. 786-793., https://pubmed.ncbi.nlm.nih.gov/29864437/
574. Rodriguez-Rivera, J. A., Rodriguez-Lay, R., Zegarra-Montes, L., Benzaghou, F., Gaillac, B., Azzouzi, A. R., et.al. Extensión de la indicación de terapia fotodinámica dirigida vascular con padeliporfina (WST11), Actas urologicas espanolas, 2018. 42(10): p. 632-638., https://pubmed.ncbi.nlm.nih.gov/29699883/
575. Aus, G., Current status of HIFU and cryotherapy in prostate cancer--a review, Eur Urol, 2006. 50(5): p. 927-934., http://www.ncbi.nlm.nih.gov/pubmed/16971038
576. Blana, A., Rogenhofer, S., Ganzer, R., Lunz, J.C., Schostak, M., Wieland, W.F., et.al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer, Urology, 2008. 72(6): p. 1329-1333., http://www.ncbi.nlm.nih.gov/pubmed/18829078
577. Cordeiro, E.R., Cathelineau, X., Thuroff, S., Marberger, M., Crouzet, S., de la Rosette, J.J., High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer, BJU Int, 2012. 110(9): p. 1228-1242., http://www.ncbi.nlm.nih.gov/pubmed/22672199
578. Golan, R., Bernstein, A. N., McClure, T. D., Sedrakyan, A., Patel, N. A., Parekh, D. J., et.al. Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings, The Journal of urology, 2017. 198(5): p. 1000-1009., https://pubmed.ncbi.nlm.nih.gov/28433640/
579. Shoji, S., Nakano, M., Fujikawa, H., Endo, K., Hashimoto, A., Tomonaga, T., et.al. Urethra-sparing high-intensity focused ultrasound for localized prostate cancer, International journal of urology : official journal of the Japanese Urological Association, 2015. 22(11): p. 1043-1049., https://pubmed.ncbi.nlm.nih.gov/26251127/
580. Muto, S., Yoshii, T., Saito, K., Kamiyama, Y., Ide, H., Horie, S., Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer, Japanese journal of clinical oncology, 2008. 38(3): p. 192-199., https://pubmed.ncbi.nlm.nih.gov/18281309/
581. Ziglioli, F., Baciarello, M., Maspero, G., Bellini, V., Bocchialini, T., Cavalieri, D., et.al. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review, Ann Med Surg (Lond), 2020. 56: p. 110-115., www.ncbi.nlm.nih.gov/pubmed/32637083
582. Crouzet, S., Chapelon, J.Y., Rouviere, O., Mege-Lechevallier, F., Colombel, M., Tonoli-Catez, H., et.al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients, Eur Urol, 2014. 65(5): p. 907-914., http://www.ncbi.nlm.nih.gov/pubmed/23669165
583. Uchida, T., Tomonaga, T., Kim, H., Nakano, M., Shoji, S., Nagata, Y., et.al. Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer, J Urol, 2015. 193(1): p. 103-110., http://www.ncbi.nlm.nih.gov/pubmed/25079940
584. Thuroff, S., Chaussy, C., Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years, J Urol, 2013. 190(2): p. 702-710., http://www.ncbi.nlm.nih.gov/pubmed/23415962
585. Dickinson, L., Arya, M., Afzal, N., Cathcart, P., Charman, S.C., Cornaby, A., et.al. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort, Eur Urol, 2016. 70(4): p. 668-674., http://www.ncbi.nlm.nih.gov/pubmed/26951947
586. Ganzer, R., Fritsche, H.M., Brandtner, A., Brundl, J., Koch, D., Wieland, W.F., et.al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer, BJU Int, 2013. 112(3): p. 322-329., http://www.ncbi.nlm.nih.gov/pubmed/23356910
587. Berge, V., Dickinson, L., McCartan, N., Hindley, R.G., Diep, L.M., Emberton, M., et.al. Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer, J Urol, 2014. 191(6): p. 1764-1769., http://www.ncbi.nlm.nih.gov/pubmed/24373800
588. Cytron, S., Greene, D., Witzsch, U., Nylund, P., Bjerklund Johansen, T. E., Cryoablation of the prostate, Prostate cancer and prostatic diseases, 2009. 12(4): p. 339-346., https://pubmed.ncbi.nlm.nih.gov/19901934/
589. Donnelly, B. J., Saliken, J. C., Brasher, P. M. A., Ernst, S. D., Rewcastle, J. C., Lau, H., et.al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer, Cancer, 2010. 116(2): p. 323-330., https://pubmed.ncbi.nlm.nih.gov/19937954/
590. Shelley, M., Wilt, T.J., Coles, B., Mason, M.D., Cryotherapy for localised prostate cancer, Cochrane. Database. Syst. Rev, 2007. p. CD005010., http://www.ncbi.nlm.nih.gov/pubmed/17636783
591. Chin, J. L., Al-Zahrani, A. A., Autran-Gomez, A. M., Williams, A. K., Bauman, G., Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b), The Journal of urology, 2012. 188(4): p. 1170-1175., https://pubmed.ncbi.nlm.nih.gov/22901586/
592. Jung, J. H., Risk, M. C., Goldfarb, R., Reddy, B., Coles, B., Dahm, P., Primary cryotherapy for localised or locally advanced prostate cancer, Cochrane Database Syst Rev, 2018. p. CD005010., http://dx.doi.org/10.1002/14651858.CD005010.pub3, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494517/
593. Gao, L., Yang, L., Qian, S., Tang, Z., Qin, F., Wei, Q., et.al. Cryosurgery would be An Effective Option for Clinically Localized Prostate Cancer, Scientific reports, 2016. 6: p. 27490., https://pubmed.ncbi.nlm.nih.gov/27271239/
594. Blazevski, A., Scheltema, M. J., Amin, A., Thompson, J. E., Lawrentschuk, N., Stricker, P. D., Irreversible electroporation (IRE), BJU international, 2020. 125(3): p. 369-378., https://pubmed.ncbi.nlm.nih.gov/31725935/
595. Collettini, F., Enders, J., Stephan, C., Fischer, T., Baur, A. D. J., Penzkofer, T., et.al. Image-guided Irreversible Electroporation of Localized Prostate Cancer, Radiology, 2019. 292(1): p. 250-257., https://pubmed.ncbi.nlm.nih.gov/31161973/
596. Blazevski, A., Scheltema, M. J., Yuen, B., Masand, N., Nguyen, T. V., Delprado, W., et.al. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer, European urology oncology, 2020. 3(3): p. 283-290., https://pubmed.ncbi.nlm.nih.gov/31103721/
597. Morozov, A., Taratkin, M., Barret, E., Singla, N., Bezrukov, E., Chinenov, D., et.al. A systematic review of irreversible electroporation in localised prostate cancer treatment, Andrologia, 2020. p. e13789., https://pubmed.ncbi.nlm.nih.gov/32786087/
598. Akakura, K., Suzuki, H., Ichikawa, T., Fujimoto, H., Maeda, O., Usami, M., et.al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months, Jpn J Clin Oncol, 2006. 36(12): p. 789-793., http://www.ncbi.nlm.nih.gov/pubmed/17082219
599. White, W.M., Sadetsky, N., Waters, W.B., Carroll, P.R., Litwin, M.S., Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database, J. Urol, 2008. 180(6): p. 2409-2413., http://www.ncbi.nlm.nih.gov/pubmed/18930270
600. Carver, B.S., Bianco, F.J., Jr., Scardino, P.T., Eastham, J.A., Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer, J Urol, 2006. 176(2): p. 564-568., http://www.ncbi.nlm.nih.gov/pubmed/16813890
601. Edamura, K., Saika, T., Senoh, T., Koizumi, F., Manabe, D., Ebara, S., et.al. Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute, Acta Med Okayama, 2005. 59(5): p. 195-199., http://www.ncbi.nlm.nih.gov/pubmed/16286958
602. Fletcher, S.G., Mills, S.E., Smolkin, M.E., Theodorescu, D., Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer, Int J Radiat Oncol Biol Phys, 2006. 66(4): p. 1092-1099., http://www.ncbi.nlm.nih.gov/pubmed/16965872
603. Hachiya, T., Akakura, K., Saito, S., Shinohara, N., Sato, K., Harada, M., et.al. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan, BJU Int, 2005. 95(4): p. 534-540., http://www.ncbi.nlm.nih.gov/pubmed/15705075
604. Johnstone, P.A., Ward, K.C., Goodman, M., Assikis, V., Petros, J.A., Radical prostatectomy for clinical T4 prostate cancer, Cancer, 2006. 106(12): p. 2603-2609., http://www.ncbi.nlm.nih.gov/pubmed/16700037
605. Saito, T., Kitamura, Y., Komatsubara, S., Matsumoto, Y., Sugita, T., Hara, N., Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan, Asian J. Androl, 2006. 8(5): p. 555-561., https://www.ncbi.nlm.nih.gov/pubmed/16847528
606. Ward, J.F., Slezak, J.M., Blute, M.L., Bergstralh, E.J., Zincke, H., Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome, BJU. Int, 2005. 95(6): p. 751-756., http://www.ncbi.nlm.nih.gov/pubmed/15794776
607. Namiki, S., Tochigi, T., Ishidoya, S., Ito, A., Numata, I., Arai, Y., Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer, Qual. Life Res, 2011. 20(1): p. 111-118., http://www.ncbi.nlm.nih.gov/pubmed/20680687
608. Amling, C.L., Leibovich, B.C., Lerner, S.E., Bergstralh, E.J., Blute, M.L., Myers, R.P., et.al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate, Semin Urol Oncol, 1997. 15(4): p. 215-221., http://www.ncbi.nlm.nih.gov/pubmed/9421448
609. Berglund, R.K., Jones, J.S., Ulchaker, J.C., Fergany, A., Gill, I., Kaouk, J., et.al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis, Urology, 2006. 67(6): p. 1253-1256., http://www.ncbi.nlm.nih.gov/pubmed/16678888
610. Freedland, S.J., Partin, A.W., Humphreys, E.B., Mangold, L.A., Walsh, P.C., Radical prostatectomy for clinical stage T3a disease, Cancer, 2007. 109(7): p. 1273-1278., http://www.ncbi.nlm.nih.gov/pubmed/17315165
611. Gerber, G.S., Thisted, R.A., Chodak, G.W., Schroder, F.H., Frohmuller, H.G., Scardino, P.T., et.al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis, Eur Urol, 1997. 32(4): p. 385-390., http://www.ncbi.nlm.nih.gov/pubmed/9412793
612. Ham, W.S., Park, S.Y., Rha, K.H., Kim, W.T., Choi, Y.D., Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a single-institution study, J. Laparoendosc. Adv. Surg. Tech. A, 2009. 19(3): p. 329-332., http://www.ncbi.nlm.nih.gov/pubmed/19397390
613. Hsu, C.Y., Joniau, S., Oyen, R., Roskams, T., Van Poppel, H., Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience, Eur Urol, 2007. 51(1): p. 121-128., http://www.ncbi.nlm.nih.gov/pubmed/16797831
614. Hsu, C.Y., Wildhagen, M.F., Van Poppel, H., Bangma, C.H., Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy, BJU. Int, 2010. 105(11): p. 1536-1540., http://www.ncbi.nlm.nih.gov/pubmed/19912180
615. Riva, Isorna Martinez de la, Belon Lopez-Tomasety, J., Marrero, Dominguez R., Alvarez, Cruz E., Santamaria, Blanco P., Prostatectomia radical como monoterapia en el cancer de prostata localmente avanzado T3a: 12 anos de seguimiento, Arch Esp Urol, 2004. 57(7): p. 679-692., http://www.ncbi.nlm.nih.gov/pubmed/15536949
616. Mearini, L., Zucchi, A., Costantini, E., Bini, V., Nunzi, E., Porena, M., Outcomes of radical prostatectomy in clinically locally advanced N0M0 prostate cancer, Urol. Int, 2010. 85(2): p. 166-172., http://www.ncbi.nlm.nih.gov/pubmed/20558980
617. Patel, V.R., Palmer, K.J., Coughlin, G., Samavedi, S., Robot-assisted laparoscopic radical prostatectomy: perioperative outcomes of 1500 cases, J. Endourol, 2008. 22(10): p. 2299-2305., http://www.ncbi.nlm.nih.gov/pubmed/18837657
618. Powell, I.J., Tangen, C.M., Miller, G.J., Lowe, B.A., Haas, G., Carroll, P.R., et.al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109, J. Urol, 2002. 168(5): p. 2016-2019., http://www.ncbi.nlm.nih.gov/pubmed/12394698
619. Sciarra, A., Gentile, V., Voria, G., Mariotti, G., Seccareccia, F., Pastore, A., et.al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10, Urol. Int, 2003. 70(3): p. 186-194., http://www.ncbi.nlm.nih.gov/pubmed/12660455
620. Van Poppel, H., Goethuys, H., Callewaert, P., Vanuytsel, L., Van de Voorde, W.M., Baert, L., Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer, Eur. Urol, 2000. 38(4): p. 372-379., http://www.ncbi.nlm.nih.gov/pubmed/11025373
621. Xylinas, E., Drouin, S.J., Comperat, E., Vaessen, C., Renard-Penna, R., Misrai, V., et.al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience, BJU. Int, 2009. 103(9): p. 1173-1178., http://www.ncbi.nlm.nih.gov/pubmed/19040530
622. Yossepowitch, O., Eggener, S.E., Serio, A.M., Carver, B.S., Bianco, F.J., Jr., Scardino, P.T., et.al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy, Eur. Urol, 2008. 53(5): p. 950-959., http://www.ncbi.nlm.nih.gov/pubmed/17950521
623. Loeb, S., Smith, N.D., Roehl, K.A., Catalona, W.J., Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer, Urology, 2007. 69(6): p. 1170-1175., http://www.ncbi.nlm.nih.gov/pubmed/17572209
624. Van Poppel, H., Vekemans, K., Da, Pozzo L., Bono, A., Kliment, J., Montironi, R., et.al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001), Eur. J Cancer, 2006. 42(8): p. 1062-1067., http://www.ncbi.nlm.nih.gov/pubmed/16624554
625. Walz, J., Joniau, S., Chun, F.K., Isbarn, H., Jeldres, C., Yossepowitch, O., et.al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy, BJU. Int, 2011. 107(5): p. 765-770., http://www.ncbi.nlm.nih.gov/pubmed/20875089
626. Casey, J.T., Meeks, J.J., Greco, K.A., Wu, S.D., Nadler, R.B., Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy, J. Endourol, 2009. 23(9): p. 1519-1522., http://www.ncbi.nlm.nih.gov/pubmed/19694528
627. Verhagen, P.C., Schroder, F.H., Collette, L., Bangma, C.H., Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review, Eur Urol, 2010. 58(2): p. 261-269., http://www.ncbi.nlm.nih.gov/pubmed/20627403
628. Vickers, A.J., Bianco, F.J., Gonen, M., Cronin, A.M., Eastham, J.A., Schrag, D., et.al. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique, Eur. Urol, 2008. 53(5): p. 960-966., http://www.ncbi.nlm.nih.gov/pubmed/18207316
629. Heidenreich, A., Bolla, M., Joniau, S., Mason, M.D., Matveev, V., Mottet, N., et.al. EAU guidelines on prostate cancer, 2010., https://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2010.pdf
630. Menon, M., Bhandari, M., Gupta, N., Lane, Z., Peabody, J.O., Rogers, C.G., et.al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up, Eur. Urol, 2010. 58(6): p. 838-846., http://www.ncbi.nlm.nih.gov/pubmed/20869162
631. Thompson, I.M., Jr., Tangen, C.M., Paradelo, J., Lucia, M.S., Miller, G., Troyer, D., et.al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial, JAMA, 2006. 296(19): p. 2329-2335., http://www.ncbi.nlm.nih.gov/pubmed/17105795
632. Thompson, I.M., Tangen, C.M., Paradelo, J., Lucia, M.S., Miller, G., Troyer, D., et.al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial, J Urol, 2009. 181(3): p. 956-962., http://www.ncbi.nlm.nih.gov/pubmed/19167731
633. Gontero, P., Marchioro, G., Pisani, R., Zaramella, S., Sogni, F., Kocjancic, E., et.al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study, Eur Urol, 2007. 51(4): p. 922-929., http://www.ncbi.nlm.nih.gov/pubmed/17049718
634. Bolla, M., de Reijke, T.M., van Tienhoven, G., Van Den Bergh, A.C., Oddens, J., Poortmans, P.M., et.al. Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med, 2009. 360(24): p. 2516-2527., http://www.ncbi.nlm.nih.gov/pubmed/19516032
635. Denham, J.W., Steigler, A., Lamb, D.S., Joseph, D., Mameghan, H., Turner, S., et.al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial, Lancet Oncol, 2005. 6(11): p. 841-850., http://www.ncbi.nlm.nih.gov/pubmed/16257791
636. Pilepich, M.V., Winter, K., John, M.J., Mesic, J.B., Sause, W., Rubin, P., et.al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate, Int J Radiat Oncol Biol Phys, 2001. 50(5): p. 1243-1252., http://www.ncbi.nlm.nih.gov/pubmed/11483335
637. Laverdiere, J., Nabid, A., De Bedoya, L.D., Ebacher, A., Fortin, A., Wang, C.S., et.al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer, J Urol, 2004. 171(3): p. 1137-1140., http://www.ncbi.nlm.nih.gov/pubmed/14767287
638. Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T.J., Mason, M.D., Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst Rev, 2006. p. CD006019., http://www.ncbi.nlm.nih.gov/pubmed/17054269
639. Pilepich, M.V., Winter, K., Lawton, C.A., Krisch, R.E., Wolkov, H.B., Movsas, B., et.al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31, Int. J. Radiat. Oncol. Biol. Phys, 2005. 61(5): p. 1285-1290., https://www.ncbi.nlm.nih.gov/pubmed/15817329
640. Zagars, G.K., Johnson, D.E., von Eschenbach, A.C., Hussey, D.H., Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study, Int. J Radiat. Oncol. Biol. Phys, 1988. 14(6): p. 1085-1091., https://www.ncbi.nlm.nih.gov/pubmed/3133327
641. Tyrrell, C.J., Payne, H., See, W.A., McLeod, D.G., Wirth, M.P., Iversen, P., et.al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme, Radiother. Oncol, 2005. 76(1): p. 4-10., http://www.ncbi.nlm.nih.gov/pubmed/16145740
642. Granfors, T., Modig, H., Damber, J.E., Tomic, R., Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone, J Urol, 2006. 176(2): p. 544-547., http://www.ncbi.nlm.nih.gov/pubmed/16813885
643. See, W.A., Tyrrell, C.J., The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer, J. Cancer Res. Clin. Oncol, 2006. 132 Suppl 1: p. S7-16., http://www.ncbi.nlm.nih.gov/pubmed/16896884
644. Shelley, M.D., Kumar, S., Wilt, T., Staffurth, J., Coles, B., Mason, M.D., A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma, Cancer Treat Rev, 2009. 35(1): p. 9-17., http://www.ncbi.nlm.nih.gov/pubmed/18926640
645. Widmark, A., Klepp, O., Solberg, A., Damber, J.E., Angelsen, A., Fransson, P., et.al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, Lancet, 2009. 373(9660): p. 301-308., http://www.ncbi.nlm.nih.gov/pubmed/19091394
646. Shelley, M.D., Kumar, S., Coles, B., Wilt, T., Staffurth, J., Mason, M.D., Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials, Cancer Treat. Rev, 2009. 35(7): p. 540-546., http://www.ncbi.nlm.nih.gov/pubmed/19493624
647. Roach, M., III, Bae, K., Speight, J., Wolkov, H.B., Rubin, P., Lee, R.J., et.al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610, J. Clin. Oncol, 2008. 26(4): p. 585-591., http://www.ncbi.nlm.nih.gov/pubmed/18172188
648. Cuppone, F., Bria, E., Giannarelli, D., Vaccaro, V., Milella, M., Nistico, C., et.al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials, BMC Cancer, 2010. 10: p. 675., https://www.ncbi.nlm.nih.gov/pubmed/21143897
649. Bria, E., Cuppone, F., Giannarelli, D., Milella, M., Ruggeri, E.M., Sperduti, I., et.al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials, Cancer, 2009. 115(15): p. 3446-3456., http://www.ncbi.nlm.nih.gov/pubmed/19484790
650. Denham, J.W., Steigler, A., Lamb, D.S., Joseph, D., Turner, S., Matthews, J., et.al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial, Lancet Oncol, 2011. 12(5): p. 451-459., http://www.ncbi.nlm.nih.gov/pubmed/21440505
651. Bolla, M., Van, Tienhoven G., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., et.al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 2010. 11(11): p. 1066-1073., http://www.ncbi.nlm.nih.gov/pubmed/20933466
652. Zagars, G.K., von Eschenbach, A.C., Johnson, D.E., Oswald, M.J., Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation, Cancer, 1987. 60(7): p. 1489-1499., http://www.ncbi.nlm.nih.gov/pubmed/3113715
653. D'Amico, A.V., Denham, J.W., Bolla, M., Collette, L., Lamb, D.S., Tai, K.H., et.al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate, Cancer, 2007. 109(10): p. 2004-2010., http://www.ncbi.nlm.nih.gov/pubmed/17397033
654. D'Amico, A.V., Chen, M.H., Catalona, W.J., Sun, L., Roehl, K.A., Moul, J.W., Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors, Cancer, 2007. 110(1): p. 56-61., http://www.ncbi.nlm.nih.gov/pubmed/17530618
655. Hanks, G.E., Pajak, T.F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., et.al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02, J Clin Oncol, 2003. 21(21): p. 3972-3978., http://www.ncbi.nlm.nih.gov/pubmed/14581419
656. Deger, S., Boehmer, D., Turk, I., Roigas, J., Wernecke, K.D., Wiegel, T., et.al. High dose rate brachytherapy of localized prostate cancer, Eur Urol, 2002. 41(4): p. 420-426., http://www.ncbi.nlm.nih.gov/pubmed/12074814
657. Kalkner, K.M., Wahlgren, T., Ryberg, M., Cohn-Cedermark, G., Castellanos, E., Zimmerman, R., et.al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up, Acta Oncol, 2007. 46(7): p. 909-917., http://www.ncbi.nlm.nih.gov/pubmed/17917823
658. Rades, D., Schwarz, R., Todorovic, M., Thurmann, H., Graefen, M., Walz, J., et.al. Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer, Strahlenther. Onkol, 2007. 183(7): p. 398-402., http://www.ncbi.nlm.nih.gov/pubmed/17609874
659. Partin, A.W., Kattan, M.W., Subong, E.N., Walsh, P.C., Wojno, K.J., Oesterling, J.E., et.al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update, JAMA, 1997. 277(18): p. 1445-1451., http://www.ncbi.nlm.nih.gov/pubmed/9145716
660. Cagiannos, I., Karakiewicz, P., Eastham, J.A., Ohori, M., Rabbani, F., Gerigk, C., et.al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer, J Urol, 2003. 170(5): p. 1798-1803., http://www.ncbi.nlm.nih.gov/pubmed/14532779
661. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., Walsh, P.C., Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 1999. 281(17): p. 1591-1597., http://www.ncbi.nlm.nih.gov/pubmed/10235151
662. Bader, P., Burkhard, F.C., Markwalder, R., Studer, U.E., Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?, J Urol, 2003. 169(3): p. 849-854., http://www.ncbi.nlm.nih.gov/pubmed/12576797
663. Catalona, W.J., Miller, D.R., Kavoussi, L.R., Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy, J Urol, 1988. 140(3): p. 540-543., http://www.ncbi.nlm.nih.gov/pubmed/3411669
664. Heidenreich, A., Varga, Z., von Knobloch, R., Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis, J Urol, 2002. 167(4): p. 1681-1686., http://www.ncbi.nlm.nih.gov/pubmed/11912387
665. Stone, N.N., Stock, R.G., Unger, P., Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques, J. Urol, 1997. 158(5): p. 1891-1894., http://www.ncbi.nlm.nih.gov/pubmed/9334624
666. Burkhard, F.C., Schumacher, M., Studer, U.E., The role of lymphadenectomy in prostate cancer, Nat. Clin Pract Urol, 2005. 2(7): p. 336-342., http://www.ncbi.nlm.nih.gov/pubmed/16474786
667. Uchida, T., Shoji, S., Nakano, M., Hongo, S., Nitta, M., Murota, A., et.al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience, Int J Urol, 2009. 16(11): p. 881-886., http://www.ncbi.nlm.nih.gov/pubmed/19863624
668. Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., Reijke, T. M., et.al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer, Lancet, 2012. 380(9858): p. 2018-2027., https://pubmed.ncbi.nlm.nih.gov/23084481/
669. Parker, C. C., Clarke, N. W., Cook, A. D., Kynaston, H. G., Petersen, P. M., Catton, C., et.al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT), Lancet, 2020. 396(10260): p. 1413-1421., https://pubmed.ncbi.nlm.nih.gov/33002429/
670. Vale, C.L., Fisher, D., Kneebone, A., Parker, C., Pearse, M., Richaud, P., et.al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer, Lancet, 2020. 396(10260): p. 1422-1431., https://pubmed.ncbi.nlm.nih.gov/33002431/
671. Kneebone, A., Fraser-Browne, C., Duchesne, G. M., Fisher, R., Frydenberg, M., Herschtal, A., et.al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES), Lancet Oncol, 2020. 21(10): p. 1331-1340., https://pubmed.ncbi.nlm.nih.gov/33002437/
672. Sargos, P., Chabaud, S., Latorzeff, I., Magné, N., Benyoucef, A., Supiot, S., et.al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17), Lancet Oncol, 2020. 21(10): p. 1341-1352., https://pubmed.ncbi.nlm.nih.gov/33002438/
673. Wiegel, T., Bartkowiak, D., Bottke, D., Bronner, C., Steiner, U., Siegmann, A., et.al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy, European urology, 2014. 66(2): p. 243-250., www.ncbi.nlm.nih.gov/pubmed/24680359
674. Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., et.al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer, Eur Urol, 2021. 79(2): p. 263-282., https://www.ncbi.nlm.nih.gov/pubmed/33039206
675. Hackman, G., Taari, K., Tammela, T. L., Matikainen, M., Kouri, M., Joensuu, T., et.al. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension, Eur Urol, 2019. 76(5): p. 586-595., https://pubmed.ncbi.nlm.nih.gov/31375279/
676. Tilki, D., D'Amico, A.V., Timing of radiotherapy after radical prostatectomy, Lancet, 2020. 396(10260): p. 1374-1375., https://pubmed.ncbi.nlm.nih.gov/33002430/
677. Ghadjar, P., Wiegel, T., Re, European urology, 2021., https://pubmed.ncbi.nlm.nih.gov/33612373/
678. Swanson, G.P., Thompson, I.M., Basler, J., Treatment options in lymph node-positive prostate cancer, Cancer, 2006. 106(12): p. 2531-2539., http://www.ncbi.nlm.nih.gov/pubmed/16700035
679. Horwitz, E.M., Bae, K., Hanks, G.E., Porter, A., Grignon, D.J., Brereton, H.D., et.al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, J Clin Oncol, 2008. 26(15): p. 2497-2504., http://www.ncbi.nlm.nih.gov/pubmed/18413638
680. Fossati, N., Willemse, P.M., Van den Broeck, T., van den Bergh, R.C.N., Yuan, C.Y., Briers, E., et.al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review, Eur Urol, 2017. 72(1): p. 84-109., http://www.ncbi.nlm.nih.gov/pubmed/28126351
681. Da Pozzo, L.F., Cozzarini, C., Briganti, A., Suardi, N., Salonia, A., Bertini, R., et.al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy, Eur Urol, 2009. 55(5): p. 1003-1011., http://www.ncbi.nlm.nih.gov/pubmed/19211184
682. Briganti, A., Karnes, R.J., Da Pozzo, L.F., Cozzarini, C., Capitanio, U., Gallina, A., et.al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis, Eur Urol, 2011. 59(5): p. 832-840., http://www.ncbi.nlm.nih.gov/pubmed/21354694
683. Abdollah, F., Karnes, R.J., Suardi, N., Cozzarini, C., Gandaglia, G., Fossati, N., et.al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer, J Clin Oncol, 2014. 32(35): p. 3939-3947., http://www.ncbi.nlm.nih.gov/pubmed/25245445
684. Tilki, D., Preisser, F., Tennstedt, P., Tober, P., Mandel, P., Schlomm, T., et.al. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy, BJU Int, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27743493
685. Jegadeesh, N., Liu, Y., Zhang, C., Zhong, J., Cassidy, R.J., Gillespie, T., et.al. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer, Cancer, 2017. 123(3): p. 512-520., http://www.ncbi.nlm.nih.gov/pubmed/27859018
686. Schröder, F.H., Kurth, K.H., Fossa, S.D., Hoekstra, W., Karthaus, P.P., de Prijck, L., et.al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial), Eur. Urol, 2009. 55(1): p. 14-22., http://www.ncbi.nlm.nih.gov/pubmed/18823693
687. Lawton, C.A., Winter, K., Grignon, D., Pilepich, M.V., Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31, J Clin Oncol, 2005. 23(4): p. 800-807., http://www.ncbi.nlm.nih.gov/pubmed/15681524
688. Lawton, C.A., Winter, K., Murray, K., Machtay, M., Mesic, J.B., Hanks, G.E., et.al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate, Int J Radiat Oncol Biol Phys, 2001. 49(4): p. 937-946., http://www.ncbi.nlm.nih.gov/pubmed/11240234
689. Kleeberg, U.R., Endokrine Therapie versus Beobachtung nach R0-Resektion nodal positiver Prostatakarzinome, Strahlenther Onkol, 2000. 176(6): p. 293-294., http://www.ncbi.nlm.nih.gov/pubmed/10897259
690. Iversen, P., Wirth, M.P., See, W.A., McLeod, D.G., Klimberg, I., Gleason, D., et.al. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program, Urology, 2004. 63(5): p. 928-933., http://www.ncbi.nlm.nih.gov/pubmed/15134983
691. Messing, E.M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., et.al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 2006. 7(6): p. 472-479., http://www.ncbi.nlm.nih.gov/pubmed/16750497
692. Aus, G., Nordenskjold, K., Robinson, D., Rosell, J., Varenhorst, E., Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort, Eur Urol, 2003. 43(6): p. 627-631., http://www.ncbi.nlm.nih.gov/pubmed/12767363
693. Schmidt, J.D., Gibbons, R.P., Murphy, G.P., Bartolucci, A., Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project, Prostate, 1996. 28(1): p. 51-57., http://www.ncbi.nlm.nih.gov/pubmed/8545281
694. deVere, White R., Babaian, R.K., Feldman, M., Krane, R.J., Olsson, C.A., Adjunctive therapy with interstitial irradiation for prostate cancer, Urology, 1982. 19(4): p. 395-398., http://www.ncbi.nlm.nih.gov/pubmed/6803419
695. Robnett, T.J., Whittington, R., Malkowicz, S.B., Brereton, H.D., van Arsdalen, K., Drach, G., et.al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 2002. 53(5): p. 1146-1151., http://www.ncbi.nlm.nih.gov/pubmed/12128114
696. Briganti, A., Karnes, J.R., Da Pozzo, L.F., Cozzarini, C., Gallina, A., Suardi, N., et.al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy, Eur Urol, 2009. 55(2): p. 261-270., http://www.ncbi.nlm.nih.gov/pubmed/18838212
697. Boorjian, S.A., Thompson, R.H., Siddiqui, S., Bagniewski, S., Bergstralh, E.J., Karnes, R.J., et.al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era, J Urol, 2007. 178(3 Pt 1): p. 864-870., http://www.ncbi.nlm.nih.gov/pubmed/17631342
698. Wong, A.T., Schwartz, D., Osborn, V., Safdieh, J., Weiner, J., Schreiber, D., Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer, Urol Oncol, 2016. 34(12): p. 529-529., http://www.ncbi.nlm.nih.gov/pubmed/27443637
699. Aus, G., Abrahamsson, P.A., Ahlgren, G., Hugosson, J., Lundberg, S., Schain, M., et.al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial, BJU Int, 2002. 90(6): p. 561-566., http://www.ncbi.nlm.nih.gov/pubmed/12230618
700. Klotz, L.H., Goldenberg, S.L., Jewett, M.A., Fradet, Y., Nam, R., Barkin, J., et.al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy, J Urol, 2003. 170(3): p. 791-794., http://www.ncbi.nlm.nih.gov/pubmed/12913699
701. Schulman, C.C., Debruyne, F.M., Forster, G., Selvaggi, F.P., Zlotta, A.R., Witjes, W.P., 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer, Eur. Urol, 2000. 38(6): p. 706-713., http://www.ncbi.nlm.nih.gov/pubmed/11111188
702. Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T.J., Mason, M.D., Neo-adjuvant and adjuvant hormone therapy for localised prostate cancer, Cochrane Database Syst Rev, 2006. p. CD006018., https://pubmed.ncbi.nlm.nih.gov/17054269/
703. Messing, E.M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E.D., Trump, D., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N. Engl. J. Med, 1999. 341(24): p. 1781-1788., http://www.ncbi.nlm.nih.gov/pubmed/10588962
704. Wirth, M.P., Weissbach, L., Marx, F.J., Heckl, W., Jellinghaus, W., Riedmiller, H., et.al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer, Eur. Urol, 2004. 45(3): p. 267-270., http://www.ncbi.nlm.nih.gov/pubmed/15036669
705. McLeod, D.G., Iversen, P., See, W.A., Morris, T., Armstrong, J., Wirth, M.P., Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer, BJU. Int, 2006. 97(2): p. 247-254., http://www.ncbi.nlm.nih.gov/pubmed/16430622
706. Jones, C.U., Hunt, D., McGowan, D.G., Amin, M.B., Chetner, M.P., Bruner, D.W., et.al. Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 2011. 365(2): p. 107-118., http://www.ncbi.nlm.nih.gov/pubmed/21751904
707. Schmidt-Hansen, M., Hoskin, P., Kirkbride, P., Hasler, E., Bromham, N., Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses, Clin Oncol (R Coll Radiol), 2014. 26(10): p. e21-e46., http://www.ncbi.nlm.nih.gov/pubmed/25059922
708. D'Amico, A.V., Manola, J., Loffredo, M., Renshaw, A.A., DellaCroce, A., Kantoff, P.W., 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial, JAMA, 2004. 292(7): p. 821-827., http://www.ncbi.nlm.nih.gov/pubmed/15315996
709. Hu, J., Xu, H., Zhu, W., Wu, F., Wang, J., Ding, Q., et.al. Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients, World J Surg Oncol, 2015. 13: p. 73., http://www.ncbi.nlm.nih.gov/pubmed/25884478
710. Bolla, M., Maingon, P., Carrie, C., Villa, S., Kitsios, P., Poortmans, P.M., et.al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991, J Clin Oncol, 2016. 34(15): p. 1748-1756., http://www.ncbi.nlm.nih.gov/pubmed/26976418
711. McPartlin, A.J., Glicksman, R., Pintilie, M., Tsuji, D., Mok, G., Bayley, A., et.al. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer, Cancer, 2016. 122(16): p. 2595-2603., http://www.ncbi.nlm.nih.gov/pubmed/27219522
712. Zhou, Z.R., Zhu, X.D., Xia, J., Zou, Z.Y., Qu, S., Zeng, X.T., et.al. Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis, J Cancer Res Clin Oncol, 2013. 139(5): p. 783-796., https://www.ncbi.nlm.nih.gov/pubmed/23380891
713. Leal, F., Figueiredo, M.A., Sasse, A.D., Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis, Int Braz J Urol, 2015. 41(3): p. 425-434., http://www.ncbi.nlm.nih.gov/pubmed/26200535
714. Zapatero, A., Guerrero, A., Maldonado, X., Alvarez, A., Gonzalez San, Segundo C., Cabeza Rodriguez, M.A., et.al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol, 2015. 16(3): p. 320-327., https://www.ncbi.nlm.nih.gov/pubmed/25702876
715. Denham, J.W., Joseph, D., Lamb, D.S., Spry, N.A., Duchesne, G., Matthews, J., et.al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial, Lancet Oncol, 2014. 15(10): p. 1076-1089., http://www.ncbi.nlm.nih.gov/pubmed/25130995
716. D'Amico, A.V., Chen, M.H., Renshaw, A.A., Loffredo, M., Kantoff, P.W., Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial, JAMA, 2008. 299(3): p. 289-295., http://www.ncbi.nlm.nih.gov/pubmed/18212313
717. Noldus, J., Die Nerverhaltende radikale retropubische Prostatektomie, Forum DKI, 2002. Sonderheft 1: p. 49.
718. Soloway, M.S., Pareek, K., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D.P., Jr., et.al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results, J. Urol, 2002. 167(1): p. 112-116., http://www.ncbi.nlm.nih.gov/pubmed/11743286
719. Selli, C., Montironi, R., Bono, A., Pagano, F., Zattoni, F., Manganelli, A., et.al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer, J. Clin. Pathol, 2002. 55(7): p. 508-513., http://www.ncbi.nlm.nih.gov/pubmed/12101195
720. van der Kwast, T.H., Labrie, F., Tetu, B., Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy, Hum. Pathol, 1999. 30(12): p. 1503-1507., http://www.ncbi.nlm.nih.gov/pubmed/10667430
721. Gleave, M.E., Goldenberg, S.L., Chin, J.L., Warner, J., Saad, F., Klotz, L.H., et.al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects, J Urol, 2001. 166(2): p. 500-506., http://www.ncbi.nlm.nih.gov/pubmed/11458055
722. Zumsteg, Z.S., Spratt, D.E., Pei, I., Zhang, Z., Yamada, Y., Kollmeier, M., et.al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, Eur Urol, 2013. 64(6): p. 895-902., http://www.ncbi.nlm.nih.gov/pubmed/23541457
723. Lawton, C.A.F., Lin, X., Hanks, G.E., Lepor, H., Grignon, D.J., Brereton, H.D., et.al. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202, Int J Radiat Oncol Biol Phys, 2017. 98(2): p. 296-303., http://www.ncbi.nlm.nih.gov/pubmed/28463149
724. Nabid, A., Garant, M.-P., Martin, A.-G., Bahary, J.P., Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial, J Clin Oncol, 2017. 35(15 Suppl): p. 5008., http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5008
725. D'Amico, A.V., Chen, M.H., Renshaw, A.A., Loffredo, M., Kantoff, P.W., Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death, Int J Radiat. Oncol Biol Phys, 2009. 75(1): p. 10-15., http://www.ncbi.nlm.nih.gov/pubmed/19395184
726. Nanda, A., Chen, M.H., Braccioforte, M.H., Moran, B.J., D'Amico, A.V., Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction, JAMA, 2009. 302(8): p. 866-873., http://www.ncbi.nlm.nih.gov/pubmed/19706860
727. Nguyen, P.L., Chen, M.H., Beard, C.J., Suh, W.W., Renshaw, A.A., Loffredo, M., et.al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group, Int J Radiat Oncol Biol Phys, 2010. 77(4): p. 1046-1052., http://www.ncbi.nlm.nih.gov/pubmed/19864082
728. Iversen, P., Johansson, J.E., Lodding, P., Kylmala, T., Lundmo, P., Klarskov, P., et.al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years, Scand J Urol Nephrol, 2006. 40(6): p. 441-452., http://www.ncbi.nlm.nih.gov/pubmed/17130095
729. Studer, U.E., Whelan, P., Albrecht, W., Casselman, J., de, Reijke T., Hauri, D., et.al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891, J. Clin. Oncol, 2006. 24(12): p. 1868-1876., http://www.ncbi.nlm.nih.gov/pubmed/16622261
730. The Medical Research Council Prostate Cancer Working Party Investigators Group, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial., Br. J. Urol, 1997. 79(2): p. 235-246., http://www.ncbi.nlm.nih.gov/pubmed/9052476
731. Parker, M.C., Cook, A., Riddle, P.R., Fryatt, I., O'Sullivan, J., Shearer, R.J., Is delayed treatment justified in carcinoma of the prostate?, Br. J. Urol, 1985. 57(6): p. 724-728., http://www.ncbi.nlm.nih.gov/pubmed/4084734
732. Herr, H.W., O'Sullivan, M., Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy, J Urol, 2000. 163(6): p. 1743-1746., http://www.ncbi.nlm.nih.gov/pubmed/10799173
733. Boustead, G., Edwards, S.J., Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials, BJU Int, 2007. 99(6): p. 1383-1389., http://www.ncbi.nlm.nih.gov/pubmed/17346269
734. Wilt, T.J., air, B., MacDonald, R., Rutks, I., Early versus deferred androgen suppression in the treatment of advanced prostatic cancer, Cochrane. Database. Syst. Rev, 2001. p. CD003506., http://www.ncbi.nlm.nih.gov/pubmed/11869665
735. Studer, U.E., Whelan, P., Wimpissinger, F., Casselman, J., de Reijke, T.M., Knonagel, H., et.al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up, Eur Urol, 2014. 66(5): p. 829-838., http://www.ncbi.nlm.nih.gov/pubmed/23932338
736. Studer, U.E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., de, Reijke T., et.al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891), Eur. Urol, 2008. 53(5): p. 941-949., http://www.ncbi.nlm.nih.gov/pubmed/18191322
737. Loblaw, D.A., Mendelson, D.S., Talcott, J.A., Virgo, K.S., Somerfield, M.R., Ben-Josef, E., et.al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer, J. Clin. Oncol, 2004. 22(14): p. 2927-2941., http://www.ncbi.nlm.nih.gov/pubmed/15184404
738. Studer, U.E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., 19 which subgroups of patients with newly diagnosed to-4 no-2 mo prostate cancer not suitable for local treatment with curative intent (eortc 30891) are at risk to die from prostate cancer and benefit from immediate androgen deprivation?, Eur Urol Suppl, 2007. 6(2): p. 27., http://www.sciencedirect.com/science/article/pii/S1569905607600190
739. Byar, D.P., Corle, D.K., Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies, NCI. Monogr, 1988. p. 165-170., http://www.ncbi.nlm.nih.gov/pubmed/3050535
740. Amling, C.L., Bergstralh, E.J., Blute, M.L., Slezak, J.M., Zincke, H., Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?, J Urol, 2001. 165(4): p. 1146-1151., http://www.ncbi.nlm.nih.gov/pubmed/11257657
741. Stephenson, A.J., Kattan, M.W., Eastham, J.A., Dotan, Z.A., Bianco, F.J., Jr., Lilja, H., et.al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition, J. Clin. Oncol, 2006. 24(24): p. 3973-3978., http://www.ncbi.nlm.nih.gov/pubmed/16921049
742. Freedland, S.J., Sutter, M.E., Dorey, F., Aronson, W.J., Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen, Urology, 2003. 61(2): p. 365-369., http://www.ncbi.nlm.nih.gov/pubmed/12597949
743. Roach, M., III, Hanks, G., Thames, H., Jr., Schellhammer, P., Shipley, W.U., Sokol, G.H., et.al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int. J. Radiat. Oncol. Biol. Phys, 2006. 65(4): p. 965-974., http://www.ncbi.nlm.nih.gov/pubmed/16798415
744. Foster, L.S., Jajodia, P., Fournier, G., Jr., Shinohara, K., Carroll, P., Narayan, P., The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy, J Urol, 1993. 149(5): p. 1024-1028., http://www.ncbi.nlm.nih.gov/pubmed/7683341
745. Fowler, J.E., Jr., Brooks, J., Pandey, P., Seaver, L.E., Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy, J Urol, 1995. 153(3 Pt 2): p. 1011-1014., http://www.ncbi.nlm.nih.gov/pubmed/7531783
746. Heidenreich, A., Bolla, M., Joniau, S., van der Kwast, T.H., Matveev, V., Mason, M.D., et.al. EAU guidelines on prostate cancerEAU, 2009.
747. Nguyen, P.L., D'Amico, A.V., Lee, A.K., Suh, W.W., Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature, Cancer, 2007. 110(7): p. 1417-1428., http://www.ncbi.nlm.nih.gov/pubmed/17694553
748. Horwitz, E.M., Thames, H.D., Kuban, D.A., Levy, L.B., Kupelian, P.A., Martinez, A.A., et.al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis, J Urol, 2005. 173(3): p. 797-802., http://www.ncbi.nlm.nih.gov/pubmed/15711272
749. Fitch, D.L., McGrath, S., Martinez, A.A., Vicini, F.A., Kestin, L.L., Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation, Int J Radiat Oncol Biol Phys, 2006. 66(5): p. 1430-1439., http://www.ncbi.nlm.nih.gov/pubmed/16765527
750. Buyyounouski, M.K., Hanlon, A.L., Eisenberg, D.F., Horwitz, E.M., Feigenberg, S.J., Uzzo, R.G., et.al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer, Int J Radiat Oncol Biol Phys, 2005. 63(5): p. 1455-1462., http://www.ncbi.nlm.nih.gov/pubmed/16169682
751. Denham, J.W., Kumar, M., Gleeson, P.S., Lamb, D.S., Joseph, D., Atkinson, C., et.al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer, Int J Radiat Oncol Biol Phys, 2009. 74(2): p. 404-411., http://www.ncbi.nlm.nih.gov/pubmed/19176272
752. Crook, J., Malone, S., Perry, G., Bahadur, Y., Robertson, S., Abdolell, M., Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients, Int J Radiat Oncol Biol Phys, 2000. 48(2): p. 355-367., http://www.ncbi.nlm.nih.gov/pubmed/10974448
753. Scardino, P.T., The prognostic significance of biopsies after radiotherapy for prostatic cancer, Semin. Urol, 1983. 1(4): p. 243-252., http://www.ncbi.nlm.nih.gov/pubmed/6399610
754. Scattoni, V., Picchio, M., Suardi, N., Messa, C., Freschi, M., Roscigno, M., et.al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy, Eur. Urol, 2007. 52(2): p. 423-429., http://www.ncbi.nlm.nih.gov/pubmed/17397992
755. Gomez, P., Manoharan, M., Kim, S.S., Soloway, M.S., Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?, BJU Int, 2004. 94(3): p. 299-302., http://www.ncbi.nlm.nih.gov/pubmed/15291855
756. van den Broeck, T., van den Bergh, R.C.N., Arfi, N., Gross, T., Moris, L., Briers, E., et.al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer, Eur Urol, 2019. 75(6): p. 967-987., https://pubmed.ncbi.nlm.nih.gov/30342843/
757. Trock, B.J., Han, M., Freedland, S.J., Humphreys, E.B., DeWeese, T.L., Partin, A.W., et.al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy, JAMA, 2008. 299(23): p. 2760-2769., http://www.ncbi.nlm.nih.gov/pubmed/18560003
758. Carrie, C., Magné, N., Burban-Provost, P., Sargos, P., Latorzeff, I., Lagrange, J. L., et.al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16), The Lancet. Oncology, 2019. 20(12): p. 1740-1749., https://pubmed.ncbi.nlm.nih.gov/31629656/
759. Shipley, W.U., Seiferheld, W., Lukka, H.R., Major, P.P., Heney, N.M., Grignon, D.J., et.al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer, The New England journal of medicine, 2017. 376(5): p. 417-428., https://pubmed.ncbi.nlm.nih.gov/28146658/
760. Tilki, D., Preisser, F., Graefen, M., Huland, H., Pompe, R.S., External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort, Eur Urol, 2019. 75(6): p. 896-900., https://pubmed.ncbi.nlm.nih.gov/30955970/
761. van den Broeck, T., van den Bergh, R.C.N., Briers, E., Cornford, P., Cumberbatch, M., Tilki, D., et.al. Biochemical Recurrence in Prostate Cancer, European urology focus, 2020. 6(2): p. 231-234., https://pubmed.ncbi.nlm.nih.gov/31248850/
762. Tendulkar, R.D., Agrawal, S., Gao, T., Efstathiou, J.A., Pisansky, T.M., Michalski, J.M., et.al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy, Journal of clinical oncology, 2016. 34(30): p. 3648-3654., https://pubmed.ncbi.nlm.nih.gov/27528718/
763. Bottke, D., Bartkowiak, D., Siegmann, A., Thamm, R., Böhmer, D., Budach, V., et.al. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer, Prostate cancer and prostatic diseases, 2019. 22(2): p. 344-349., https://pubmed.ncbi.nlm.nih.gov/30487644/
764. Wiegel, T., Lohm, G., Bottke, D., Hocht, S., Miller, K., Siegmann, A., et.al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study, Int. J Radiat. Oncol. Biol. Phys, 2009. 73(4): p. 1009-1016., http://www.ncbi.nlm.nih.gov/pubmed/18963539
765. King, C. R., The dose-response of salvage radiotherapy following radical prostatectomy, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016. 121(2): p. 199-203., https://pubmed.ncbi.nlm.nih.gov/27863963/
766. Ghadjar, P., Aebersold, D. M., Albrecht, C., Böhmer, D., Flentje, M., Ganswindt, U., et.al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy, Strahlenther Onkol, 2018. 194(7): p. 619-626., https://pubmed.ncbi.nlm.nih.gov/29383406/
767. Ghadjar, P., Hayoz, S., Bernhard, J., Zwahlen, D. R., Hölscher, T., Gut, P., et.al. Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy, Journal of clinical oncology, 2015. 33(35): p. 4158-4166., https://pubmed.ncbi.nlm.nih.gov/26527774/
768. Dess, R. T., Sun, Y., Jackson, W. C., Jairath, N. K., Kishan, A. U., Wallington, D. G., et.al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer, JAMA oncology, 2020. 6(5): p. 735-743., https://pubmed.ncbi.nlm.nih.gov/32215583/
769. Spratt, D.E., Dess, R.T., Zumsteg, Z.S., Lin, D.W., Tran, P.T., Morgan, T.M., et.al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer, European urology, 2018. 73(2): p. 156-165., https://pubmed.ncbi.nlm.nih.gov/28716370/
770. Kishan, A. U., Tendulkar, R.l D., Tran, P. T., Parker, C. C., Nguyen, P. L., Stephenson, A. J., et.al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer, European urology oncology, 2018. 1(1): p. 3-18., https://pubmed.ncbi.nlm.nih.gov/31100226/
771. Bartkowiak, D., Thamm, R., Siegmann, A., Böhmer, D., Budach, V., Wiegel, T., Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020. 154: p. 255-259., https://pubmed.ncbi.nlm.nih.gov/32920006/
772. Preisser, F., Chun, F. K. H., Pompe, R. S., Heinze, A., Salomon, G., Graefen, M., et.al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes, European urology, 2019. 76(1): p. 106-114., https://pubmed.ncbi.nlm.nih.gov/30772034/
773. Ploussard, G., Fossati, N., Wiegel, T., D'Amico, A., Hofman, M. S., Gillessen, S., et.al. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy, European urology oncology, 2021. p. [Epub ahead of print]., https://pubmed.ncbi.nlm.nih.gov/33574012/
774. Wiegel, T., Bartkowiak, D., Bottke, D., Thamm, R., Hinke, A., Stöckle, M., et.al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival, International journal of radiation oncology, biology, physics, 2015. 91(2): p. 288-294., www.ncbi.nlm.nih.gov/pubmed/25445556
775. Bartkowiak, D., Siegmann, A., Böhmer, D., Budach, V., Wiegel, T., The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer, BJU international, 2019. 124(5): p. 785-791., https://pubmed.ncbi.nlm.nih.gov/31220400/
776. Heidenreich, A., Richter, S., Thuer, D., Pfister, D., Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy, Eur Urol, 2010. 57(3): p. 437-443., http://www.ncbi.nlm.nih.gov/pubmed/19303197
777. Parekh, A., Graham, P.L., Nguyen, P.L., Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review, Semin Radiat Oncol, 2013. 23(3): p. 222-234., http://www.ncbi.nlm.nih.gov/pubmed/23763889
778. Crouzet, S., Blana, A., Murat, F.J., Pasticier, G., Brown, S.C., Conti, G.N., et.al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients, BJU Int, 2017. 119(6): p. 896-904., http://www.ncbi.nlm.nih.gov/pubmed/28063191
779. Kanthabalan, A., Peters, M., van Vulpen, M., McCartan, N., Hindley, R.G., Emara, A., et.al. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer, BJU Int, 2017. 120(2): p. 246-256., http://www.ncbi.nlm.nih.gov/pubmed/28258616
780. Leonardo, C., Simone, G., Papalia, R., Franco, G., Guaglianone, S., Gallucci, M., Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy, Int J Urol, 2009. 16(6): p. 584-586., http://www.ncbi.nlm.nih.gov/pubmed/19453762
781. Murat, F.J., Poissonnier, L., Rabilloud, M., Belot, A., Bouvier, R., Rouviere, O., et.al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer, Eur Urol, 2009. 55(3): p. 640-647., http://www.ncbi.nlm.nih.gov/pubmed/18508188
782. Bianco, F.J., Jr., Scardino, P.T., Stephenson, A.J., Diblasio, C.J., Fearn, P.A., Eastham, J.A., Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy, Int J Radiat Oncol Biol Phys, 2005. 62(2): p. 448-453., http://www.ncbi.nlm.nih.gov/pubmed/15890586
783. Heidenreich, A., Semrau, R., Thuer, D., Pfister, D., Die radikale Salvageprostatektomie: Therapie der lokalen Prostatarezidivs nach Strahlentherapie, Urologe A, 2008. 47(11): p. 1441-1446., http://www.ncbi.nlm.nih.gov/pubmed/18806991
784. Goluboff, E.T., Prager, D., Rukstalis, D., Giantonio, B., Madorsky, M., Barken, I., et.al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy, J Urol, 2001. 166(3): p. 882-886., http://www.ncbi.nlm.nih.gov/pubmed/11490238
785. Moul, J.W., Wu, H., Sun, L., McLeod, D.G., Amling, C., Donahue, T., et.al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy, J. Urol, 2004. 171(3): p. 1141-1147., http://www.ncbi.nlm.nih.gov/pubmed/14767288
786. Fizazi, K., Tran, N.P., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., et.al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE), Lancet Oncol, 2019. 20(5): p. 686-700., https://pubmed.ncbi.nlm.nih.gov/30987939/
787. Fizazi, K., Tran, N. P., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., et.al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, The New England journal of medicine, 2017. 377(4): p. 352-360., https://pubmed.ncbi.nlm.nih.gov/28578607/
788. Sweeney, C.J., Chen, Y.H., Carducci, M., Liu, G., Jarrard, D.F., Eisenberger, M., et.al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, 2015. 373(8): p. 737-746., http://www.ncbi.nlm.nih.gov/pubmed/26244877
789. Kunath, F., Jensen, K., Pinart, M., Kahlmeyer, A., Schmidt, S., Price, C. L., et.al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer, The Cochrane database of systematic reviews, 2019. 6: p. CD003506., https://pubmed.ncbi.nlm.nih.gov/31194882/
790. Agarwal, N., McQuarrie, K., Bjartell, A., Chowdhury, S., Pereira de Santana Gomes, A.J., Chung, B.H., et.al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN), Lancet Oncol, 2019. 20(11): p. 1518-1530., https://pubmed.ncbi.nlm.nih.gov/31578173/
791. Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., et.al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med, 2019. 381(1): p. 13-24., https://pubmed.ncbi.nlm.nih.gov/31150574/
792. Armstrong, A.J., Szmulewitz, R.Z., Petrylak, D.P., Holzbeierlein, J., Villers, A., Azad, A., et.al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer, J Clin Oncol, 2019. 37(32): p. 2974-2986., https://pubmed.ncbi.nlm.nih.gov/31329516/
793. Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., et.al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 2013. 14(2): p. 149-158., http://www.ncbi.nlm.nih.gov/pubmed/23306100
794. James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., et.al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 2016. 387(10024): p. 1163-1177., http://www.ncbi.nlm.nih.gov/pubmed/26719232
795. Magnan, S., Zarychanski, R., Pilote, L., Bernier, L., Shemilt, M., Vigneault, E., et.al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis, JAMA Oncol, 2015. 1(9): p. 1261-1269., http://www.ncbi.nlm.nih.gov/pubmed/26378418
796. Niraula, S., Le, L.W., Tannock, I.F., Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials, J Clin Oncol, 2013. 31(16): p. 2029-2036., http://www.ncbi.nlm.nih.gov/pubmed/23630216
797. Hussain, M., Tangen, C.M., Berry, D.L., Higano, C.S., Crawford, E.D., Liu, G., et.al. Intermittent versus continuous androgen deprivation in prostate cancer, N Engl J Med, 2013. 368(14): p. 1314-1325., https://pubmed.ncbi.nlm.nih.gov/23550669/
798. Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B.Y., et.al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med, 2017. 377(4): p. 352-360., http://www.ncbi.nlm.nih.gov/pubmed/28578607
799. Institut für Qualität und Wirtschaftlichkeit im, Gesundheitswesen, Apalutamid (Prostatakarzinom). Addendum zum Auftrag A20-20. Version: 1.0, IQWiG-Berichte, 2020., G:\ÄZQ-Berlin\7000, IVS\Citavi\Prostata, 2020\PCa2020Attachments\30459.pdf
800. Institut für Qualität und Wirtschaftlichkeit im, Gesundheitswesen, Apalutamid (Prostatakarzinom). Nutzenbewertung gemäß § 35a SGB V, IQWiG-Berichte, 2020., G:\ÄZQ-Berlin\7000, IVS\Citavi\Prostata, 2020\PCa2020Attachments\30458.pdf
801. Gemeinsamer, Bundesausschuss, Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL), 2020., G:\ÄZQ-Berlin\7000, IVS\Citavi\Prostata, 2020\PCa2020Attachments\30460.pdf
802. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Apalutamid (Neubewertung nach Fristablauf: Prostatakarzinom, nicht metastasiert, hohes Metastasenrisiko), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/542/
803. James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., et.al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy, N Engl J Med, 2017. 377(4): p. 338-351., http://www.ncbi.nlm.nih.gov/pubmed/28578639
804. Vale, C.L., Burdett, S., Rydzewska, L.H., Albiges, L., Clarke, N.W., Fisher, D., et.al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 2016. 17(2): p. 243-256., http://www.ncbi.nlm.nih.gov/pubmed/26718929
805. Gravis, G., Boher, J. M., Chen, Y. H., Liu, G., Fizazi, K., Carducci, M. A., et.al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel, European urology, 2018. 73(6): p. 847-855., https://pubmed.ncbi.nlm.nih.gov/29475737/
806. Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., et.al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer, Annals of oncology : official journal of the European Society for Medical Oncology, 2019. 30(12): p. 1992-2003., https://pubmed.ncbi.nlm.nih.gov/31560068/
807. Jakob, Joachim J., Schmidt, Stefanie, Kunath, Frank, Meerpohl, Joerg J., Blümle, Anette, Schmucker, Christine, et.al. Degarelix for treating advanced hormone‐sensitive prostate cancer, The Cochrane Database of Systematic Reviews, 2017. 2017(2): p. CD012548., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464394/
808. Cameron, M.G., Kersten, C., Guren, M.G., Fossa, S.D., Vistad, I., Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - A systematic review, Radiother. Oncol, 2013., http://www.ncbi.nlm.nih.gov/pubmed/24044801
809. Gzell, C.E., Kench, J.G., Stockler, M.R., Hruby, G., Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature, Int Urol Nephrol, 2013. 45(3): p. 735-742., http://www.ncbi.nlm.nih.gov/pubmed/23666549
810. Repetto, L., Venturino, A., Vercelli, M., Gianni, W., Biancardi, V., Casella, C., et.al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions, Cancer, 1998. 82(4): p. 760-765., http://www.ncbi.nlm.nih.gov/pubmed/9477110
811. Extermann, M., Overcash, J., Lyman, G.H., Parr, J., Balducci, L., Comorbidity and functional status are independent in older cancer patients, J Clin Oncol, 1998. 16(4): p. 1582-1587., http://www.ncbi.nlm.nih.gov/pubmed/9552069
812. Puts, M.T., Hardt, J., Monette, J., Girre, V., Springall, E., Alibhai, S.M., Use of geriatric assessment for older adults in the oncology setting: a systematic review, J Natl. Cancer Inst, 2012. 104(15): p. 1133-1163., http://www.ncbi.nlm.nih.gov/pubmed/22851269
813. Friedrich, C., Kolb, G., Wedding, U., Pientka, L., Comprehensive geriatric assessment in the elderly cancer patient, Onkologie, 2003. 26(4): p. 355-360., http://www.ncbi.nlm.nih.gov/pubmed/12972703
814. Extermann, M., Aapro, M., Bernabei, R., Cohen, H.J., Droz, J.P., Lichtman, S., et.al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG), Crit Rev Oncol. Hematol, 2005. 55(3): p. 241-252., http://www.ncbi.nlm.nih.gov/pubmed/16084735
815. Pallis, A.G., Fortpied, C., Wedding, U., Van Nes, M.C., Penninckx, B., Ring, A., et.al. EORTC elderly task force position paper: approach to the older cancer patient, Eur J Cancer, 2010. 46(9): p. 1502-1513., http://www.ncbi.nlm.nih.gov/pubmed/20227872
816. Pallis, A.G., Wedding, U., Lacombe, D., Soubeyran, P., Wildiers, H., Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?, Eur J Cancer, 2010. 46(6): p. 1019-1025., http://www.ncbi.nlm.nih.gov/pubmed/20138506
817. Droz, J.P., Balducci, L., Bolla, M., Emberton, M., Fitzpatrick, J.M., Joniau, S., et.al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults, Crit Rev Oncol Hematol, 2010. 73(1): p. 68-91., http://www.ncbi.nlm.nih.gov/pubmed/19836968
818. Extermann, M., Boler, I., Reich, R.R., Lyman, G.H., Brown, R.H., DeFelice, J., et.al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score, Cancer, 2012. 118(13): p. 3377-3386., http://www.ncbi.nlm.nih.gov/pubmed/22072065
819. Hurria, A., Togawa, K., Mohile, S.G., Owusu, C., Klepin, H.D., Gross, C.P., et.al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol, 2011. 29(25): p. 3457-3465., http://www.ncbi.nlm.nih.gov/pubmed/21810685
820. Soubeyran, P., Fonck, M., Blanc-Bisson, C., Blanc, J.F., Ceccaldi, J., Mertens, C., et.al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer, J Clin Oncol, 2012. 30(15): p. 1829-1834., http://www.ncbi.nlm.nih.gov/pubmed/22508806
821. Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De, Santis M., Gross, T., et.al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer, Eur Urol, 2017. 71(4): p. 630-642., http://www.ncbi.nlm.nih.gov/pubmed/27591931
822. Saad, F., Cella, D., Basch, E., Hadaschik, B.A., Mainwaring, P.N., Oudard, S., et.al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer, Lancet Oncol, 2018. 19(10): p. 1404-1416., https://pubmed.ncbi.nlm.nih.gov/30213449/
823. Small, E.J., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., et.al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer, Ann Oncol, 2019. 30(11): p. 1813-1820., https://pubmed.ncbi.nlm.nih.gov/31560066/
824. Smith, M.R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., et.al. Apalutamide and Overall Survival in Prostate Cancer, Eur Urol, 2020. 79(1): p. 150-158., https://pubmed.ncbi.nlm.nih.gov/32907777/
825. Smith, M.R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., et.al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer, N Engl J Med, 2018. 378(15): p. 1408-1418., https://pubmed.ncbi.nlm.nih.gov/29420164/
826. Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., et.al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 2019. 380(13): p. 1235-1246., https://pubmed.ncbi.nlm.nih.gov/30763142/
827. Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., et.al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide, N Engl J Med, 2020. 383(11): p. 1040-1049., https://pubmed.ncbi.nlm.nih.gov/32905676/
828. Sternberg, C.N., Fizazi, K., Saad, F., Shore, N.D., Giorgi, U., Penson, D.F., et.al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 2020. 382(23): p. 2197-2206., https://pubmed.ncbi.nlm.nih.gov/32469184/
829. Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., et.al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 2018. 378(26): p. 2465-2474., https://pubmed.ncbi.nlm.nih.gov/29949494/
830. Tombal, B., Saad, F., Penson, D., Hussain, M., Sternberg, C.N., Morlock, R., et.al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER), Lancet Oncol, 2019. 20(4): p. 556-569., https://pubmed.ncbi.nlm.nih.gov/30770294/
831. Smith, M.R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M.C., Bilhartz, D.L., et.al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, Journal of clinical oncology, 2005. 23(13): p. 2918-2925., https://pubmed.ncbi.nlm.nih.gov/15860850/
832. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Darolutamid (Prostatakarzinom, nicht metastasiert, hohes Metastasenrisiko), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/548/
833. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Enzalutamid (Neubewertung nach Fristablauf: Prostatakarzinom, nicht metastasiert, Hochrisiko), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/551/
834. Deutsche Gesellschaft für Hämatologie und Medizinische, Onkologie, Arzneimittelinteraktionen. Onkopedia-Leitlinien, 2020.
835. Tannock, I.F., de, Wit R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., et.al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N. Engl. J. Med, 2004. 351(15): p. 1502-1512., http://www.ncbi.nlm.nih.gov/pubmed/15470213
836. Berthold, D.R., Pond, G.R., Soban, F., de, Wit R., Eisenberger, M., Tannock, I.F., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 2008. 26(2): p. 242-245., http://www.ncbi.nlm.nih.gov/pubmed/18182665
837. Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de, Souza P., et.al. Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 2013. 368(2): p. 138-148., http://www.ncbi.nlm.nih.gov/pubmed/23228172
838. Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., et.al. Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 2014. 371(5): p. 424-433., http://www.ncbi.nlm.nih.gov/pubmed/24881730
839. Scher, H.I., Halabi, S., Tannock, I., Morris, M., Sternberg, C.N., Carducci, M.A., et.al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 2008. 26(7): p. 1148-1159., http://www.ncbi.nlm.nih.gov/pubmed/18309951
840. Berthold, D.R., Pond, G.R., Roessner, M., de, Wit R., Eisenberger, M., Tannock, A.I., Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study, Clin Cancer Res, 2008. 14(9): p. 2763-2767., http://www.ncbi.nlm.nih.gov/pubmed/18451243
841. Ryan, C.J., Smith, M.R., Fizazi, K., Saad, F., Mulders, P.F., Sternberg, C.N., et.al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 2015. 16(2): p. 152-160., http://www.ncbi.nlm.nih.gov/pubmed/25601341
842. European Medicines Agency, Abirateron. Anhang I. Zusammenfassung der Merkmale des Arzneimittels, 2013., http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf
843. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Enzalutamid (neues Anwendungsgebiet) - Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung A14-48. Version 1.0, 2015., http://www.g-ba.de/downloads/92-975-750/Nutzenbewertung%20IQWiG_Enzalutamid_nAWG.pdf
844. Beer, T.M., Armstrong, A.J., Rathkopf, D., Loriot, Y., Sternberg, C.N., Higano, C.S., et.al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer, European urology, 2017. 71(2): p. 151-154., https://pubmed.ncbi.nlm.nih.gov/27477525/
845. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Xtandi® (Enzalutamid), 2013., http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/201315-Xtandi.pdf
846. European Medicines Agency, Xtandi. Enzalutamid. Zusammenfassung des EPAR für die Öffentlichkeit. Anhang I. Zusammenfassung der Merkmale des Arzneimittels, 2013., http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002639/WC500144996.pdf
847. Khalaf, D. J., Annala, M., Taavitsainen, S., Finch, D. L., Oja, C., Vergidis, J., et.al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer, The Lancet. Oncology, 2019. 20(12): p. 1730-1739., https://pubmed.ncbi.nlm.nih.gov/31727538/
848. Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., et.al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment, Journal of clinical oncology, 2018. 36(25): p. 2639-2646., https://pubmed.ncbi.nlm.nih.gov/30028657/
849. Kellokumpu-Lehtinen, P.L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., et.al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial, Lancet Oncol, 2013. 14(2): p. 117-124., http://www.ncbi.nlm.nih.gov/pubmed/23294853
850. European Medicines Agency, Docetaxel. Zusammenfassung des EPAR für die Öffentlichkeit. Anhang I. Zusammenfassung der Merkmale des Arzneimittels, 2013., http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000073/WC500035264.pdf
851. Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., et.al. Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 2013. 369(3): p. 213-223., http://www.ncbi.nlm.nih.gov/pubmed/23863050
852. Wit, R., Bono, J., Sternberg, C.N., Fizazi, K., Tombal, B., Wülfing, C., et.al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer, N Engl J Med, 2019. 381(26): p. 2506-2518., www.ncbi.nlm.nih.gov/pubmed/31566937
853. Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., et.al. Olaparib for Metastatic Castration-Resistant Prostate Cancer, N Engl J Med, 2020. 382(22): p. 2091-2102., https://pubmed.ncbi.nlm.nih.gov/32343890/
854. Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., et.al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, N Engl J Med, 2020. 383(24): p. 2345-2357., https://pubmed.ncbi.nlm.nih.gov/32955174/
855. Nakazawa, M., Lu, C., Chen, Y., Paller, C.J., Carducci, M.A., Eisenberger, M. A., et.al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancerAnn Oncol, 2015. 9: p. 1859 - 1865., https://pubmed.ncbi.nlm.nih.gov/26117829/
856. Nakazawa, M., Paller, C., Kyprianou, N., Mechanisms of Therapeutic Resistance in Prostate CancerCurr Oncol Rep, 2017. 2: p. 13., https://pubmed.ncbi.nlm.nih.gov/28229393/
857. Pritchard, C.C., Mateo, J., Walsh, M.F., Sarkar, N., Abida, W., Beltran, H., et.al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer, The New England journal of medicine, 2016. 375(5): p. 443-453., https://pubmed.ncbi.nlm.nih.gov/27433846/
858. Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., et.al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer, European urology, 2015. 68(2): p. 186-193., https://pubmed.ncbi.nlm.nih.gov/25454609/
859. Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., et.al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clinical cancer research, 2010. 16(7): p. 2115-2121., https://pubmed.ncbi.nlm.nih.gov/20215531/
860. European Medicines, Agency, Lynparza, 2020., https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza
861. Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., et.al. Increased survival with enzalutamide in prostate cancer after chemotherapy, The New England journal of medicine, 2012. 367(13): p. 1187-1197., https://pubmed.ncbi.nlm.nih.gov/22894553/
862. de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et.al. Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 2011. 364(21): p. 1995-2005., http://www.ncbi.nlm.nih.gov/pubmed/21612468
863. Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., et.al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 2012. 13(10): p. 983-992., http://www.ncbi.nlm.nih.gov/pubmed/22995653
864. Logothetis, C.J., Basch, E., Molina, A., Fizazi, K., North, S.A., Chi, K.N., et.al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial, Lancet Oncol, 2012. 13(12): p. 1210-1217., http://www.ncbi.nlm.nih.gov/pubmed/23142059
865. de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., et.al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 2010. 376(9747): p. 1147-1154., http://www.ncbi.nlm.nih.gov/pubmed/20888992
866. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., et.al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 2011. 377(9768): p. 813-822., http://www.ncbi.nlm.nih.gov/pubmed/21353695
867. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et.al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J. Natl. Cancer Inst, 2002. 94(19): p. 1458-1468., http://www.ncbi.nlm.nih.gov/pubmed/12359855
868. Yuen, K.K., Shelley, M., Sze, W.M., Wilt, T., Mason, M.D., Bisphosphonates for advanced prostate cancer, Cochrane Database Syst Rev, 2006. p. CD006250., http://www.ncbi.nlm.nih.gov/pubmed/17054286
869. Vogelzang, N.J., Coleman, R.E., Michalski, J.M., Nilsson, S., O'Sullivan, J.M., Parker, C., et.al. Hematologic Safety of Radium-223 Dichloride, Clin Genitourin Cancer, 2017. 15(1): p. 42-52.e8., https://pubmed.ncbi.nlm.nih.gov/27613490/
870. Parker, C. C., Coleman, R. E., Sartor, O., Vogelzang, N. J., Bottomley, D., Heinrich, D., et.al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial, Eur Urol, 2018. 73(3): p. 427-435., https://pubmed.ncbi.nlm.nih.gov/28705540/
871. Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q.S., et.al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223), Lancet Oncol, 2019. 20(3): p. 408-419., https://pubmed.ncbi.nlm.nih.gov/30738780/
872. Fossa, S.D., Jacobsen, A.B., Ginman, C., Jacobsen, I.N., Overn, S., Iversen, J.R., et.al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study, Eur Urol, 2007. 52(6): p. 1691-1698., http://www.ncbi.nlm.nih.gov/pubmed/17306441
873. Yadav, M.P., Ballal, S., Sahoo, R.K., Dwivedi, S.N., Bal, C., Radioligand Therapy With (177) Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer, AJR Am J Roentgenol, 2019. 213(2): p. 275-285., www.ncbi.nlm.nih.gov/pubmed/30995089
874. Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., et.al. Increased survival with enzalutamide in prostate cancer after chemotherapy, N. Engl. J Med, 2012. 367(13): p. 1187-1197., http://www.ncbi.nlm.nih.gov/pubmed/22894553
875. Heidenreich, A., Scholz, H.J., Rogenhofer, S., Arsov, C., Retz, M., Muller, S.C., et.al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme, Eur Urol, 2013. 63(6): p. 977-982., http://www.ncbi.nlm.nih.gov/pubmed/23116658
876. de Bono, J.S., Hardy-Bessard, A.C., Kim, C.-S., Geczi, L., Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D), J Clin Oncol, 2016. 34(15 Suppl): p. 5008., http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.5008
877. European Medicines Agency, Cabazitaxel. Zusammenfassung des EPAR für die Öffentlichkeit. Anhang I. Zusammenfassung der Merkmale des Arzneimittels, 2013., http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002018/WC500104764.pdf
878. European Medicines, Agency, Radium-233-Dichloride, 2013., https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo
879. European Medicines Agency, Radium. Zusammenfassung des EPAR für die Öffentlichkeit. Anhang I. Zusammenfassung der Merkmale des Arzneimittels, 2013., http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002653/WC500156172.pdf
880. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Radium-223-dichlorid (Erneute Nutzenbewertung § 13: Prostatakarzinom), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/455/
881. Tombal, Bertrand F., Loriot, Yohann, Saad, Fred, McDermott, Raymond S., Elliott, Tony, Rodriguez-Vida, Alejo, et.al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone, Journal of clinical oncology, 2019. 37(15_suppl): p. 5007., https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5007
882. Yennurajalingam, S., Atkinson, B., Masterson, J., Hui, D., Urbauer, D., Tu, S.M., et.al. The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients, J Palliat Med, 2012. 15(1): p. 20-24., https://pubmed.ncbi.nlm.nih.gov/22141432/
883. Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schafers, M., Essler, M., et.al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients, J Nucl Med, 2017. 58(1): p. 85-90., http://www.ncbi.nlm.nih.gov/pubmed/27765862
884. Yadav, M.P., Ballal, S., Tripathi, M., Damle, N.A., Sahoo, R.K., Seth, A., et.al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment, Eur J Nucl Med Mol Imaging, 2017. 44(1): p. 81-91., http://www.ncbi.nlm.nih.gov/pubmed/27506431
885. Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., et.al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP), Lancet, 2021. 351(suppl 1): p. 1502., https://www.sciencedirect.com/science/article/pii/S0140673621002373?via%3Dihub
886. Cassinello, J., Domínguez-Lubillo, T., Gómez-Barrera, M., Hernando, T., Parra, R., Asensio, I., et.al. Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer, Cancer treatment reviews, 2021. 93: p. 102152., https://pubmed.ncbi.nlm.nih.gov/33486302/
887. Fossa, S.D., Slee, P.H., Brausi, M., Horenblas, S., Hall, R.R., Hetherington, J.W., et.al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group, J Clin Oncol, 2001. 19(1): p. 62-71., http://www.ncbi.nlm.nih.gov/pubmed/11134196
888. Venkitaraman, R., Thomas, K., Huddart, R.A., Horwich, A., Dearnaley, D.P., Parker, C.C., Efficacy of low-dose dexamethasone in castration-refractory prostate cancer, BJU. Int, 2008. 101(4): p. 440-443., http://www.ncbi.nlm.nih.gov/pubmed/17941935
889. Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., et.al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer, Eur Urol, 2019. 76(1): p. 115-124., https://pubmed.ncbi.nlm.nih.gov/30826218/
890. Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., et.al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE), Lancet, 2018. 392(10162): p. 2353-2366., https://pubmed.ncbi.nlm.nih.gov/30355464/
891. Buelens, S., Poelaert, F., Dhondt, B., Fonteyne, V., Visschere, P., Ost, P., et.al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer, Urologic oncology, 2018. 36(4): p. 158.e13-158.e20., https://pubmed.ncbi.nlm.nih.gov/29336978/
892. Boevé, L. M. S., Hulshof, M. C. C. M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J., et.al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial, Eur Urol, 2019. 75(3): p. 410-418., https://pubmed.ncbi.nlm.nih.gov/30266309/
893. Slaoui, A., Albisinni, S., Aoun, F., Assenmacher, G., Al Hajj Obeid, W., Diamand, R., et.al. A systematic review of contemporary management of oligometastatic prostate cancer, World J Urol, 2019. 37(11): p. 2343-2353., https://pubmed.ncbi.nlm.nih.gov/30706122/
894. Xiao, M., Cong, R., Zhang, Q., Xiang, W., Xiao, H., Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis, Ann Palliat Med, 2020. 9(3): p. 648-660., www.ncbi.nlm.nih.gov/pubmed/32312070
895. Connor, M. J., Smith, A., Miah, S., Shah, T. T., Winkler, M., Khoo, V., et.al. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer, Eur Urol Oncol, 2020. 3(5): p. 582-593., https://pubmed.ncbi.nlm.nih.gov/32891600/
896. Falkmer, U., Jarhult, J., Wersall, P., Cavallin-Stahl, E., A systematic overview of radiation therapy effects in skeletal metastases, Acta Oncol, 2003. 42(5-6): p. 620-633., http://www.ncbi.nlm.nih.gov/pubmed/14596519
897. Bauman, G., Charette, M., Reid, R., Sathya, J., Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review, Radiother Oncol, 2005. 75(3): p. 258-270., http://www.ncbi.nlm.nih.gov/pubmed/16299924
898. Smith, M.R., Coleman, R.E., Klotz, L., Pittman, K., Milecki, P., Ng, S., et.al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, Ann Oncol, 2015. 26(2): p. 368-374., http://www.ncbi.nlm.nih.gov/pubmed/25425475
899. James, N.D., Pirrie, S.J., Pope, A.M., Barton, D., Andronis, L., Goranitis, I., et.al. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial, JAMA Oncol, 2016. 2(4): p. 493-499., http://www.ncbi.nlm.nih.gov/pubmed/26794729
900. Kamba, T., Kamoto, T., Maruo, S., Kikuchi, T., Shimizu, Y., Namiki, S., et.al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial, Int J Clin Oncol, 2016. p. 1-8., http://www.ncbi.nlm.nih.gov/pubmed/27614621
901. Smith, M.R., Halabi, S., Ryan, C.J., Hussain, A., Vogelzang, N., Stadler, W., et.al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), J Clin Oncol, 2014. 32(11): p. 1143-1150., http://www.ncbi.nlm.nih.gov/pubmed/24590644
902. Saad, F., Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer, Clin Prostate Cancer, 2005. 4(1): p. 31-37., http://www.ncbi.nlm.nih.gov/pubmed/15992459
903. Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., et.al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients, Hum Pathol, 2000. 31(5): p. 578-583., http://www.ncbi.nlm.nih.gov/pubmed/10836297
904. Carlin, B.I., Andriole, G.L., The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma, Cancer, 2000. 88(12 Suppl): p. 2989-2994., http://www.ncbi.nlm.nih.gov/pubmed/10898342
905. Eaton, C.L., Coleman, R.E., Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment, Cancer Treat Rev, 2003. 29(3): p. 189-198., http://www.ncbi.nlm.nih.gov/pubmed/12787713
906. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et.al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J. Natl. Cancer Inst, 2004. 96(11): p. 879-882., http://www.ncbi.nlm.nih.gov/pubmed/15173273
907. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Empfehlungen zur Therapie von TumorschmerzenAkdÄ, Arzneiverordnung in der Praxis; 34, 2007.
908. Hartsell, W.F., Scott, C.B., Bruner, D.W., Scarantino, C.W., Ivker, R.A., Roach, M., III, et.al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases, J Natl Cancer Inst, 2005. 97(11): p. 798-804., http://www.ncbi.nlm.nih.gov/pubmed/15928300
909. Roos, D.E., Turner, S.L., O'Brien, P.C., Smith, J.G., Spry, N.A., Burmeister, B.H., et.al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05), Radiother. Oncol, 2005. 75(1): p. 54-63., http://www.ncbi.nlm.nih.gov/pubmed/15878101
910. Sze, W.M., Shelley, M., Held, I., Mason, M., Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials, Cochrane Database Syst Rev, 2011. p. CD004721.
911. Chow, E., Harris, K., Fan, G., Tsao, M., Sze, W.M., Palliative radiotherapy trials for bone metastases: a systematic review, J. Clin. Oncol, 2007. 25(11): p. 1423-1436., http://www.ncbi.nlm.nih.gov/pubmed/17416863
912. Koswig, S., Budach, V., Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10 mal 3 Gy vs. 1 mal 8 Gy). Eine prospektive Studie, Strahlenther Onkol, 1999. 175(10): p. 500-508., http://www.ncbi.nlm.nih.gov/pubmed/10554645
913. Patchell, R.A., Tibbs, P.A., Regine, W.F., Payne, R., Saris, S., Kryscio, R.J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366(9486): p. 643-648., http://www.ncbi.nlm.nih.gov/pubmed/16112300
914. George, R., Jeba, J., Ramkumar, G., Chacko, A.G., Leng, M., Tharyan, P., Interventions for the treatment of metastatic extradural spinal cord compression in adults, Cochrane. Database. Syst. Rev, 2008. p. CD006716., http://www.ncbi.nlm.nih.gov/pubmed/18843728
915. Sartor, O., Reid, R.H., Hoskin, P.J., Quick, D.P., Ell, P.J., Coleman, R.E., et.al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer, Urology, 2004. 63(5): p. 940-945., http://www.ncbi.nlm.nih.gov/pubmed/15134985
916. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Rote-Hand-Brief zu Aclasta® (Wirkstoff: Zoledronsäure): Berichte über Nierenfunktionsstörungen und Nierenversagen, 2010., http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2010/rhb-aclasta.pdf
917. Paul-Ehrlich-Institut (PEI), Rote-Hand-Brief: Prolia® (Denosumab), 2014., http://www.pei.de/SharedDocs/Downloads/vigilanz/rhb/14-09-04-rhb-prolia.pdf
918. Paul-Ehrlich-Institut (PEI), Rote-Hand-Brief: Xgeva® (Denosumab), 2015., http://www.pei.de/SharedDocs/Downloads/vigilanz/rhb/15-07-30-rhb-xgeva.pdf
919. Leitlinienprogramm Onkologie (OL), Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. AWMF-Register-Nummer (032/054OL). Langversion 1.1, 2017., http://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.1.pdf
920. Saad, F., Chen, Y.M., Gleason, D.M., Chin, J., Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases, Clin Genitourin Cancer, 2007. 5(6): p. 390-396., http://www.ncbi.nlm.nih.gov/pubmed/17956712
921. World Health, Organization, Palliative care [Internet], 2015., https://www.who.int/classifications/icf/en/U6, -, https://www.who.int/health-topics/palliative-careY3, -, 2021-02-22M4, -, Citavi
922. Dindo, D., Demartines, N., Clavien, P.A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 2004. 240(2): p. 205-213., https://pubmed.ncbi.nlm.nih.gov/15273542/
923. Musch, M., Klevecka, V., Roggenbuck, U., Kroepfl, D., Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006, J. Urol, 2008. 179(3): p. 923-928., http://www.ncbi.nlm.nih.gov/pubmed/18207170
924. Briganti, A., Chun, F.K., Salonia, A., Suardi, N., Gallina, A., Da Pozzo, L.F., et.al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer, Eur Urol, 2006. 50(5): p. 1006-1013., http://www.ncbi.nlm.nih.gov/pubmed/16959399
925. Beyer, J., Wessela, S., Hakenberg, O.W., Kuhlisch, E., Halbritter, K., Froehner, M., et.al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery, J Thromb Haemost, 2009. 7(4): p. 597-604., http://www.ncbi.nlm.nih.gov/pubmed/19143928
926. Vernia, P., Fracasso, P.L., Casale, V., Villotti, G., Marcheggiano, A., Stigliano, V., et.al. Topical butyrate for acute radiation proctitis: randomised, crossover trial, Lancet, 2000. 356(9237): p. 1232-1235., http://www.ncbi.nlm.nih.gov/pubmed/11072942
927. Sanguineti, G., Franzone, P., Marcenaro, M., Foppiano, F., Vitale, V., Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study, Strahlenther. Onkol, 2003. 179(7): p. 464-470., http://www.ncbi.nlm.nih.gov/pubmed/12835883
928. National Institutes of Health (NIH), National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, 2010., https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
929. Sherman, D.M., Mangini, L., Poirier, P., Kadish, S.P., Double-blind comparison of loperamide and placebo in the treatment of radiation-induced diarrhea, Adv Ther, 1989. 6: p. 103-111.
930. Yavuz, M.N., Yavuz, A.A., Aydin, F., Can, G., Kavgaci, H., The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study, Int. J Radiat. Oncol. Biol. Phys, 2002. 54(1): p. 195-202., http://www.ncbi.nlm.nih.gov/pubmed/12182992
931. Denton, A., Forbes, A., Andreyev, J., Maher, E.J., Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis, Cochrane Database Syst Rev, 2002. p. CD003455., http://www.ncbi.nlm.nih.gov/pubmed/11869662
932. McGough, C., Baldwin, C., Frost, G., Andreyev, H.J., Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy, Br. J. Cancer, 2004. 90(12): p. 2278-2287., http://www.ncbi.nlm.nih.gov/pubmed/15162154
933. Spetz, A.C., Zetterlund, E.L., Varenhorst, E., Hammar, M., Incidence and management of hot flashes in prostate cancer, J. Support. Oncol, 2003. 1(4): p. 263-70, 272., http://www.ncbi.nlm.nih.gov/pubmed/15334868
934. Cervenakov, I., Kopecny, M., Jancar, M., Chovan, D., Mal'a, M., 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate, Int Urol Nephrol, 2000. 32(1): p. 77-79., http://www.ncbi.nlm.nih.gov/pubmed/11057778
935. Morote, J., Orsola, A., Planas, J., Trilla, E., Raventos, C.X., Cecchini, L., et.al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy, J. Urol, 2007. 178(4 Pt 1): p. 1290-1295., http://www.ncbi.nlm.nih.gov/pubmed/17698136
936. Abrahamsen, B., Nielsen, M.F., Eskildsen, P., Andersen, J.T., Walter, S., Brixen, K., Fracture risk in Danish men with prostate cancer: a nationwide register study, BJU Int, 2007. 100(4): p. 749-754., http://www.ncbi.nlm.nih.gov/pubmed/17822455
937. Malcolm, J.B., Derweesh, I.H., Kincade, M.C., Diblasio, C.J., Lamar, K.D., Wake, R.W., et.al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer, Can. J. Urol, 2007. 14(3): p. 3551-3559., http://www.ncbi.nlm.nih.gov/pubmed/17594745
938. Qaseem, A., Snow, V., Shekelle, P., Casey, D.E., Jr., Cross, J.T., Jr., Owens, D.K., et.al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians, Ann. Intern. Med, 2008. 148(2): p. 141-146., http://www.ncbi.nlm.nih.gov/pubmed/18195338
939. Weissbach, L., Diagnostik von Knochenmetastasen urologischer Tumoren und deren Behandlung mit Bisphosphonaten. Interdisziplinäre Konsensuskonferenz Frankfurt 2006, Urologe A, 2006. 45(12): p. 1527-1531., http://www.ncbi.nlm.nih.gov/pubmed/17091278
940. Hakimian, P., Blute, M., Jr., Kashanian, J., Chan, S., Silver, D., Shabsigh, R., Metabolic and cardiovascular effects of androgen deprivation therapy, BJU Int, 2008. 102(11): p. 1509-1514., http://www.ncbi.nlm.nih.gov/pubmed/18727614
941. Saylor, P.J., Smith, M.R., Metabolic complications of androgen deprivation therapy for prostate cancer, J. Urol, 2009. 181(5): p. 1998-2006., http://www.ncbi.nlm.nih.gov/pubmed/19286225
942. Efstathiou, J.A., Bae, K., Shipley, W.U., Hanks, G.E., Pilepich, M.V., Sandler, H.M., et.al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31, J Clin Oncol, 2009. 27(1): p. 92-99., http://www.ncbi.nlm.nih.gov/pubmed/19047297
943. Efstathiou, J.A., Bae, K., Shipley, W.U., Hanks, G.E., Pilepich, M.V., Sandler, H.M., et.al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02, Eur Urol, 2008. 54(4): p. 816-823., http://www.ncbi.nlm.nih.gov/pubmed/18243498
944. Beer, T.M., Myrthue, A., Calcitriol in the treatment of prostate cancer, Anticancer Res, 2006. 26(4A): p. 2647-2651., http://www.ncbi.nlm.nih.gov/pubmed/16886675
945. Johansson, J.E., Wersall, P., Brandberg, Y., Andersson, S.O., Nordstrom, L., Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study, Scand J Urol Nephrol, 2001. 35(4): p. 288-294., http://www.ncbi.nlm.nih.gov/pubmed/11676354
946. Bogdanos, J., Karamanolakis, D., Milathianakis, K., Repousis, P., Chloraki-Bobota, A., Majed, H., et.al. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases, Anticancer Res, 2004. 24(3b): p. 1957-1961., http://www.ncbi.nlm.nih.gov/pubmed/15274384
947. Winquist, E., Julian, J.A., Moore, M.J., Nabid, A., Sathya, J., Wood, L., et.al. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia, J Clin Oncol, 2009. 27(4): p. 644-646., http://www.ncbi.nlm.nih.gov/pubmed/19103725
948. Iversen, P., Tammela, T.L., Vaage, S., Lukkarinen, O., Lodding, P., Bull-Njaa, T., et.al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6, Eur Urol, 2002. 42(3): p. 204-211., http://www.ncbi.nlm.nih.gov/pubmed/12234503
949. Widmark, A., New principles in the treatment of prostate cancer--the oncologist's view, Scand. J Urol. Nephrol. Suppl, 2003. p. 23-27., http://www.ncbi.nlm.nih.gov/pubmed/12841324
950. Tyrrell, C., Immediate Treatment with Bicalutamide, 150 mg/d, Following Radiotherapy in Localized or Locally Advanced Prostate Cancer, Rev. Urol, 2004. 6 Suppl 2: p. S29-S36., http://www.ncbi.nlm.nih.gov/pubmed/16985858
951. Perdona, S., Autorino, R., De, Placido S., D'Armiento, M., Gallo, A., Damiano, R., et.al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial, Lancet Oncol, 2005. 6(5): p. 295-300., http://www.ncbi.nlm.nih.gov/pubmed/15863377
952. Dachverband Osteologie (DVO), Evidenz-basierte Konsensus-Leitlinien zur Osteoporose, 2006.
953. Levy, M.H., Back, A., Benedetti, C., Billings, J.A., Block, S., Boston, B., et.al. NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr. Canc. Netw, 2009. 7(4): p. 436-473., https://pubmed.ncbi.nlm.nih.gov/19406043/
954. Roila, F., Hesketh, P.J., Herrstedt, J., Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference, Ann. Oncol, 2006. 17(1): p. 20-28., http://www.ncbi.nlm.nih.gov/pubmed/16314401
955. Kris, M.G., Hesketh, P.J., Somerfield, M.R., Feyer, P., Clark-Snow, R., Koeller, J.M., et.al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, J Clin Oncol, 2006. 24(18): p. 2932-2947., http://www.ncbi.nlm.nih.gov/pubmed/16717289
956. Jordan, K., Sippel, C., Schmoll, H.J., Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations, Oncologist, 2007. 12(9): p. 1143-1150., http://www.ncbi.nlm.nih.gov/pubmed/17914084
957. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., et.al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J. Clin. Oncol, 2006. 24(19): p. 3187-3205., http://www.ncbi.nlm.nih.gov/pubmed/16682719
958. European Society for Medical Oncology (ESMO), ESMO Clinical RecommendationsESMO, 2009.
959. Schiffer, C.A., Anderson, K.C., Bennett, C.L., Bernstein, S., Elting, L.S., Goldsmith, M., et.al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology, J. Clin. Oncol, 2001. 19(5): p. 1519-1538., http://www.ncbi.nlm.nih.gov/pubmed/11230498
960. Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., et.al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials, Lancet, 2009. 373(9674): p. 1532-1542., http://www.ncbi.nlm.nih.gov/pubmed/19410717
961. Rizzo, J.D., Somerfield, M.R., Hagerty, K.L., Seidenfeld, J., Bohlius, J., Bennett, C.L., et.al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update, J. Clin. Oncol, 2008. 26(1): p. 132-149., http://www.ncbi.nlm.nih.gov/pubmed/17954713
962. Peterson, D.E., Bensadoun, R.J., Roila, F., Management of oral and gastrointestinal mucositis: ESMO clinical recommendations, Ann. Oncol, 2008. 19 Suppl 2: p. ii122-ii125., http://www.ncbi.nlm.nih.gov/pubmed/18456749
963. Gilbar, P., Hain, A., Peereboom, V.M., Nail toxicity induced by cancer chemotherapy, J Oncol Pharm Pract, 2009. 15(3): p. 143-155., http://www.ncbi.nlm.nih.gov/pubmed/19171552
964. Scotte, F., Banu, E., Medioni, J., Levy, E., Ebenezer, C., Marsan, S., et.al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot, Cancer, 2008. 112(7): p. 1625-1631., http://www.ncbi.nlm.nih.gov/pubmed/18286527
965. Scotte, F., Tourani, J.M., Banu, E., Peyromaure, M., Levy, E., Marsan, S., et.al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand, J. Clin. Oncol, 2005. 23(19): p. 4424-4429., http://www.ncbi.nlm.nih.gov/pubmed/15994152
966. Leitliniengruppe Hessen, Palliativversorgung. Hausärztliche LeitlinieLeitliniengruppe Hessen, 2009.
967. Deutsche Krebsgesellschaft (DKG), Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Therapie und Nachsorge des Mammakarzinoms. 1. AktualisierungZuckschwerdt, 2008.
968. Oefelein, M.G., Prognostic significance of obstructive uropathy in advanced prostate cancer, Urology, 2004. 63(6): p. 1117-1121., http://www.ncbi.nlm.nih.gov/pubmed/15183963
969. Ku, J.H., Lee, S.W., Jeon, H.G., Kim, H.H., Oh, S.J., Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?, Urology, 2004. 64(5): p. 895-899., http://www.ncbi.nlm.nih.gov/pubmed/15533473
970. Chung, S.Y., Stein, R.J., Landsittel, D., Davies, B.J., Cuellar, D.C., Hrebinko, R.L., et.al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents, J Urol, 2004. 172(2): p. 592-595., http://www.ncbi.nlm.nih.gov/pubmed/15247739
971. Docimo, S.G., Dewolf, W.C., High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions, J Urol, 1989. 142(2 Pt 1): p. 277-279., http://www.ncbi.nlm.nih.gov/pubmed/2746744
972. Yossepowitch, O., Lifshitz, D.A., Dekel, Y., Gross, M., Keidar, D.M., Neuman, M., et.al. Predicting the success of retrograde stenting for managing ureteral obstruction, J Urol, 2001. 166(5): p. 1746-1749., http://www.ncbi.nlm.nih.gov/pubmed/11586215
973. Feng, M.I., Bellman, G.C., Shapiro, C.E., Management of ureteral obstruction secondary to pelvic malignancies, J Endourol, 1999. 13(7): p. 521-524., http://www.ncbi.nlm.nih.gov/pubmed/10569528
974. Anast, J.W., Andriole, G.L., Grubb, R.L., Managing the local complications of locally advanced prostate cancer, Curr Urol Rep, 2007. 8(3): p. 211-216., http://www.ncbi.nlm.nih.gov/pubmed/17459270
975. Ganatra, A.M., Loughlin, K.R., The management of malignant ureteral obstruction treated with ureteral stents, J Urol, 2005. 174(6): p. 2125-2128., http://www.ncbi.nlm.nih.gov/pubmed/16280741
976. Dowling, R.A., Carrasco, C.H., Babaian, R.J., Percutaneous urinary diversion in patients with hormone-refractory prostate cancer, Urology, 1991. 37(2): p. 89-91., http://www.ncbi.nlm.nih.gov/pubmed/1992595
977. MacDonald, R., Fink, H.A., Huckabay, C., Monga, M., Wilt, T.J., Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness, BJU. Int, 2007. 100(1): p. 76-81., http://www.ncbi.nlm.nih.gov/pubmed/17433028
978. Manassero, F., Traversi, C., Ales, V., Pistolesi, D., Panicucci, E., Valent, F., et.al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial, Neurourol. Urodyn, 2007. 26(7): p. 985-989., http://www.ncbi.nlm.nih.gov/pubmed/17487874
979. Anderson, C.A., Omar, M.I., Campbell, S.E., Hunter, K.F., Cody, J.D., Glazener, C.M., Conservative management for postprostatectomy urinary incontinence, Cochrane Database Syst Rev, 2015. 1: p. CD001843., http://www.ncbi.nlm.nih.gov/pubmed/25602133
980. Wang, W., Huang, Q.M., Liu, F.P., Mao, Q.Q., Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis, BMC Urol, 2014. 14: p. 99., http://www.ncbi.nlm.nih.gov/pubmed/25515968
981. Zhu, Y.P., Yao, X.D., Zhang, S.L., Dai, B., Ye, D.W., Pelvic floor electrical stimulation for postprostatectomy urinary incontinence: a meta-analysis, Urology, 2012. 79(3): p. 552-555., http://www.ncbi.nlm.nih.gov/pubmed/22386394
982. Geraerts, I., Van, Poppel H., Devoogdt, N., De, Groef A., Fieuws, S., Van, Kampen M., Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial, Int J Impot. Res, 2016. 28(1): p. 9-13., http://www.ncbi.nlm.nih.gov/pubmed/26538105
983. Prota, C., Gomes, C.M., Ribeiro, L.H., de, Bessa J., Jr., Nakano, E., Dall'oglio, M., et.al. Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial, Int J Impot. Res, 2012. 24(5): p. 174-178., http://www.ncbi.nlm.nih.gov/pubmed/22573231
984. Zippe, C.D., Pahlajani, G., Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy, Urol Clin. North Am, 2007. 34(4): p. 601-18, viii., https://www.ncbi.nlm.nih.gov/pubmed/17983900
985. Otto, U., Dombo, O., Studie zur Identifikation von Prädiktoren für die individuelle Rehabilitationsdauer und den langfristigen Rehabilitationserfolg. Patienten mit Prostatacarcinom, in Stationäre Rehabilitation bei Mamma-, Magen- und Prostatacarcinom, Arbeitsgemeinschaft für Krebsbekämpfung der Träger der gesetzlichen Kranken- und Rentenversicherung im Lande Nordrhein-Westfalen , Editor. 2002, Roderer: Regensburg. p. 85-138.
986. Vahlensieck, W., Gack, M., Gleissner, J., Hoffmann, W., Liedke, S., Otto, U., et.al. Struktur- und Prozessqualität der stationären urologischen Rehabilitation, Urologe A, 2005. 44(1): p. 51-56., http://www.ncbi.nlm.nih.gov/pubmed/15602650
987. Dombo, O., Otto, U., Rehabilitation. Allgemeine Grundlagen, in Uroonkologie, Rübben, H. , Editor. 2007, Springer: Berlin. p. 203-218.
988. Dombo, O., Otto, U., Stress-Inkontinenz beim Mann: Anatomische und funktionelle Besonderheiten, J Urol Gynaecol, 2004. p. 7-12.
989. Dorschner, W., Stolzenburg, J.U., Neuhaus, J., Anatomische Grundlagen der Harninkontinenz, Urologe A, 2001. 40(3): p. 223-233., http://www.ncbi.nlm.nih.gov/pubmed/11405132
990. Otto, U., Grosemans, P., Hoffmann, W., Dombo, O., Rehabilitation in der urologischen Onkologie, Urologe B, 1998. 38(Suppl 1): p. 35-40.
991. Dombo, O., Rehabilitation der postoperativen Stressinkontinenz beim Mann nach radikaler Prostatovesikulektomie und Zystoprostatektomie. DissertationUniv. Hamburg, 1998.
992. Hoffmann, W., Liedtke, S., Otto, U., Das videoendoskopische Biofeedback-Sphinktertraining zur Therapie der postoperativen Harninkontinenz nach radikalchirurgischen Operationen, Extracta Urol, 2002. 3: p. 32-33.
993. Hoffmann, W., Liedke, S., Dombo, O., Otto, U., Die Elektrostimulation in der Therapie der postoperativen Harninkontinenz. Therapeutischer Nutzen unter Berücksichtigung der Lebensqualität, Urologe A, 2005. 44(1): p. 33-40., http://www.ncbi.nlm.nih.gov/pubmed/15580472
994. Davison, B.J., So, A.I., Goldenberg, S.L., Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer, BJU. Int, 2007. 100(4): p. 780-785., http://www.ncbi.nlm.nih.gov/pubmed/17578466
995. Herkommer, K., Niespodziany, S., Zorn, C., Gschwend, J.E., Volkmer, B.G., Versorgung der erektilen Dysfunktion nach radikaler Prostatektomie in Deutschland. Einschätzung durch den Urologen vs. Patientenbefragung, Urologe A, 2006. 45(3): p. 336, 338-336, 342., http://www.ncbi.nlm.nih.gov/pubmed/16341512
996. Walsh, P.C., Partin, A.W., Epstein, J.I., Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years, J Urol, 1994. 152(5 Pt 2): p. 1831-1836., http://www.ncbi.nlm.nih.gov/pubmed/7523730
997. Walsh, P.C., Marschke, P., Ricker, D., Burnett, A.L., Patient-reported urinary continence and sexual function after anatomic radical prostatectomy, Urology, 2000. 55(1): p. 58-61., http://www.ncbi.nlm.nih.gov/pubmed/10654895
998. Walsh, P.C., Preservation of sexual function in the surgical treatment of prostatic cancer--an anatomic surgical approach, Important Adv. Oncol, 1988. p. 161-170., http://www.ncbi.nlm.nih.gov/pubmed/3042603
999. Catalona, W.J., Ramos, C.G., Carvalhal, G.F., Contemporary results of anatomic radical prostatectomy, CA Cancer J Clin, 1999. 49(5): p. 282-296., http://www.ncbi.nlm.nih.gov/pubmed/11198955
1000. Michel, M.S., Trojan, L., Knoll, T., Bross, S., Alken, P., Bewährte und neue urologische Therapien des Prostatakarzinoms, Radiologe, 2003. 43(6): p. 441-447., http://www.ncbi.nlm.nih.gov/pubmed/12827258
1001. Bannowsky, A., Schulze, H., van der, Horst C., Seif, C., Braun, P.M., Junemann, K.P., Nocturnal tumescence: a parameter for postoperative erectile integrity after nerve sparing radical prostatectomy, J Urol, 2006. 175(6): p. 2214-2217., http://www.ncbi.nlm.nih.gov/pubmed/16697842
1002. Sommer, F., Klotz, T., Schmitz-Drager, B.J., Lifestyle issues and genitourinary tumours, World J. Urol, 2004. 21(6): p. 402-413., http://www.ncbi.nlm.nih.gov/pubmed/14673616
1003. Montorsi, F., Brock, G., Lee, J., Shapiro, J., Van Poppel, H., Graefen, M., et.al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy, Eur. Urol, 2008. 54(4): p. 924-931., http://www.ncbi.nlm.nih.gov/pubmed/18640769
1004. Bannowsky, A., Schulze, H., van der, Horst C., Stubinger, J.H., Portillo, F.J., Junemann, K.P., Erektionsstatus nach nervenerhaltender radikaler Prostatektomie. Nächtliche Früherektion als Parameter der postoperativen organisch-erektilen Integrität, Urologe A, 2005. 44(5): p. 521-526., http://www.ncbi.nlm.nih.gov/pubmed/15726311
1005. Zellner, M., Riedel, R., Rehabilitation der Erektionsfunktion nach radikaler Prostatektomie, Uro news, 2008. p. 28-34.
1006. Schwarz, R., Psychosoziale Onkologie: Position, Prinzipien und Perspektiven, Forum DKG, 2000. 15: p. 22-24.
1007. Weis, J., Leitlinien und Qualitätssicherung in der Psychoonkologie, in Diagnostik und Behandlungsziele in der Psychoonkologie, Schumacher, A. and Broeckamann, S., Editors. 2004, Pabst: Lengerich. p. 84-92.
1008. Cella, D., Quality of life, in Psycho-Oncology, Holland, J.C. , Editor. 1998, Oxford University Pr.: Oxford. p. 1135-1146.
1009. Faller, H., Krebs, in Psychologische Gesundheitsförderung, Diagnostik und Prävention, Jerusalem, M. and Weber, H., Editors. 2003, Hogrefe: Göttingen. p. 655-675.
1010. Koch, U., Weis, J., Krankheitsbewältigung bei Krebs und Möglichkeiten der UnterstützungSchattauer, 1998.
1011. Mehnert, A., Lehmanns, C., Koch, U., Prävalenz und Diagnostik psychischer Störungen in der Onkologie, Onkologe, 2006. 12(1): p. 18-26.
1012. Leitlinienprogramm Onkologie (OL), Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten. AWMF-Register-Nummer (032/051OL). Langversion 1.1, 2014., http://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Psychoonkologieleitlinie_1.1/LL_PSO_Langversion_1.1.pdf
1013. Zettl, S., Psychoonkologische Betreuung von Patienten mit Prostatakarzinom: Was kann der Urologe leisten?, J Urol Urogyn, 2003. 10: p. 12-15.
1014. Herschbach, P., Das "Zufriedenheitsparadox" in der Lebensqualitätsforschung - wovon hängt unser Wohlbefinden ab?, Psychother. Psychosom Med Psychol, 2002. 52(3-4): p. 141-150., http://www.ncbi.nlm.nih.gov/pubmed/11941521
1015. Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., Goldhirsch, A., Depression and degree of acceptance of adjuvant cytotoxic drugs, Lancet, 2000. 356(9238): p. 1326-1327., http://www.ncbi.nlm.nih.gov/pubmed/11073026
1016. Herschbach, P., Heussner, P., Sellschopp, A., eds., Psycho-Onkologie. Perspektiven heuteDustri, 2006.
1017. Stetinga, S.K., Dunn, J., Gardiner, R., Heathcote, P., Yaxley, J., The supportive care needs of men with prostate cancer, Psychooncology, 2001. 10: p. 66-75.
1018. Zettl, S., Hartlapp, J., Sexualstörungen durch Krankheit und TherapieSpringer, 1997.
1019. Kuchler, T., Bestmann, B., Rappat, S., Henne-Bruns, D., Wood-Dauphinee, S., Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial, J Clin Oncol, 2007. 25(19): p. 2702-2708., http://www.ncbi.nlm.nih.gov/pubmed/17602075
1020. Watzke, B., Psychotherapeutische Versorgung in der Onkologie, PsychotherapeutenJ, 2008. 4: p. 328-336.
1021. Bo, Y., Jiansheng, W., Effects of Exercise on Cancer-related Fatigue and Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Meta-analysis of Randomized Clinical Trials, Chin Med Sci J, 2017. 32(1): p. 13-21., http://www.ncbi.nlm.nih.gov/pubmed/28399980
1022. Teleni, L., Chan, R.J., Chan, A., Isenring, E.A., Vela, I., Inder, W.J., et.al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials, Endocr. Relat Cancer, 2016. 23(2): p. 101-112., http://www.ncbi.nlm.nih.gov/pubmed/26584972
1023. Hasenoehrl, T., Keilani, M., Sedghi Komanadj, T., Mickel, M., Margreiter, M., Marhold, M., et.al. The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review, Support Care Cancer, 2015. 23(8): p. 2479-2497., http://www.ncbi.nlm.nih.gov/pubmed/26003426
1024. Warren, K.S., McFarlane, J.P., Is routine digital rectal examination required for the followup of prostate cancer?, J Urol, 2007. 178(1): p. 115-119., http://www.ncbi.nlm.nih.gov/pubmed/17499293
1025. Haider, M.A., Chung, P., Sweet, J., Toi, A., Jhaveri, K., Menard, C., et.al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy, Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 425-430., http://www.ncbi.nlm.nih.gov/pubmed/17881141
1026. Sarosdy, M.F., Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy, Cancer, 2007. 109(3): p. 536-541., http://www.ncbi.nlm.nih.gov/pubmed/17183557
1027. Agarwal, P.K., Oefelein, M.G., Testosterone replacement therapy after primary treatment for prostate cancer, J Urol, 2005. 173(2): p. 533-536., https://www.ncbi.nlm.nih.gov/pubmed/15643240
1028. Kaufman, J.M., Graydon, R.J., Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men, J Urol, 2004. 172(3): p. 920-922., https://www.ncbi.nlm.nih.gov/pubmed/15310998
1029. Lopez, A.M., Pena, M.A., Hernandez, R., Val, F., Martin, B., Riancho, J.A., Fracture risk in patients with prostate cancer on androgen deprivation therapy, Osteoporos. Int, 2005. 16(6): p. 707-711., http://www.ncbi.nlm.nih.gov/pubmed/15714259
1030. Keating, N.L., O'Malley, A.J., Smith, M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J Clin Oncol, 2006. 24(27): p. 4448-4456., http://www.ncbi.nlm.nih.gov/pubmed/16983113
1031. D'Amico, A.V., Denham, J.W., Crook, J., Chen, M.H., Goldhaber, S.Z., Lamb, D.S., et.al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions, J Clin Oncol, 2007. 25(17): p. 2420-2425., http://www.ncbi.nlm.nih.gov/pubmed/17557956
1032. Pinthus, J.H., Trachtenberg, J., Klotz, L., Cardiovascular effects of androgen depletion and replacement therapy, Urology, 2006. 67(6): p. 1126-1132., http://www.ncbi.nlm.nih.gov/pubmed/16765164
1033. Bojesen, A., Juul, S., Birkebaek, N., Gravholt, C.H., Increased mortality in Klinefelter syndrome, J Clin Endocrinol. Metab, 2004. 89(8): p. 3830-3834., http://www.ncbi.nlm.nih.gov/pubmed/15292313
1034. Bojesen, A., Juul, S., Birkebaek, N.H., Gravholt, C.H., Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses, J Clin Endocrinol. Metab, 2006. 91(4): p. 1254-1260., http://www.ncbi.nlm.nih.gov/pubmed/16394093
1035. Edelman, M.J., Meyers, F.J., Siegel, D., The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis, J Gen Intern Med, 1997. 12(5): p. 318-331., http://www.ncbi.nlm.nih.gov/pubmed/9159703
1036. Echlin, K.N., Rees, C.E., Information needs and information-seeking behaviors of men with prostate cancer and their partners: a review of the literature, Cancer Nurs, 2002. 25(1): p. 35-41., http://www.ncbi.nlm.nih.gov/pubmed/11838718
1037. Kornblith, A.B., Herr, H.W., Ofman, U.S., Scher, H.I., Holland, J.C., Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care, Cancer, 1994. 73(11): p. 2791-2802., http://www.ncbi.nlm.nih.gov/pubmed/8194021
1038. Carlson, L.E., Ottenbreit, N., St, Pierre M., Bultz, B.D., Partner understanding of the breast and prostate cancer experience, Cancer Nurs, 2001. 24(3): p. 231-239., http://www.ncbi.nlm.nih.gov/pubmed/11409068
1039. Lavery, J.F., Clarke, V.A., Prostate cancer: Patients' and spouses' coping and marital adjustment, Health Med, 1999. 4: p. 289-302.
1040. Feldman-Stewart, D., Brundage, M.D., Hayter, C., Groome, P., Nickel, J.C., Downes, H., et.al. What questions do patients with curable prostate cancer want answered?, Med Decis Making, 2000. 20(1): p. 7-19., http://www.ncbi.nlm.nih.gov/pubmed/10638532
1041. Crawford, E.D., Bennett, C.L., Stone, N.N., Knight, S.J., DeAntoni, E., Sharp, L., et.al. Comparison of perspectives on prostate cancer: analyses of survey data, Urology, 1997. 50(3): p. 366-372., http://www.ncbi.nlm.nih.gov/pubmed/9301699
1042. da Silva, F.C., Fossa, S.D., Aaronson, N.K., Serbouti, S., Denis, L., Casselman, J., et.al. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853, Eur J Cancer, 1996. 32A(1): p. 72-77., http://www.ncbi.nlm.nih.gov/pubmed/8695246
1043. Davison, B.J., Goldenberg, S.L., Gleave, M.E., Degner, L.F., Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer, Oncol Nurs Forum, 2003. 30(1): p. 107-114., http://www.ncbi.nlm.nih.gov/pubmed/12515988
1044. Fischer, M., Visser, A., Voerman, B., Garssen, B., van Andel, G., Bensing, J., Treatment decision making in prostate cancer: patients' participation in complex decisions, Patient Educ Couns, 2006. 63(3): p. 308-313., http://www.ncbi.nlm.nih.gov/pubmed/16965887
1045. Voerman, B., Visser, A., Fischer, M., Garssen, B., van Andel, G., Bensing, J., Determinants of participation in social support groups for prostate cancer patients, Psychooncology, 2007. 16(12): p. 1092-1099., http://www.ncbi.nlm.nih.gov/pubmed/17278186
1046. Roesch, S.C., Adams, L., Hines, A., Palmores, A., Vyas, P., Tran, C., et.al. Coping with prostate cancer: a meta-analytic review, J. Behav. Med, 2005. 28(3): p. 281-293., http://www.ncbi.nlm.nih.gov/pubmed/16015462
1047. Gray, R.E., Fitch, M., Phillips, C., Labrecque, M., Fergus, K., To tell or not to tell: patterns of disclosure among men with prostate cancer, Psychooncology, 2000. 9(4): p. 273-282., http://www.ncbi.nlm.nih.gov/pubmed/10960925
1048. Gray, R.E., Fitch, M., Davis, C., Phillips, C., Interviews with men with prostate cancer about their self-help group experience, J Palliat Care, 1997. 13(1): p. 15-21., http://www.ncbi.nlm.nih.gov/pubmed/9105153
1049. Fayers, P.M., Machin, P., Quality of Life: The assessment, analysis and interpretation of patient-reported outcomesWiley, 2013., http://www.wiley.com/WileyCDA/WileyTitle/productCd-1118699459.html
1050. Cella, D.F., Tulsky, D.S., Quality of life in cancer: definition, purpose, and method of measurement, Cancer Invest, 1993. 11(3): p. 327-336., http://www.ncbi.nlm.nih.gov/pubmed/8485655
1051. Koller, M., Lorenz, W., Quality of life: a deconstruction for clinicians, J. R. Soc. Med, 2002. 95(10): p. 481-488., http://www.ncbi.nlm.nih.gov/pubmed/12356967
1052. Koller, M., Neugebauer, E.A., Augustin, M., Bussing, A., Farin, E., Klinkhammer-Schalke, M., et.al. Die Erfassung von Lebensqualität in der Versorgungsforschung - konzeptionelle, methodische und strukturelle Voraussetzungen (Memorandum III: Methoden der Versorgungsforschung), Gesundheitswesen, 2009. 71(12): p. 864-872., http://www.ncbi.nlm.nih.gov/pubmed/19806535
1053. Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D'haese, S., et.al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?, J Clin Oncol, 2003. 21(18): p. 3502-3511., http://www.ncbi.nlm.nih.gov/pubmed/12972527
1054. Martin, N.E., Massey, L., Stowell, C., Bangma, C., Briganti, A., Bill-Axelson, A., et.al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer, Eur Urol, 2015. 67(3): p. 460-467., http://www.ncbi.nlm.nih.gov/pubmed/25234359
1055. Szymanski, K.M., Wei, J.T., Dunn, R.L., Sanda, M.G., Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors, Urology, 2010. 76(5): p. 1245-1250., http://www.ncbi.nlm.nih.gov/pubmed/20350762
1056. Beyer, B., Huland, H., Feick, G., Graefen, M., "Expanded prostate cancer index composite"(EPIC-26): Funktionelles Behandlungsergebnis bei Patienten mit lokalisiertem Prostatakarzinom, Urologe A, 2015. 54(11): p. 1591-1595., http://www.ncbi.nlm.nih.gov/pubmed/26347350
1057. Aaronson, N.K., Methodologic issues in assessing the quality of life of cancer patients, Cancer, 1991. 67(3 Suppl): p. 844-850., http://www.ncbi.nlm.nih.gov/pubmed/1986856
1058. van Andel, G., Bottomley, A., Fossa, S.D., Efficace, F., Coens, C., Guerif, S., et.al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer, Eur. J Cancer, 2008. 44(16): p. 2418-2424., http://www.ncbi.nlm.nih.gov/pubmed/18774706
1059. Koller, M., Aaronson, N.K., Blazeby, J., Bottomley, A., Dewolf, L., Fayers, P., et.al. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach, Eur J Cancer, 2007. 43(12): p. 1810-1820., http://www.ncbi.nlm.nih.gov/pubmed/17689070
1060. Dewolf, L., Koller, M., Velikova, G., Johnson, C., Scott, N., Bottomley, A., EORTC Quality of Life Group translation procedureEORTC, 2009.